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The guanine exchange factor p63RhoGEF was identified as a specific activator of the 
RhoGTPase RhoA and its transcript was found to be abundant in brain and heart tissue. 
Amongst cardiac cells, the highest expression of p63RhoGEF was detected in smooth muscle 
cells and cardiac fibroblasts. Within this thesis the relevance of p63RhoGEF in the healthy 
myocardium and under pathological conditions was under investigation with a special focus 
on its function in cardiac fibroblasts in the context of auto- and paracrine signaling. 
In a model of cardiac fibrosis, in which wild type mice were subjected to transverse aortic 
constriction (TAC), p63RhoGEF expression was found to be up-regulated in the myocardium. 
Furthermore, its expression correlated positively with the fibrosis marker CTGF (connective 
tissue growth factor) as well as with the level of hypertrophy, and negatively with the 
contractility of the heart. Due to the lack of specific mouse models targeting cardiac 
fibroblasts, the role of p63RhoGEF was first assessed with the help of 2D and 3D cultures of 
neonatal rat cardiac fibroblasts (NRCF). In 2D culture it was demonstrated that p63RhoGEF 
regulates the expression and secretion of CTGF involving the activation of the serum 
response factor (SRF) and its actin-dependent co-factor myocardin-related transcription 
factor (MRTF). Moreover, confocal microscopy studies revealed a partial co-localization of 
p63RhoGEF and CTGF at the trans-Golgi network. In 3D engineered connective tissue 
cultures (ECT), p63RhoGEF was demonstrated to regulate viscoelastic properties. While 
overexpression of p63RhoGEF increased the stiffness, the dominant negative truncated 
p63ΔN decreased the rigidity of the tissue. An influence of p63RhoGEF on CTGF expression in 
ECT could be detected. CTGF itself was however not sufficient to regulate viscoelastic 
properties of ECT. Next the heterogeneous engineered heart muscle model (EHM) was used 
to demonstrate that p63RhoGEF overexpression in cardiac fibroblasts enhanced resting and 
twitch tension, whereas p63ΔN reduced both. In contrast, overexpression of p63RhoGEF in 
cardiomyocytes (CM) failed to improve the contractile function validating the importance of 
p63RhoGEF in cardiac fibroblasts for cell-cell communication via paracrine signaling.  
In the following, a global p63RhoGEF knockout mouse line was used to study the effect of a 
complete (KO) and partial (HET) deletion of p63RhoGEF. In HET mice already under basal 
condition an impaired cardiac phenotype was present, while the KO mice showed no major 
difference compared to the WT phenotype. Mice subjected to TAC developed all heart 
failure within 5 weeks after intervention. While the HET mice showed the most detrimental 
cardiac dysfunction accompanied by a faster dilation of the left ventricle, the KO animals 
resembled the WT phenotype. Interestingly, mortality was increased in KO male mice 
leading to a survival rate of less than 60% within the first 2 weeks after TAC. So far, excessive 
hypertrophy and fibrosis as a cause could be excluded. In the surviving animals the degree of 
hypertrophy was identical after 5 weeks independent of the genotype. However, in the HET 
mice a decrease in fibrosis could be detected.  
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To further study the role p63RhoGEF in adult mouse cardiac fibroblasts (AMCF), cells were 
isolated from the generated mouse line and displayed a prominent myofibroblast character 
in culture regardless of the genotype. The genetic deletion of p63RhoGEF in these cells 
exhibited a paradox signaling. While the total RhoA and cytoskeletal protein expression was 
unchanged, the genetic deletion resulted in a higher phosphorylation of direct ROCK targets 
cofilin and ERM proteins, increased CTGF secretion and up-regulation of fibrosis-associated 
factors TGF-β and collagen in a dose-dependent manner showing the most pronounced 
response detected in the KO AMCF. Moreover, the knockout of p63RhoGEF led to activation 
of cell survival and growth pathways and improved proliferation as well as prevented cell 
death.  
1.1 Zusammenfassung 
Der Nukleotid-Austauschfaktor p63RhoGEF wurde als spezifischer Aktivator der RhoGTPase 
RhoA identifiziert und sein Transkript konnte vermehrt in Hirn-und Herzgewebe detektiert 
werden. Innerhalb der kardialen Zellen konnte die höchste Expression von p63RhoGEF in 
glatten Muskelzellen der Aorta sowie kardialen Fibroblasten nachgewiesen werden. Im 
Rahmen dieser Arbeit wurde die Bedeutung von p63RhoGEF im gesunden Herzen und unter 
pathologischen Bedingungen untersucht, wobei ein Fokus auf seine Funktion in kardialen 
Fibroblasten im Zusammenhang mit autokrinen und parakrinen Signalwegen gelegt wurde. 
Anhand eine Tiermodells der kardialen Fibrose, in denen Wildtyp Mäuse einer transversalen 
Aortenkonstriktion (TAC) unterzogen wurden, konnte eine erhöhte Expression von 
p63RhoGEF im Herzgewebe nachgewiesen werden. Zudem konnte eine positive Korrelation 
der Expression von p63RhoGEF mit dem Fibrose-Marker CTGF („connective tissue growth 
factor“) und dem Ausmaß der Hypertrophie, sowie ein negativer Zusammenhang mit der 
Kontraktilität des Herzen gezeigt werden. Aus Mangel an fehlenden Fibroblasten-
spezifischen Mausmodellen, wurde die Rolle von p63RhoGEF zunächst in 2D und 3D 
Zellkulturen neonataler kardialer Fibroblasten der Ratte (NRCF) analysiert. Mit Hilfe von 2D 
Zellkulturen konnte belegt werden, dass p63RhoGEF sowohl die Expression als auch 
Sekretion von CTGF reguliert und dies durch die Aktivierung des Serum-Response-Faktor 
(SRF) und des Aktin-abhängigen Co-Faktor Myocardin-related Transkriptionsfaktor (MRTF) 
vermittlelt wird. Konfokal mikroskopische Aufnahmen konnten zudem eine partielle 
Kolokalisation von p63RhoGEF mit CTGF am trans-Golgi Netzwerk belegen. Im 3D 
Gewebemodell des “engineered connective tissue“ (ECT) konnte gezeigt werden, dass 
p63RhoGEF die Viskoelastizität reguliert, indem eine Überexpression von p63RhoGEF zu 
einer erhöhten Steifigkeit des Gewebes führt, während Gewebe mit der Expression des 
dominant negativen Konstrukts p63ΔN eine verminderte Steifigkeit aufweist. In diesem 
Zusammenhang konnte der Einfluss von p63RhoGEF auf die Expression von CTGF auch in den 
Geweben gezeigt werden, wobei eine vermehrte Expression von CTGF allein nicht ausreichte 
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die Eigenschaften des Gewebes zu beeinflussen. In einem heterogenen 3D Herzgewebe, dem 
„engineered heart muscle“ (EHM) führte eine erhöhte Expression von p63RhoGEF 
ausschließlich in kardialen Fibroblasten zu einer verbesserten Calcium-abhängigen 
Kontraktilität und gleichzeitig gesteigerten Gewebespannung, während Gewebe mit der 
Expression des blockierenden p63ΔN Konstruktes beide Eigenschaften negativ regulierte. Im 
Gegensatz dazu, konnte eine Überexpression von p63RhoGEF ausschließlich in 
Kardiomyozyten keine Verbesserung der Kontraktilität erzielen, was auf eine entscheidende 
Rolle von p63RhoGEF in kardialen Fibroblasten für die parakrin-vermittelte Zell-Zell-
Kommunikation hinweist. 
Des Weiteren wurde eine Mauslinie mit einem globalen p63RhoGEF Knockout generiert, um 
den Effekt eines kompletten (KO) und eines partiellen (HET) Verlustes von p63RhoGEF zu 
untersuchen. Bei den HET Mäusen zeigte sich bereits unter basalen Bedingungen ein 
Beeinträchtigung des kardialen Phänotyps, während die KO Mäuse keinen sichtbaren 
Unterschied im Vergleich mit zu dem WT Phänotyp aufwiesen. Alle Mäuse, die einer TAC-OP 
unterzogen wurden, entwickelten innerhalb von 5 Wochen nach dem Eingriff ein 
progressives Herzversagen. Die HET Mäuse zeigten hierbei die größte kontraktile 
Verschlechterung einhergehend mit einer schnelleren Dilation des linken Ventrikels, 
während die KO Mäuse hingegen das Erscheinungsbild des  WT Phänotyp widerspiegelten. 
Dennoch war die Mortalität der KO Mäuse mit einer Überlebensrate von unter 60% 
innerhalb der ersten 2 Wochen nach der OP stark erhöht. Eine massive Zunahme der 
Hypertrophie und Fibrose konnten als mögliche Gründe ausgeschlossen werden und bei den 
überlebenden KO Tieren war das Ausmaß der Hypertrophie ziemlich identisch. 
Interessanterweise wurde in den HET Mäusen eine Reduzierung von fibrotischem Gewebe 
verzeichnet.  
Um die Funktion von p63RhoGEF in adulten kardialen Fibroblasten der Maus (AMCF) näher 
zu charakterisieren, wurden diese Zellen aus den transgenen Mäusen isoliert. In Kultur 
entwickelten die Zellen unabhängig vom Genotyp einen sehr ausgeprägten Myofibroblasten-
Charakter. Die Reduzierung bzw. der totale Verlust von p63RhoGEF äußerte sich durch eine 
paradoxe Regulation. Während keine Veränderung hinsichtlich der Expression von total 
RhoA sowie diverser Zytoskelettproteinen zu verzeichnen war, führte die Deletion von 
p63RhoGEF zu einer erhöhten Phosphorylierung der direkten ROCK Zielproteine Cofilin und 
ERM, zu einem Anstieg an sezerniertem CTGF und zu einer Zunahme von Fibrose-Markern 
wie TGF-β und Kollagen auf mRNA Ebene. Dabei zeigte sich die größte Zellantwort in den KO 
AMCF. Zusätzlich konnte in den KO Zellen eine Aktivierung von Signalwegen, die für das 
Überleben und Wachstum eine entscheidende Rolle spielen, beobachtet werden, wodurch 
die Zellen einerseits eine erhöhte Proliferation und gleichzeitig einen besseren Schutz vor 




2.1 Heart failure 
Cardiovascular diseases are one of the most common death causes worldwide. According to 
the World Health Organization (WHO) 17.5 million people died from cardiovascular diseases 
in 2012, representing 31% of all global death. Despite improved drug treatments and 
therapies over the last decades this trend is further increasing. For this reason, further 
investigations about the underlying mechanisms leading to the development of heart failure 
are needed to define new therapeutic targets. 
2.1.1 Cardiac remodeling 
Cardiac remodeling occurs when myocardial injury or hemodynamic overload initiates a 
series of structural changes throughout the myocardium that eventually leads to a global 
deterioration of cardiac function [1]. The most prominent structural changes include 
compensatory cardiomyocyte hypertrophy and myocardial fibrosis.  
Myocardial hypertrophy is an essential adaptive process through which the heart responds 
to various mechanical, metabolic or genetic stresses. For instance, physiological 
hypertrophy, which is in most cases reversible, occurs during pregnancy or chronic exercise 
in an athlete´s heart improving the cardiac output to fulfill the body´s demand for nutrients 
and oxygen [2]. 
Figure 2.1: Transition from normal healthy heart to heart failure by cardiac remodeling 
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However, hypertrophy due to persistent overload ultimately leads to contractile dysfunction 
and dilation of the left ventricle (Figure 2.1) [4]. Pathological remodeling, as a consequence 
of hypertension, valve malfunction, virus infection or genetic predisposition, is often 
irreversible and results in severe heart failure [5]. In addition to growth of individual 
cardiomyocytes, the hypertrophied myocardium undergoes further complex structural 
remodeling involving rearrangement of the muscle fibers and interstitial as well as 
perivascular fibrosis [6-8]. 
Like cardiomyocyte hypertrophy, the remodeling of the extracellular matrix (ECM) may 
initially represent an adaptive response to cardiac stress, but ultimately impairs cardiac 
structure and function [9], thereby contributing to the high morbidity and mortality of 
cardiac diseases [8].  
2.1.2 Myocardial fibrosis 
Cardiac fibrosis is an important contributor to the development of cardiac dysfunction in 
diverse pathological conditions, such as ischaemic and hypertensive cardiac disease. It can 
be defined as an inappropriate accumulation of connective tissue in the myocardium [7, 10-
12], resulting from excessive deposition and/or decreased degradation of extracellular 
matrix (ECM) components, including mainly collagen type 1 [13]. 
Cardiac fibrosis leads to an increased myocardial stiffness, impairment of electrical 
connections between cardiomyocytes and hence to a higher risk of arrhythmias [14]. 
Additionally, the increased diffusion distance for nutrients and oxygen from the blood 
vessels to the cardiomyocytes can negatively influence the myocardial balance between 
energy demand and supply [7, 11].  
Cardiac fibrosis is generally categorized in two types: reparative and reactive fibrosis. 
Reparative fibrosis occurs immediately after a myocardial infarction (MI). During the acute 
ischemic event cardiomyocytes are lost due to necrosis and apoptosis. This leads to 
hyperplasia of non-myocytes, including fibroblasts. As a consequence more collagen fibers 
are deposited and scar tissue is formed to ensure structural integrity. In contrast, reactive 
fibrosis generally occurs in the absence of cell loss as a result of changes in local mechanical 
and biochemical factors in the process of cardiac remodelling, as can be seen e.g. in 
hypertensive conditions. While reparative fibrosis usually affects interstitial ECM, reactive 
fibrosis with excessive collagen deposition can be observed in the interstitial as well as 
perivascular area [10, 11, 15].  
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2.2 Cardiac fibroblasts 
The normal heart is comprised of four major cell types: cardiomyocytes, endothelial cells, 
smooth muscle cells and fibroblasts. While cardiomyocytes make up most of the volume, 
fibroblasts are considered to be numerously the most abundant cell type in the heart, which 
can make up to 70% of the total cell population depending on the species [16]. Recently, a 
study revisited the cellular composition of the heart, demonstrating that fibroblasts comprise 
with less than 20% a relatively minor population [17]. Cardiac fibroblasts depict a spindle 
shaped cell body, a prominent Golgi apparatus and endoplasmatic reticulum indicative of 
high cellular activity [18]. Like all fibroblasts, cardiac fibroblasts do not have a basement 
membrane [19]. 
As cardiac fibroblasts are of mesenchymal origin they do not possess definite cell marker and 
share most of the available marker with other cell types. Amongst the more robust marker 
for detection of fibroblasts are the Discoidin Domain Receptor 2 (DDR2) [20], Transcription 
factor 21 (TCF21) [21] and the Platelet-derived growth factor receptor-alpha (PDGFRα) [22]. 
Subsets, but not all fibroblasts also express the classical myofibroblast marker α-smooth 
muscle actin (αSMA) [15]. In the tissue, cardiac fibroblasts are located in the interstitial 
matrix surrounding the cardiomyocytes [23] and contribute to the structural, mechanical 
and electric properties of the healthy myocardium. As the predominant matrix-producing 
cells [24], fibroblasts play a key role in regulating the structural integrity of the heart through 
controlled proliferation and ECM turnover [11, 16]. To maintain ECM homeostasis cardiac 
fibroblasts secrete ECM proteins, mostly collagen type 1 and 3 and fibronectin, to create a 
scaffold [25]. Simultaneously, they express and secrete matrix degrading proteins, e.g. 
matrix metalloproteases (MMPs) to maintain the balance between ECM synthesis and 
degradation [11, 26]. Beside the control of ECM homeostasis, cardiac fibroblasts support the 
distribution of contractile force and mechanical stress through the heart [25], as they are 
connected to cardiomyocytes via gap junctions and to the ECM via integrins [19, 27]. 
Moreover, cardiac fibroblasts can serve as conductors propagating electrical signals, as they 
possess a high membrane resistance and are not electrically excitable. In that way, they 
could also act as insulators [28]. 
2.2.1 Myofibroblasts – the activated fibroblast 
Within a healthy tissue cardiac fibroblasts remain rather quiescent with a low potential for 
migration, proliferation and secretion [16, 29]. In response to neurohumoral or 
biomechanical stress, cardiac fibroblasts become activated and undergo a phenotypic 
transition to profibrogenic myofibroblasts, which are characterized by the expression of 
αSMA and pronounced stress fiber formation [11, 16], significantly increasing their 
contractile activity. Myofibroblasts display a more mobile phenotype and migrate through 
the tissue to sites of injury [18] and highly produce and secrete collagen-rich ECM and a 
number of profibrotic and inflammatory cytokines including the transforming growth  
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factor-β (TGF-β) and IL-1β [30]. Like fibroblasts, myofibroblasts are non-excitable cells and 
are not directly involved in conduction of the heart. Instead, they are more likely to produce 
conduction barriers by increasing the distance between adjacent cardiomyocytes and thus 
decreasing cardiomyocyte to cardiomyocyte coupling via gap junctions [31].  
Over time, excessive formation of fibrous connective tissue and ECM leads to cardiac 
fibrosis. This impairs electrical coupling between cardiomyocytes and increases myocardial 
stiffness, leading to arrhythmias and severe diastolic dysfunctions [32]. 
Myofibroblasts are involved in both reparative and fibrotic processes and increased 
myofibroblast accumulation in the cardiac interstitium was found not only in myocardial 
infarction [33], but also in the pressure and volume overloaded myocardium [34, 35] and in 
the aging heart [36]. 
Figure 2.2: Sources of myofibroblasts 
Shown are possible sources of cells that could contribute to a myofibroblast phenotype. Figure was adapted 
from Kong et al., 2014
[37]
.
The origin of myofibroblasts constituting the fibrotic lesions of failing hearts is still not clear. 
Some reports have shown that myofibroblasts are derived solely from resident fibroblasts 
[15, 38], whereas others have suggested that other cell types transdifferentiate into 
fibroblasts (Figure 2.2). Other sources of myofibroblasts include epithelial cells undergoing 
epithelial-to-mesenchymal transition (EMT), bone marrow derived progenitor cell like 
fibrocytes, endothelial cells undergoing endothelial-to-mesenchymal transition (EndMT), 
pericytes or smooth muscle cells [37]. After scar formation most of the myofibroblasts 
undergo apoptosis, while some still reside in the scar tissue [39]. 
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2.3 Connective tissue growth factor 
The connective tissue growth factor (CTGF), also referred to as CCN2, is a cysteine-rich 36-
38 kDa secreted protein and a member of the CCN (Cyr61, CTGF and Nov) family of 
multifunctional matricellular proteins [40-42]. Matricellular proteins do not fulfill a 
significant structural role, but bind to cell surface receptors, ECM proteins, growth factors 
and proteases. In this way they modulate the biological activity of other growth factors, cell-
matrix interaction and cell function. CTGF is a typical example of such a matricellular protein, 
involved in modulating the activity of a variety of local factors in ECM homeostasis, and 
strongly implicated in fibrogenic processes in several tissues, including the heart [15]. 
2.3.1 Protein structure of CTGF 
Like other members of the CCN family, CTGF has a similar genomic organization and modular 
protein structure. The CTGF gene contains five exons. Exon 1 encodes a signal peptide (SP) 
for secretion, while exons 2–5 encode for 4 different modules, which can bind to various 
growth factors, ECM components and cell membrane proteins (Figure 2.3). Module 1 is the 
insulin-like growth factor binding protein (IGFBP) domain, which interacts with IGF-I and IGF-
II [43]. These two growth factors are involved in physiological cell growth [44], but at high 
level contribute to the development of cardiac fibrosis [45]. In this context, it was shown 
that IGF-I induces proliferation of cardiac fibroblasts and promotes collagen production [46, 
47]. Module 2, the von Willebrand factor type C (VWC) domain, was shown to bind to bone 
morphogenetic protein 4 (BMP4) and TGF-β1. Interaction of CTGF with BMP4 inhibits BMP 
signaling, whereas binding of CTGF to TGF-β1 increased TGF-β signaling [48]. CTGF also 
interacts with BMP7 by antagonizing BMP7 signaling, thereby contributing to the 
development of fibrosis as demonstrated in various fibrotic kidney diseases [49, 50]. The 
third module, named the thrombospondin type 1 (TSP1) domain, serves as a binding domain 
for the vascular endothelial growth factor (VEGF) inhibiting angiogenesis induced by VEGF 
[51]. Finally, module 4 encodes for the C-terminal (CT) Cysteine knot module, which binds to 
proteoglycans allowing the interaction with ECM proteins [52].   
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Figure 2.3: Protein structure of CTGF 
Scheme of the 4 modules of CTGF and its interaction partners including growth factors, cell surface and ECM 
proteins. The scheme was adapted with modifications from Gressner and Gressner, 2008
[53]
.
In addition, the region between module 2 and 3, rich in cysteine residues, is prone to 
proteolytic cleavage. CTGF can be cleaved by several elastases, MMPs, e.g. MMP2 and 
plasmin [54, 55], which, in turn, influences the activity and function of CTGF and its 
fragments. For instance, cleavage of CTGF can reactivate the angiogenic activity of VEGF, by 
relieving the competitive binding of VEGF with the TSP-1 domain [54, 55]. Based on the 
structure and its numerous binding partners, CTGF is suggested to be involved in a variety of 
cellular processes including adhesion, migration, proliferation, differentiation, angiogenesis 
and apoptosis [56, 57], all common features of cardiac remodeling. Under pathological 
condition CTGF mediates tissue repair and fibrosis of several organs through the regulation 
of several factors in ECM homeostasis [52, 58, 59]. 
2.3.2 Function and regulation of CTGF in the heart 
CTGF is expressed in multiple tissues and cell types [58, 60, 61]. With respect to the heart, 
CTGF expression was found in the fetal mouse myocardium [62] and becomes restricted to 
the atria and large blood vessels in the adult heart [62, 63]. Mice deficient in CTGF did not 
show any cardiac abnormalities or signs of cardiac dysfunction at birth [64]. The expression 
of CTGF is regulated by a variety of stimuli [52, 65]. TGF-β is a potent fibrogenic factor and a 
major inducer of CTGF expression in many cell types including cardiomyocytes and 
fibroblasts [61, 66, 67]. 
Besides angiotensin II (Ang II), other G protein coupled receptor (GPCR) agonists such as 
endothelin-1 and phenylephrine were demonstrated to enhance CTGF expression in 
neonatal cardiomyocytes [68-71]. In a human fibroblast cell line it was shown that induction 
of CTGF by Ang II involved the Ang II-type 1 receptor (AT1R) and activation of mitogen-
activated protein kinases ERK1/2 (p42/44 MAPK). In line with this, a role of RhoA and SRF 
controlling CTGF expression in cardiomyocytes was postulated [72, 73]. 
















Many in vitro studies have shown that CTGF stimulates the proliferation of fibroblasts, their 
differentiation towards myofibroblasts and enhances ECM production [74-77]. As CTGF 
expression correlates with the level of fibrosis, CTGF seems to play an important role in 
tissue response to injury and fibrosis [78-80].  
2.3.3 Role of CTGF in myocardial fibrosis 
With respect to cardiac diseases, increased levels of CTGF were found in patients with heart 
failure, MI, ischemia, hypertension and coronary artery disease [61, 81-83] as well as in 
injury-induced animal models of cardiac hypertrophy and fibrosis [69, 83-86].  
As an example, pressure-overload cardiac hypertrophy in aorta-banded rats showed 
increased CTGF expression accompanied with elevated levels of TGF-β, collagen I and brain 
natriuretic peptide (BNP) [83], supporting CTGF as a profibrotic factor. In this context, it was 
shown that CTGF alone is not sufficient to initiate fibrosis, but the presence of both CTGF 
and TGF-β resulted in persistent fibrosis [74, 87]. 
In contrast, some studies also reported a decrease in fibrosis after inhibition of CTGF [88]. 
However, recent studies using transgenic mice overexpressing CTGF with similar amount of 
fibrosis as in the control mice pointed towards a cardio-protective effect of CTGF and 
thereby a beneficial effect of CTGF expression for cardiomyocyte survival [89]. Other reports 
demonstrated that neither a cardiac specific CTGF deletion in mice [90] nor a conditional 
knockout of CTGF had any influence on the development of fibrosis [86]. To date, no direct 
proof for a causal role of CTGF in the development of cardiac fibrosis has been reported.  
2.4. RhoGTPases 
2.4.1 Structure and function of RhoGTPases 
RhoGTPases are monomeric GDP/GTP binding proteins (G proteins) belonging to the Ras-
superfamily of small (~21 kDa) G proteins [91]. There are 22 RhoGTPases identified in 
humans, which can be classified into eight subgroups [92, 93]. RhoGTPases act as molecular 
switches that mediate a wide variety of cellular processes, such as actin cytoskeletal 
organization, cell migration, cell cycle progression, and transcriptional control [94-96]. 
Moreover, they have been implicated in phagocytosis, cytokinesis, neurite extension and 
retraction, cellular morphogenesis and polarization, growth and cell survival [97-99]. 
The best characterized members are RhoA, Rac1 and Cdc42, which can induce different 
cytoskeletal structures. RhoA activation leads to the formation of stress fibers associated 
with focal adhesions, Rac1 induces the formation of lamellipodia or membrane ruffles and 
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Cdc42 produces filopodia [91, 100, 101]. They also stimulate gene transcription through 
several transcription factors, such as the serum response factor (SRF) or NFκB [102, 103]. All 
RhoGTPases share a similar GTP binding site and most of them are posttranslationally 
modified at the C-terminus by an isoprenoid lipid, which serves as a plasma membrane 
anchor [104]. 
In the cardiovascular field, RhoGTPases play a key role in several signaling pathways 
activated by GPCR agonists such as endothelin-1 [105, 106], Ang II [107], phenylephrine (PE) 
[108] and lysophosphatidic acid (LPA) [109]. It has been demonstrated that RhoA is involved
in the α1-adrenergic receptor-mediated hypertrophy in cardiomyocytes along with an 
increased gene expression of atrial natriuretic peptide (ANP), myosin light chain 2 (MLC-2), 
β-myosin heavy chain (β-MHC) and skeletal α-actin [108].  
2.4.2 Activation of RhoGTPases 
As mentioned above, RhoGTPases act as bi-molecular switches cycling between an inactive 
(GDP-bound) and an active (GTP-bound) conformation. This cycling is regulated by three 
types of accessory proteins (Figure 2.4). Guanine nucleotide exchange factors (GEFs) catalyze 
the exchange of GDP for GTP, thereby activating the GTPase [110], whereas GTPase-
activating proteins (GAPs) increase the relatively slow intrinsic GTP hydrolysis rate of the 
GTPase, which inactivates the RhoGTPase. Guanine nucleotide dissociation inhibitors (GDIs) 
sequester the GDP-bound form of some GTPases in the cytosol, stabilize the inactive GDP-
bound state and prevent them from localizing at membranes or being activated by GEFs 
[110].  
Figure 2.4: Activation cycle of RhoGTPases 
Schematic overview of the activation of RhoGTPases by guanine nucleotide exchange factor (GEF), the 
inactivation by GTPase-activating protein (GAP) and stabilization of the inactive GDP-bound RhoGTPase by 




















The activation of Rho family proteins is often mediated through various cell-surface 
receptors, including the cytokine, tyrosine kinase and adhesion receptors, as well as GPCRs 
[111, 112]. Upon activation, RhoGTPases actively transduce signals by interacting with 
downstream effectors [113, 114] including kinases, actin regulators and adaptor proteins, 
leading to changes in cell behavior. A single RhoGTPase can activate a range of cellular 
responses, depending on the stimulus and cell type [115]. 
2.4.3 The RhoGTPase RhoA 
RhoA is a monomeric GTPase of 21kDa in size and belongs to the Rho subfamily of GTP-
binding proteins [116] . It is expressed in all type of cells, where it controls many cellular 
functions mainly by regulation of the actin cytoskeleton [117]. In this way, RhoA promotes 
the formation of stress fibers and focal adhesions important for cell shape, attachment and 
motility of cells [91, 118, 119]. In addition, RhoA is also involved in transcriptional regulation. 
In common with all monomeric GTPases, RhoA acts as a molecular switch, which is activated 
and inactivated by GDP/GTP exchange and GTP hydrolysis, respectively. The exchange of 
guanine nucleotide is mediated by the two switch regions, switch I and II, of the N-terminal 
sequence of RhoA, which undergo massive conformational changes. In addition, both switch 
regions interact with the Dbl-homology domain of GEFs and mediate the formation of the 
RhoA/RhoGEF complex [110]. The C-terminus of RhoA is modified via prenylation by a 
geranylgeranyl-residue, enabling the translocation and anchoring of RhoA to the cell 
membrane as part of the activation [120]. 
RhoA can be activated by multiple upstream signals including GPCRs, integrins and growth 
factor receptors [121]. Amongst the wide spectrum of GPCRs, the sphingosine-1-phosphate 
receptor (S1PR) in cardiomyocytes [122], the AT1R in smooth muscle cells [123] and the 
muscarinic M1 acetylcholine receptor (M1R) in embryonic neural crest cells [117] were 
identified and were shown to be involved in RhoA signaling.   
Once activated, GPCRs signal via associated heterotrimeric G proteins, which consists of an 
α- and β/γ-subunit and can be divided into four sub-classes: Gαs, Gαi/o, Gαq/11 and Gα12/13. By 
the exchange of GDP for GTP, the G-protein dissociates into the α-subunit with the bound 
GTP and the β/γ-dimer and further transduces the intracellular signal [124] by interacting 
with various downstream effectors including RhoGEFs. 
For RhoA, the subfamilies of the Gαq/11 and Gα12/13 proteins have been shown to mediate 
RhoA activation. While Gα12/13 proteins can activate RhoA by binding to the three RhoGEFs 
p115RhoGEF, PDZ-RhoGEF and the leukemia-associated RhoGEF (LARG) via their regulator of 




2.4.4 RhoA signaling in the heart and in cardiac disease 
A variety of in vitro and in vivo studies were performed, to elucidate the role of RhoA in the 
heart. In cardiomyocytes, RhoA has been associated to morphological changes and induction 
of gene expression as part of the hypertrophic response mediated by factors such as 
phenylephrine, endothelin-1 or Ang II [107, 126]. Conversely, inhibition of RhoA and its 
effectors the Rho-associated protein kinases prevented morphological and cytoskeleton 
changes as well as reduced expression of hypertrophy-associated proteins like ANP and α-
myosin heavy chain (α-MHC) [127-129]. One important downstream mediator of the 
RhoA/ROCK-dependent hypertrophic response, represents the myocardin-related 
transcription factor A (MRTF-A) and serum response factor (SRF), which initiate the 
transcriptional activation of the hypertrophic-dependent fetal gene program [130]. 
In vivo, several studies support the involvement of the RhoA/ROCK signaling during cardiac 
remodeling. It was demonstrated that RhoA was strongly activated upon pressure overload 
induced by transverse aortic constriction (TAC) [131] and its expression was also increased in 
a model of diabetic cardiomyopathy [132]. Likewise, ROCKs were found to be rapidly 
induced in the adult rat myocardium after TAC intervention [133] suggesting that activation 
of the RhoA/ROCK pathway promotes adverse effects. In accordance, pharmacological 
inhibition of RhoA [134] and ROCK [135-138] using selective inhibitors preserved the cardiac 
function and reduced cardiac remodeling. 
Genetic models provided further insights regarding the impact of RhoA/ROCK signaling 
(Figure 2.5) for the underlying processes of cardiac remodeling. Mice with a cardiomyocyte-
specific overexpression of RhoA did not develop cardiac hypertrophy as expected based on 
the in vitro data from cardiomyocytes. In contrast, these mice displayed a strong 
deterioration of the left ventricle with chamber dilation, interstitial fibrosis and reduced 
contractility and hence premature death [129]. Moreover, these animals exhibited 
conductive dysfunction observed by atrioventricular blocks accompanied by bradycardia 
[129]. 
Accordingly, the overexpression of the upstream G protein Gαq [139] and expression of a 
constitutive active form of Gαq 
[140] had showed a similar detrimental phenotype regarding
contractility and survival with development of cardiac hypertrophy. For the downstream 
effectors of Rho kinases (ROCKs), a constitutive active expression of ROCK1 resulted in 
fibrotic cardiomyopathy and diastolic dysfunction due to increased TGF-β expression [141]. 
Conversely, animal studies with a ROCK1 knockout (KO) resulted in an opposite outcome 
regarding fibrosis. In a model of global haploinsufficient ROCK1+/- mice, perivascular fibrosis 
and associated factors as TGF-β, CTGF and collagen type III were less increased in an Ang II 
infusion model and TAC model, while hypertrophy was established to the same extent [142]. 
Furthermore, mice with a global ROCK1 deletion showed a similar phenotype with a 
decrease in perivascular and interstitial fibrosis accompanied by reduced expression and 
secretion of fibrotic factors such as TGF-β and CTGF as well as ECM proteins. No effect on 
the development of hypertrophy was observed [143]. This was further supported, as mice 
with a cardiomyocyte-specific overexpression of Gαq and homozygous KO of ROCK1 led to a 
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similar outcome regarding cardiac fibrosis and hypertrophy [143]. Recently, a mouse study 
with a cardiomyocyte-specific knockout of RhoA was described. These mice exhibited an 
impaired contractile function associated with a faster dilation, but less fibrosis and reduced 
expression of fibrotic genes, e.g. TGF-β [144]. Again, the development of hypertrophy was 
not affected suggesting a relevant role for the RhoA/ROCK pathway in the development of 
cardiac fibrosis thereby influencing the contractile function in the context of cardiac 
diseases. However, ROCK2 was proposed as the Rho kinase playing a role in cardiac 
hypertrophy as the cardiomyocyte-specific deletion led to a reduced hypertrophic response 
in an Ang II infusion model [145]. 
Figure 2.5: RhoA signaling in cardiovascular cells 
The Scheme illustrates signaling pathways for p63RhoGEF, p115RhoGEF, LARG and PDZRhoGEF leading to RhoA 
activation. GPCRs for phenylephrine (PE), angiotensin (AngII), endothelin (ET-1) and thromboxane (TXA2) 
couple through Gαq/11 and or Gα12/13 to activate various RhoGEFs. Activated RhoGEFs differently or 
synergistically catalyze GTP loading and activation of RhoA and downstream effector Rho kinase (ROCK). Figure 
was adapted with modifications from Momotami and Somlyo, 2012
[146]
.
Interestingly, inhibition of the Gα12/13-pathway by cardiomyocyte-specific deletion of LARG, 
which regulates RhoA via Gα12/13-activation, exhibited a beneficial outcome, as these mice 
developed no hypertrophy, less fibrosis and were protected from cardiac decompensation 
[131]. On the other side, it was shown that expression of RhoA can have a cardioprotective 
effect on cardiomyocytes in a model of ischemia/reperfusion (I/R), as the infarct area was 




2.5.1 Structure and function of RhoGEFs 
RhoGTPases are activated by Rho guanine nucleotide exchange factors (RhoGEFs), which 
accelerate the GDP/GTP exchange. To date, about 69 GEFs for Rho family members are 
described. Several GEFs for RhoGTPases are expressed preferentially in specific cells and 
tissues, suggesting cell- and tissue-specific effects of these GEFs.  
Based on the sequence homology with the central part of the Dbl oncogene from diffuse B-
cell-lymphoma cells, the first identified mammalian RhoGEF was designated Dbl [148, 149]. 
Proteins of the Dbl family of RhoGEF share a typical tandem motif consisting of a Dbl 
homology (DH) and a pleckstrin homology (PH) domain [150]. The DH domain interacts 
directly with the RhoGTPase and is responsible for the catalytic activity that accelerates the 
exchange of GDP for GTP on the RhoGTPase [110]. In tandem with the DH domain is found a 
pleckstrin homology (PH) domain of 140 amino acids, which modulates nucleotide exchange 
by the DH domain [151, 152]. By binding to phosphoinositides, PH domains have been 
proposed to localize Dbl proteins to plasma membranes and to regulate their GEF activity 
through allosteric mechanisms [110]. The RhoGEF PH domain can promote the GEF activity, 
when it is directly in contact to the bound GTPase or vice versa. It can even inhibit the GEF 
activity by masking the binding site of the DH domain [153]. In some RhoGEFs, the PH 
domain appears to autoinhibit the intrinsic GEF activity of the DH domain [154-156]. Besides 
this tandem motif, RhoGEFs often contain one or more additional signal transduction 
domains and additional PH domains [150, 157] that might play a role for the localization or 
control of the GEF activity [158].  
Most of the Rho GEFs isolated so far display activity on RhoGTPases, at least in vitro. Some 
RhoGEFs appear to exhibit in vivo selectivity for a specific GTPase (e.g. Lbc for Rho,Tiam1 for 
Rac, and FGD1 for Cdc42), whereas others seem to act on several GTPases (e.g. Vav, Dbl and 
Trio) [150, 158]. Apart from receptor tyrosine kinases, a large variety of G-protein-coupled 
receptors (GPCRs) are upstream regulators of Rho proteins [112, 159], particularly those 
coupling to the G12/13 and Gq/11 types of heterotrimeric G proteins [160]. With respect to the 
RhoGTPase RhoA, RhoA-specific GEFs, including p115RhoGEF, PDZRhoGEF and leukemia-
associated RhoGEF (LARG) have been identified [161], which all possess a RGS homology 
domain for direct interaction with and activation by G12/13 proteins. 
In contrast to RhoGTPases, many RhoGEFs are low-abundance proteins with restricted 
expression patterns and therefore designated to be the limiting factors in the respective 
signaling cascades. In 2002, a novel member of the Dbl-family of GEFs that specifically 




The nucleotide exchange factor p63RhoGEF, encoded by the gene ARHGEF25, was originally 
identified by Souchet in 2002. The authors detected the human transcript in 
oligodendrocytes and astrocytes of the brain and in cardiomyocytes in the heart. 
Immunofluorescence analysis revealed that it is localized in the sarcomeric I-band of 
cardiomyocytes. Based on its homologues sequence (Figure 2.6), it could be classified as a 
member of the Dbl family of RhoGEFs [162]. p63RhoGEF is a protein of 580 amino acids and 
thus has a protein weight of approximately 63 kDa. It was further reported that p63RhoGEF 
specifically catalyzes the GDP/GTP exchange for RhoA, but is not involved in the activation of 
Rac1 or Cdc42 [162].  
The crystal structure of the Gαq-p63RhoGEF-RhoA complex revealed that p63RhoGEF directly 
binds to the activated Gαq/11, but not Gα12/13 subunits of heterotrimeric G proteins linking 
Gαq/11-signaling to RhoA activation. Hence, it was postulated that p63RhoGEF is regulated by 
G-protein-coupled receptors (GPCRs). Further biochemical studies revealed that p63RhoGEF
is activated by relieving the autoinhibition of the catalytic DH domain by the PH domain 
[160, 163, 164]. Moreover, p63RhoGEF is competing with PLC-β for the binding to Gαq/11, as 
it was shown that overexpression of p63RhoGEF reduced the activation of PLC-β and hence 
IP3 production [160]. 
Figure 2.6: Structure of p63RhoGEF 
The scheme shows the structure of p63RhoGEF and respective binding domains for interaction. N-ter. = N-
terminal part, DH = Dbl homology domain, PH = pleckstrin homology domain, C-ter. = C-terminal part. The 
numbers refer to the sequence in amino acids. 
Apart from p63RhoGEF, Trio and Duet, a splice variant of the GEF Kalirin, were identified as 
two other guanine nucleotide exchange factor, which contain a p63RhoGEF homologues 
sequence including the RhoA specific DH/PH domain. Like p63RhoGEF, these GEFs showed 
an interaction with Gαq/11 and are thereby involved in RhoA-dependent SRF activation. In 
addition, an N-terminally truncated variant of p63RhoGEF, termed GEFT, was identified as a 
splice variant derived from the same gene and lacking the first 106 amino acids [165]. It was 
reported that this splice variant specifically activates Rac1 and Cdc42 [166], but later studies 
showed only activation of RhoA [160, 163, 164]. 
Moreover, Goedhart et al. demonstrated that p63RhoGEF located at the plasma membrane 
due to palmitoylation [152] interacts efficiently with Gαq, while the cytoplasmatic GEFT does 
N-ter.  DH PH C-ter.
RhoA binding
1   149    338   492   580 
Gαq/11 binding  
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not, as it lacks the N-terminal lipidation motif [167]. This was further supported by van Unen, 
showing that restriction to the plasma membrane is sufficient for p63RhoGEF activity to 
mediate RhoA-dependent actin polymerization [168]. With respect to cardiac cells, for the 
first time it was shown in smooth muscle cells of the rat aorta that p63RhoGEF is specifically 
mediating the Ang II activation from activated AT1R to Gαq to RhoA/ROCK activation [169] via 
binding of the α subunit of Gαq [153, 170]. 
Recently, evidence for the relevance of p63RhoGEF within RhoA/ROCK signaling in cardiac 
disease of hypertensive patients was reported [171]. The authors compared the level of 
p63RhoGEF and the phosphorylation status of the direct ROCK downstream target myosin 
phosphatase target protein 1 (MYPT-1) and found that both were up-regulated in 
hypertensive patients. In contrast, in patients with the Bartter´s and Gitelman syndrome, a 
human model opposite to hypertension, level of p63RhoGEF and MYPT-1 were decreased 
[171]. The results of this clinical study together with the in vitro data support the importance 
of p63RhoGEF in Ang II-mediated RhoA signaling in the context of cardiovascular remodeling.
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3 Previous results and aims of the project 
As described the first time by Souchet et al. in 2002, the nucleotide exchange factor 
p63RhoGEF was found to be expressed in heart and brain tissue [162]. Initial experiments 
performed in our group aimed to determine its distribution amongst the different cells 
within the cardiac tissue. Immunohistochemistry stainings of neonatal and adults rat hearts 
using a specific antibody revealed that p63RhoGEF is predominantly expressed in cells 
located in and around blood vessels and cells residing in the interstitium (Figure 3.1). 
Amongst the different heart cells it was found that p63RhoGEF is highly expressed in smooth 
muscle cells followed by cardiac fibroblasts and to a lesser extent in cardiomyocytes 
(Wuertz, C., Dissertation "Die Rolle des Guaninnukleotid-Austauschfaktors p63RhoGEF in 
Physiologie und Pathophysiologie glatter Gefäßmuskelzellen", 2011). 
Figure 3.1: Expression of p63RhoGEF in the heart 
Paraffine sections of neonatal and adult rat hearts were stained with a specific p63RhoGEF antibody. Scale bar 
200 µm. (Wuertz, C., Dissertation "Die Rolle des Guaninnukleotid‐Austauschfaktors p63RhoGEF in Physiologie 
und Pathophysiologie glatter Gefäßmuskelzellen", 2011) 
In further experiments the endogenous function of p63RhoGEF was investigated in rat 
smooth muscle cells of the aorta showing that p63RhoGEF mediates the Ang II-dependent 
RhoA activation and is involved in the regulation of contractility. Moreover, it was 
Adult heartNeonatal heart
Adult heart longitudinal Adult heart transversal
200 µm 200 µm
200 µm 200 µm
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demonstrated that p63RhoGEF is a specific factor of the Ang II-induced proliferation in these 
cells [169]. 
Preliminary data in NRCM also demonstrated that overexpression of p63RhoGEF led to 
endothelin I (ET-1)-associated RhoA activation resulting in an enhanced CTGF secretion. 
Consequently, the role of p63RhoGEF in cardiac fibroblasts should be closer investigated. 
First experiments in neonatal rat cardiac fibroblasts illustrated that upon treatment with 
well-known cardiovascular GPCR agonists, Ang II was the only efficient activator for RhoA in 
NRCF, while ET-1 and phenylephrine (PE) did not increase the RhoA-GTP level (Figure 3.2 A). 
Figure 3.2: Impact of p63RhoGEF expression on the Ang II-dependent RhoA activation 
(A) Serum-starved NRCF were treated with 100 nM ET-1, 10 µM PE or 100 nM Ang II for 30 sec and RhoA
activation was determined by pulldown assay and subsequent immunoblot analysis. Ang II-induced RhoA 
activation is given relative to unstimulated control as means ± SEM, n=15, *p < 0.05 vs. control. (B) NRCFs were 
transduced with Ad-EGFP, Ad-p63RhoGEF or Ad-p63ΔN as well as Ad-shEGFP, Adsh-p63 and Ad-EGFP for 24 h 
and 100 nM Ang II was added for 30 sec. By pulldown assay and immunoblot RhoA activation was evaluated. 
p63RhoGEF expression was analyzed via a c-myc antibody. Representative immunoblots are shown, n = 2-3.  
Experiments were performed by Christiane Vettel, Medical Faculty Mannheim, Institute for Experimental and 
Clinical Pharmacology and Toxicology Mannheim) (Vettel, C. Dissertation “Charakterisierung des 
Guaninnukleotid‐Austauschfaktors p63RhoGEF als neuen Mediator der Gαq/11‐induzierten RhoA‐
Aktivierung”, 2009) 
Moreover, the impact of p63RhoGEF expression on the Ang II-dependent RhoA activation 
was examined by adenoviral infection with constructs resulting either in an overexpression 
of p63RhoGEF, a downregulation by shp63 or blocking of the Gαq/11-pathway by the use of 
the p63ΔN construct. Pulldown assays of RhoA-GTP with stimulation of Ang II revealed an 
increase in RhoA activation when p63RhoGEF was overexpressed. In contrast, 
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downregulation of p63RhoGEF expression and blocking with the p63ΔN resulted in a 
decrease of RhoA-GTP level, clearly underlining the p63RhoGEF-dependent regulation of the 
GTPase RhoA in cardiac fibroblasts (Figure 3.2 B). 
Figure 3.3: p63RhoGEF is involved in the regulation of CTGF 
NRCF were transduced with Ad-EGFP (A), Ad-p63RhoGEF (B) and Ad-p63ΔN (C) for 24 h and stimulated with 
100 nM Ang II for another 24 h. Cell lysates and conditioned medium were collected and the amounts of 
intracellular and secreted CTGF were determined by immunoblot. In addition the expression of p63RhoGEF was 
analyzed. Representative immunoblots are shown. Values are given as means ± SEM, normalized to tubulin and 
relative to EGFP as control, *p < 0.05 vs. EGFP, 
#
p < 0.05 vs. EGFP + Ang II, n = 5-12.
Experiments were performed by Cleo Weis, Medical Faculty Mannheim, Institute for Experimental and Clinical 
Pharmacology and Toxicology Mannheim. (Weis, C., Dissertation “Charakterisierung und zelluläre Lokalisation 
des Guaninnukleotid‐Austauschfaktors p63RhoGEF als Mediator der Ang II‐induzierten Sekretion des 
profibrotischen Faktors CTGF in neonatalen kardialen Fibroblasten“, 2013) 
- + - +
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To elucidate the effect of p63RhoGEF expression downstream of the GPCR-dependent RhoA 
activation, expression of the connective tissue growth factor (CTGF) was investigated. The 
overexpression of p63RhoGEF increased the secretion of CTGF with a 4-fold change upon 
Ang II stimulation, while the intracellular CTGF amount was only slightly affected (Figure 3.3 
A).  
According to this, downregulation of p63RhoGEF led to a 70% decrease in secreted CTGF 
compared to the stimulated control. No significant change in the amount of intracellular 
CTGF was observed (Figure 3.3 B). Similar results were obtained with the blocking p63ΔN 
construct regarding the secretion of CTGF. In this case, also a decrease of intracellular CTGF 
upon Ang II stimulation was detected (Figure 3.3 C), suggesting that the expression and 
secretion of CTGF is p63RhoGEF-dependent, but its expression also involves other 
downstream factors of the Gαq/11-signaling. 
In addition, qPCR studies confirmed the observed effects also on mRNA level (data not 
shown), demonstrating that p63RhoGEF is regulating the Ang II-induced CTGF expression. 
In summary, p63RhoGEF expression regulates the Ang II-dependent activation of RhoA as 
well as CTGF expression on mRNA level and shows a more pronounced influence on the 
secretion of this factor.  
Based on these previous data and given the fact that RhoA and CTGF are involved in 
pathomechanisms of cardiac diseases, following aims of this thesis were formulated:   
• Further establishment of  the influence of p63RhoGEF expression within the
Gαq/11-p63RhoGEF-RhoA signaling cascade in a context of auto- and paracrine
signaling in cardiac fibroblasts with a focus on the secretion factor CTGF in 2D
cell culture and 3D models
• Investigation of the relevance of p63RhoGEF expression and its genetic
deletion in the heart  under healthy and load-induced disease conditions
• Determination of the role of p63RhoGEF expression and its genetic deletion in
adult cardiac fibroblast
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4 Material and Methods 
4.1 Material 
4.1.1 Consumables 
Table 4.1: Consumables 
Article Specification/Type Company 
Cell culture flasks T25, T75, T175 Sarstedt 
Cell culture dishes 6, 10, 15 cm 
Sarstedt/ Greiner Bio 
One  
Cell scrapers 1.7 cm blade Sarstedt 
Cover slips 18 mm Ø, Menzel Thermo Scientific 
Cover slides 24 x 50 mm, Menzel Thermo Scientific 
Cryotubes 1.8 mL Nunc 
Rat EHM/ECT molds 
Inner diameter 8 mm, 
outer diameter 16 mm, 
depth 5 mm, 
2 molds per 50 mm glass 
dish  
Internal production of 
the Institute 
Embedding molds mega cassette 40 x 28 x 12 mm Bio optica 
Embedding molds Peel-a-way 22 x 22 x 20 mm Polysciences 
Filter syringes Non-pyrogenic, 0.2 μM Sarstedt 
Filtration sets 250, 500, 1000 mL, 0.22 μM Corning 
Flexitip pipette tips 0.5-200 μl Peqlab 
gentleMACS C tubes Miltenyi Biotec 
gentleMACS Dissociator Miltenyi Biotec 
Micro-Amp optical adhesive films PCR compatible Applied Biosystems 
Micro-Amp optical reaction plates 384-well Applied Biosystems 
Microsope slide 
25 x 75 x 1 mm, 
Menzel Superfrost Plus 
Thermo Scientific 
Multi-well cell culture plates 6, 12, 24, 96-well Greiner Bio One 
Nitrocellulose membrane, Protran Pore size 0.2 μM 
Whatman,  
GE Healthcare 
PCR reaction tubes 0.2 mL Sarstedt 
Pipette tips 10, 100, 200,1000 μl Sarstedt 
Pipette tips with filters 10, 100, 200, 1000 μl 4titude, Starlab 




Reaction and centrifuge tubes  15, 50 mL  Greiner Bio One  
Reaction tubes  0.5, 1.5, 2 mL  Sarstedt  
Serological pipettes  1, 2, 5, 10, 25 mL  Sarstedt  
Wide opening, serological pipettes  10 mL  Falcon  
 
4.1.2 Chemicals and reagents 
Table 4.2: Chemicals and reagents 
Chemicals and reagents Company 
Acetic acid Carl Roth 
Acrylamide rotiphorese gel 30 solution  
(30% acrylamide/0.8% bisacrylamide, mixing ratio 37.5:1)  
Carl Roth  
Agarose  AppliChem  
Ammonium persulfate (APS)  AppliChem  
Angiotensin II, human (Ang II)  Sigma-Aldrich  
Aqua B. Braun  Braun  
Ascorbic acid  AppliChem 
Atipamezole (Revertor) CP-Pharma 
Bromophenol blue  Sigma-Aldrich  
BSA, Fraction V Sigma-Aldrich 
Buprenorphine (Temgesic) RB Pharmaceuticals 
Calcium chloride (CaCl2) AppliChem 
CCG-1423 Santa Cruz 
Chicken embryo extract (CEE) Self-made 
Collagen Type 1 (rat tail) Corning 
cOmplete Protease Inhibitor Cocktail Tablets Roche Applied Science 
Dimethylsulfoxide (DMSO)  Sigma-Aldrich  
DMEM (1g/L glucose, 3.7 g/L NaHCO3) Cat-No. F 04150 Biochrom 
DMEM/F12 Glutamax, high glucose Cat-No. 31331-028 Life Technologies  
DMEM Glutamax, 1 g/L glucose, pyruvate Cat-No. 21068-028 Life Technologies  
DMEM Glutamax, 4.5 g/L glucose Cat-No. 42430-025 Life Technologies  
DMEM (powder) Cat-No. 52100-039 Life Technologies  
Dulbecco´s Phosphate-buffered saline (DPBS) without Ca2+, Mg2+ 
Cat-No. 14190-094 
Life Technologies  
DNase I, type V  Merck  
Ethanol, absolute  J.T. Baker  
Ethidium bromide  Sigma-Aldrich  




Formaldehyde (37%) (FA) Merck  
Formamide  Sigma-Aldrich  




GeneRuler 100 bp DNA ladder  Thermo-Scientific  
Glucose  AppliChem  
Glycerol  AppliChem 
Glycine  AppliChem  
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)  Carl Roth  
HEPES-buffered saline solution  Lonza  
Horse serum Life Technologies 
Igepal CA-630  Sigma-Aldrich  
Isoflurane Abbvie 
Isopropanol  Carl Roth  
Liberase DH Roche Applied System 
Lipofectamine Invitrogen 
Magnesium sulphate monohydrate (MgSO4.H2O) AppliChem 
Matrigel basement membrane matrix BD Biosciences 
Medetomidine (Cepetor) CP-Pharma 
Metamizole (Novaminsulfon) Ratiopharm 
Methanol  Carl Roth  




Non-essential amino acids (NEAA) (100x)  Life Technologies  
O.C.T. Compound Tissue Tek Sakura  
Paraformaldehyde (PFA)  Self made  
Paraplast Leica 
Penicillin/streptomycin (P/S) (100x)  Life Technologies  
PhosSTOP Phosphatase Inhibitor Cocktail Tablets Roche Applied Science 
Ponceau S  Sigma-Aldrich  
Potassium chloride (KCl) AppliChem 
Potassium dihydrogen phosphate (KH2PO4) AppliChem 
Precision plus protein Kaleidoscope, prestained protein standard  Bio-Rad 
RNaseZap, RNase decontamination solution Ambion 
Roti-block (10x)  Carl Roth  
Roti-immunoblock (10x)  Carl Roth  
Roti-mark standard, protein molecular weight marker  Carl Roth  
Sodium chloride (NaCl)  AppliChem  
Sodium dodecyl sulfate (SDS)  AppliChem  
Sodium hydrogen phosphate dihydrate (Na2HPO4*2H2O)  AppliChem  
Sodium hydroxide (NaOH)  AppliChem  
Super signal west femto Thermo Scientific 
Taurin Roth 
Tetramethylethylenediamine (TEMED)  Merck  
peqGold TriFast peqlab 
Tris ultrapure (Tris base)  AppliChem  
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Triton X-100 Carl Roth 
Trypan blue Fluka 
Tween 20 Carl Roth 
4.1.3 Buffers and solutions 
Table 4.3: Buffers and solutions 
Immunoblotting 
Lysis buffer (GST-fish buffer) 
6 g Tris  
8.8 g NaCl  
0.4g MgCl2  
100 mL glycerol (v/v)  
10 mL Igepal CA-630 (v/v) 
ad 1 L with distilled water 
10x PhosSTOP Phosphatase Inhibitor Cocktail 
1 tablet  
solved in 1 mL distilled water 
7x cOmplete Protease Inhibitor Cocktail 
1 tablet  
solved in 1.5 mL distilled water 
4x SDS loading buffer (Laemmli buffer) without 
glycerol   
10 mL β-mercaptoethanol  
5.7 g SDS  
3.6 g Tris  
0.2 g bromophenol blue 
ad 100 mL with distilled water 
4x SDS loading buffer (Laemmli buffer) with 
glycerol   
50 mL glycerol  
10 mL β-mercaptoethanol  
5.7 g SDS  
3.6 g Tris  
0.2 g bromophenol blue 
ad 100 mL with distilled water 
5x SDS-PAGE electrophoresis buffer 
15.1 g Tris  
94 g glycine  
5 g SDS  
ad 1 L with distilled water 
pH 8.3 HCL  
12% SDS-polyacrylamide gel (50 mL) 
16.5 mL distilled water  
20 mL acrylamide rotiphorese gel 30 
solution  
12.5 mL 1.5 M Tris (pH 8.8 with HCl)  
0.5 mL 10% SDS  
0.5 mL 10% APS  
0.02 mL TEMED  
15% SDS-polyacrylamide gel (50 mL) 
11.5 mL distilled water  
25 mL acrylamide rotiphorese gel 30 
solution  
12.5 mL 1.5 M Tris (pH 8.8 with HCl)  
0.5 mL 10% SDS  
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0.5 mL 10% APS 
0.02 mL TEMED  
5% SDS-polyacrylamide gel (20 mL) 
13.6 mL distilled water  
3.4 mL acrylamide rotiphorese gel 30 
solution  
2.5 mL 1 M Tris (pH 6.8 with HCl)  
0.2 mL 10% SDS  
0.2 mL 10% APS  
0.02 mL TEMED  
10% SDS 
10 g SDS  
ad 100 mL with distilled water 
10% APS 
1 g APS  
ad 10 mL with distilled water 
Immunoblot buffer 
3.02 g Tris  
14.4 g glycine  
200 mL methanol  
ad 1 L with distilled water 
10x Tris-buffered saline buffer (10x TBS) 
12.12 g Tris  
87.65 g NaCl 
ad 1000 mL with distilled water 
pH 7.4 with HCl  
Tris-buffered saline buffer with tween 20 (TBS-T) 
100 mL 10x TBS  
1 mL tween 20 
ad 1 L with distilled water 
Ponceau S 
3 mL acetic acid  
0.2 g Ponceau S powder  
ad 100 mL with distilled water 
1x Roti-block 
5 mL 10x Roti-block 
ad 50 mL with distilled water 
Immunofluorescence (IF) 
4% paraformaldehyde (PFA) 
40 g paraformaldehyde  
200 μl 10 N NaOH  
100 mL 10x PBS  
up to 1 L distilled water  
sterile filtered 
pH adjusted to 7.4 with HCl 
0.2% Triton 
1 mL 10x Triton  
ad 50 mL with PBS 
1x Roti-immunoblock 
5 mL 10x Roti-immunoblock  
ad 50 mL with distilled water 
Genotyping 
Lysis buffer 
0,05 g NaOH 
0.003 g EDTA 
ad 50  mL with distilled water 
pH 12.0 
Neutralization buffer 0.32 g Tris/HCl 




ad 50  mL with distilled water 
pH 5.0 
 
Formaldehyde (FA) agarose gel electrophoresis 
1.2% FA gel   
1.2 g agarose  
10 mL 10x FA gel buffer  
ad 100 mL RNase-free water  
1.8 mL 37% FA  
3 μl ethidium bromide (10 mg/mL) 
10x FA gel buffer   
41.46 g MOPS  
6.8 g sodium acetate  
2.9 g EDTA  
ad 1 L distilled water  
pH 7.0 with NaOH  
1x FA gel running buffer  
100 mL 10x FA gel buffer  
20 mL 37% FA  
ad 1 L RNase-free water  
5x RNA loading buffer  
16 μl saturated aqueous bromophenol 
blue solution  
80 μl 500 mM EDTA (pH 8.0 NaOH)  
720 μl 37% FA  
2 mL glycerol anhydrous  
3.084 mL formamide  
4 mL FA gel buffer  
ad 10 mL RNase-free water  
DNA agarose gel electrophoresis 
1% DNA agarose gel  
0.5 g agarose powder  
50 mL 1x TAE buffer  
2 μl ethidium bromide (10 mg/mL)  
50x TAE buffer  
242.28 g Tris  
57.1 mL acetic acid  
200 mL 0.25 M EDTA (pH 8.0 with 
NaOH)  
ad 1 L with distilled water  
1x TAE buffer 
200 mL 50x TAE buffer 
ad 10 L with distilled water  
Cell isolation 
Basal buffer (for isolation of AMCF) 
0.2 mL DNase I (2000 U/mg) 
8 g NaCl 
0.37 g KCl 
0.1 g Na2HPO4 
6 g HEPES 
2 g glucose 
ad 1 L with distilled water 
pH 7.3  
sterile filtered 
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Digestion buffer (for isolation of AMCF) 
0.5 g BSA 
80 mg Collagenase I (245 U) 
120 µL Dispase (5000 U/mg) 
240 µL 2.5% Trypsin 
376 µL 0.1 M CaCl2 
ad 50 mL basal buffer 
10x Perfusion buffer (for isolation of AMCF by 
Langendorff) 
65.922 g NaCl 
3.506 g KCl 
816.6 mg KH2PO4 
1.0679 g Na2HPO4 * 2 H2O 
2.958 g MgSO4 * 7 H2O 
10.08 g NaHCO3 
10.01 g KHCO3 
23.831 g HEPES 
ad 1 L with distilled water 
sterile filtered 
pH 7.4 with 5 N NaOH 
1x Perfusion buffer (for isolation of AMCF by 
Langendorff) 
50 mL 10x perfusion buffer 
0.5 g BDM 
0.5 g glucose 
1.8 g Taurin 
0.5 g NaHCO3 
ad 0.5 L 
Digestion buffer (for isolation of AMCF by 
Langendorff) 
29.6 mL 1x perfusion buffer 
3,75 µL CaCl2 (100mM) 
300 µL 2.5% trypsin 
300-450 µL liberase
Stop buffer 1 
2.5 mL 1x perfusion buffer 
0.025 g BSA 
1.25 µL CaCl2 
Stop buffer 2 
4,75 mL 1x perfusion buffer 
0.05 g BSA 
1.9 µL CaCl2 
Calcium- and bicarbonate- free Hanks with HEPES 
(CBFHH)   
40 mL NaCl stock (3.42 M) 
10 mL KCl stock (0.54 M) 
10 mL MgSO4 stock (0.081 M) 
10 mL KH2PO4 stock (0.044 M) 
10 mL Na2HPO4*2 H2O stock (0.034 M) 
10 mL glucose stock (0.56 M) 
100 mL HEPES stock 
ad 1 L with distilled water 
sterile filtered 
pH 7.4 with NaOH 
HEPES 
47.66 g HEPES 
ad 1 L with distilled H2O 
pH 7.4 with NaOH 
sterile filtered 
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DNase I stock solution 
100 mg DNase I type V 
ad 100 mL distilled water 
0.4% Trypan blue 
0.4 mg trypan blue  
ad 100 mL distilled water 
Contraction experiments 
Calcium-free Tyrode's solution 
40 mL stock I  
38 mL stock II 
20 mL stock III  
1 g glucose  
100 mg ascorbic acid 
ad 1 L distilled water  
Stock I (0.2 mM CaCl2) 
175 g NaCl 
10 g KCl 
25 mL MgCl2 
2.22 mL CaCl2 
ad 1 L with distilled water 
Stock II 
50 g/L NaHCO3 
ad 1 L with distilled water 
Stock III 
5.8 g/L Na2HPO4 
ad 1 L with distilled water 
0.02 M CaCl2 
0.11 g CaCl2 
ad 50 mL with distilled water 
10x DMEM 
13.3 mg DMEM (powder) 
ad 10 mL with distilled water 
sterile filtered 
2x DMEM 
1 mL 10x DMEM 
1 mL Horse serum 
0.2 mL CEE 
0.1 mL Pen/Strep 
Ad 5 mL with distilled water 
sterile filtered 
4.1.4 Cell culture media 
Table 4.4: Cell culture media 
Fibroblast growth medium (NRCF) 
DMEM GlutaMAX, 4.5 g/L glucose 
10% FCS , 1%  Pen/Strep (100x)  
Fibroblast growth medium (AMCF) 
DMEM/F12 GlutaMAX, high glucose 
10% FCS, 1% Pen/Strep (100x) 
100 µM ascorbic acid 
Non-cardiomyocyte medium (NKM) 
DMEM GlutaMAX, 1 g/L glucose  
10% FCS (heat inactivated at 56°C for 30min) 
1% Pen/Strep (100x) 
Serum-free medium 
DMEM GlutaMAX, 1 g/L glucose 
10% FCS, 1% Pen/Strep (100x) 





DMEM, 1g/L glucose, NaHCO3,  
11.6% Horse serum 
2.3% CEE 
1% Pen/Strep (100x) 
 
4.1.5 Kits 
Table 4.5: Kits 
Kit Application Company 
Dual-Luciferase reporter assay 
system 
Detection of luminescence Promega 
5x HOT FIREPOL EvaGreen qPCR Mix 
Plus  
qRT-PCR  Solis Biodyne  
GoTaq green master mix  PCR  Promega  
G-LISA RhoA Activation Assay 
Detection of GTP-bound RhoA by 
luminescence 
Cytoskeleton 
Lumi-light western blotting 
substrate  
Chemiluminescence protein blot 
visualization  
Roche  
Neonatal Heart Dissociation Kit, 
mouse and rat 




Revert Aid First Strand cDNA 
Synthesis Kit  
RNA reverse transcription into cDNA  
Thermo-
Scientific  
RNeasy Mini Kit Total RNA isolation  Qiagen  
Super signal west femto maximum 
sensitivity substrate  






Table 4.6: Enzymes 
Enzyme Company 
Collagenase I (245 U) Worthington 
Dispase (5000 U) Corning 
Liberase DH Roche Applied Science 
Trypsin-EDTA 0.05%  Life Technologies  
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4.1.7 Antibodies 




Source Type/Clone Cat. No. Company 
IB IF 







































c-myc 1:200 1:150 rabbit 
polyclonal/ 
A14 










CTGF 1:50 1:200 goat 
polyclonal/ 
L-20
















































Western Cocktail I  
(P-p90RSK, P-Akt, P-


































sc-418 Santa Cruz 

































Table 4.8: Horseradish peroxidase (HRP)-conjugated secondary antibodies for immunoblotting 
Secondary antibody (HRP-
coupled) against  
Dilution Source Catalogue No. Company 
Goat IgG 1:10000 Donkey sc-2020 Santa Cruz 
Mouse IgG 1:10000 Rabbit A9044 Sigma-Aldrich 
Rabbit IgG 1:40000 Goat A9169 Sigma-Aldrich 
Table 4.9: Fluorophore-conjugated secondary antibodies for immunofluorescence 
Secondary 
antibody against 

















Goat A-11004 Life Technologies 












Goat A-21070 Life Technologies 
Table 4.10: Fluorescence-labeled cell dyes 
Fluorescent dyes Stock concentration Dilution Company 
DAPI 1 mg/mL 1:1000 Roche 
FITC-phalloidin 0.5 mg/mL 1:1000 Sigma-Aldrich 
TRITC-phalloidin 0.5 mg/mL 1:1000 Sigma-Aldrich 
Wheat germ agglutinin (WGA), 
AlexaFluor 488 conjugate  
1 mg/mL 1:200 Life Technologies 
Wheat germ agglutinin (WGA), 
AlexaFluor 647 conjugate  
1 mg/mL 1:200 Life Technologies 






Table 4.11: Designed qRT-Primer used for endpoint PCR and qRT-PCR 




Forward CCA ATG AGT ACC GCG TGA A 57.5 °C 
Reverse ACA GTC ATG CCG GGA TGA T 57.5 °C 
ANP (Nppa) 
Forward CAT CAC CCT GGG CTT CTT CCT 63.2 °C 
Reverse TGG GCT CCA ATC CTG TCA ATC 61.2 °C 
β-MHC 
Forward ATG TGC CGG ACC TTG GAA 60 °C 
Reverse CCT CGG GTT AGC TGA GAG ATC A 60 °C 
Biglycan 
Forward CTG AGG GAA CTT CAC TTG GA 58.4 °C 
Reverse CAG ATA GAC AAC CTG GAG GA 58.4 °C 
BNP (Nppb) 
Forward AAG TCC TAG CCA GTC TCC AGA GC 66.6 °C 
Reverse CTT CAG TGC GTT ACA GCC CAA AC 64.6 °C 
Calp1 
Forward CCA GCA TGG CCA AGA CAA AAG 61.2 °C 
Reverse GGA TCA TAG AGG TGA CGC CG 62.5 °C 
Calsequestrin 
Forward GCC CAA CAG TGA AGA GGA G 59.5 °C 
Reverse TCT AAG AAC TCA TAG CCA TCA GG 60.9 °C 
CD31 
Forward AAC CCG TGG AGA TGT CCA GGC CAG C 64.4 °C 
Reverse ACA CCG TCT CTG TGG CTC TCG TTC CC 64.2 °C 
Col1a1 
Forward ACG CCA TCA AGG TCT ACT GC 60.5 °C 
Reverse ACT CGA ACG GGA ATC CAT CG 60.5 °C 
Col3a1 
Forward CCATGACTGTCCCACGTAAGCAC 66.6 °C 
Reverse GGAGGGCCATAGCTGAACTGAAAAC 67.4 °C 
CTGF 
Forward CCG GGT TAC CAA TGA CAA TA 56.4 °C 
Reverse CAC ACC CCA CAG AAC TTA GC 60.5 °C 
Desmin 
Forward GGC GAG GAG AGC AGG ATC AA 62.5 °C 
Reverse CTG TGT AGC CTC GCT GAC AAC 63.2 °C 
FSP-1/S100A4 
Forward TTC AGC ACT TCC TCT CTC TTG GT 62.9 °C 
Reverse TTC ATC TGT CCT TTT CCC CAG GA 62.9 °C 
LGALS3 
Forward ATG CTG ATC ACA ATC ATG G 53.0 °C 
Reverse CCT GAA ATC TAG AAC AAT CC 54.3 °C 
MMP2 
Forward TCCCCCGATGCTGATACTGA 60.5 °C 
Reverse CCGCCAAATAAACCGGTCCTT 61.2 °C 
PBGD 
Forward CCT GAA ACT CTG CTT CGC TG 60.5 °C 
Reverse CTG GAC CAT CTT CTT GCT GAA 59.5 °C 
p63RhoGEF 
Forward AGG GGA GGT GTC CAG AGT GCT G 67.9 °C 
Reverse CTG GCC TGA CAG GGA GGA GTG T 67.9 °C 
RhoA 
Forward GTA GAG TTG GCT TTA TGG GAC AC 62.9 °C 
Reverse TGG GAT GTT TTC TAA ACT ATC AGG G 62.5 °C 
sm22 
Forward GTG AGC CAA GCA GAC TTC CAT 61.2 °C 
Reverse TGT TGA GGC AGA GAA GGC TTG 61.2 °C 
4 Material & Methods 
34 
sm-actin 
Forward GAG AAG CCC AGC CAG TCG 60.8 °C 
Reverse TCC AAC CAT TAC TCC CTG ATG TCT 63.3 °C 
sm-MHC 
Forward GGT GAA CGC CCT CAA GAG CA 62.5 °C 
Reverse CCT CGT TTC CTC TCC TGG TG 62.5 °C 
TGF-β 
Forward AGA GCC CTG GAT ACC AAC TA 58.4 °C 
Reverse TGT TGG TTG TAG AGG GCA AG 58.4 °C 
VE-Cadherin 
Forward ACT ATG TGG GAA AGA TCA AGT C 58.4 °C 
Reverse GAT CTT GCC AGC AAA CTC TC 58.4 °C 
Table 4.12: Primer for genotyping 
Gene Primer Sequence (5´ to 3´) 
Annealing 
Temperature (°C) 
Lox1 Forward CTG GAA TTG CTG CCA GAC TGT AGC 66.9 °C 
SDL2 Reverse CCA CCG CAG CCA AAC TTC TC 62.5 °C 
Nrev Reverse ATC CTG AGC ATA GCA CAG ATC TGC GG 69.5 °C 
4.1.9 Plasmids 
Table 4.13: Plasmids 
Name Plasmid Company 
pSRE.L Luciferase reporter plasmid 
(“plasmid serum response element luciferase”) 
Invitrogen 
pRL.TK 
Control reporter plasmid 
(“plasmid renilla luciferase thymidine kinase”) 
Invitrogen 
4.1.10 Viruses 
Table 4.14: Viruses 
Virus Sequences 
Ad-CTGF He et al, 1998 
Ad-EGFP EGFP sequence 
Ad-p63RhoGEF c-Myc-tag; human p63RhoGEF sequence aa 1-580; EGFP
Ad-p63ΔN c-Myc-tag; human p63RhoGEF sequence aa 295-580; EGFP





Table 4.15: Animals 
Animal Strain 
Mice Mixed C57/Bl6-J x 129S1 x SvIm-J, inGenious, NY, USA; 
N2 generation of backcrossing on C57Bl/6-J 




Table 4.16: Devices 
Device Model Company 
Autoclave  VX-150  Systec  
Cell counter  Casy  Roche  
Cell counting chamber  Neubauer Labor Optik 
Cell culture incubator  Labotect Incubator C 200  Labotect  
Cell sieve  
Cell dissociation sieve - tissue 
grinder kit (250 μm pore size)  
Sigma-Aldrich  
Centrifuge bench top  Centrifuge 5804 R  Eppendorf  
Centrifuge bench top  PCV-2400 Grant-bio 
Cell culture centrifuge  Centrifuge 5417 R  Eppendorf  
Cell culture centrifuge  Megafuge 3.0R Heraeus 
Chemiluminescence imaging 
system  
ChemiDoc MP  Bio-Rad  
Contraction setup  IOA-5301 FMI 
Cryotome Leica CM3050 S Leica 
Double distilled water system  Milli-Q  Millipore  
Electric power supply and 
control (immunoblotting) 
Powerpac  Bio-Rad  
Electric power supply and 
control 
(agarose gel) 
Powerpac P25T Biometra  
Freezing Container Mr. Frosty Nalgene 
Gel electrophoresis chamber 
(agarose) 
 Peqlab 
Gel electrophoresis chamber 
(immunoblot) 
Mini Protean Tetra Cell 4-gel 
system 
Bio-Rad 
Gel imager  GelDoc Bio-Rad 
Heating block  Thermo mixer compact  Eppendorf  
Heating plate (magnetic) RCT basic 
Janke u. Kunkel IKA 
Labortechnik  
Homogenizer Polytron PT 1600E Kinematica 
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Immunoblot chamber Mini Trans-Blot Cell Bio-Rad 
Inverted fluorescence 
microscope  
Axiovert 200 Zeiss 
Inverted fluorescence 
microscope with climate 
chamber  
Olympus IX 81 Olympus 
Inverted light microscope Primovert Zeiss 
Microplate reader for 
luminescence 
GloMax Luminometer Promega 
Microscope camera CAM-XM10-T-Camera Olympus 
Microscope filter Cy5 BP 635/40 Olympus 
Microscope filter DAPI BP 403/12 Olympus 
Microscope filter EGFP BP 470/20 Olympus 
Microscope filter FITC BP492/18 Olympus 
Microscope filter Texas Red BP 572/23 Olympus 
Microscope objective 20x LUCPLFLN20xPH|0.45 Olympus 
Microscope objective 40x LUCPLFLN40xPH|0.60 Olympus 
Microscope objective 60x PlanApo N60x|1.42 oil Olympus 
Microscope objective 0.8x NeoLumar S Zeiss 
Microscope objective 10x EC Plan-Neofluar|0.3 Zeiss LSM 710 
Microscope objective 20x EC Plan-Neofluar|0.5 Zeiss LSM 710 
Microscope objective 63x Plan-Apochromat|1.4 oil Zeiss LSM 710 
Microtome Leica RM2255 Leica 
Multiparameter cell analyzer Cellavista Roche 
Paraffin embedding machine Leica EG1150H Leica 
pH meter WTW Inolab 
Pipettes Pipetman Gilson 




Pump ME2 Vacuubrand 
Real-time PCR system 
TaqMan 7900HT Fast Real-Time-
PCR System  
Applied Biosystems 
Scale Portable Sartorius 
Shaker (4°C) GFL 3025 GFL 
Shaker Vibramax 100 Heidolph 
Shaker GFL 3016 GFL 
Special accuracy  scale Research M power Sartorius 
Spectrophotometer Nanodrop 1000 peqlab 
Stereomicroscope Stemi 2000 Zeiss 
Stereomicroscope SteReo Lumar V.12 Zeiss 
Stereomicroscope camera AxioCam MRC Zeiss 
Sterile workbench Telstar Bio II A Prettl 
Stimulator STI 08 Current stimulator FMI 
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Stretcher STI 08 Current stimulator FMI 
Thermocycler Mastercycler gradient Eppendorf 
Tissue Lyzer II Qiagen 
UV agarose gel imaging system Gel doc XR Bio-Rad 
UV lamp plate TI 1 Biometra 
Vibratome Leica VT1000S Leica 
Vortexer VF 2 Vortexer 
Janke u. Kunkel IKA 
Labortechnik  
Water bath 1002 GFL 
4.1.13 Software 
Table 4.17: Software 
Software Use/Analysis Company 
Amon32 Analysis of contraction measurement FMI VitroDat 3.52 
AxioVision Rel. 4.8 
Imaging of EHM/ECT tissue and whole heart 
sections 
Zeiss 
BeMon32 Contraction measurement FMI VitroDat 3.52 
Fiji (Image J 5.1) Evaluation of fluorescence images 
National Institutes 
of Health, USA  
GloMax 1.9.2 Luminescence measurement Promega 
GraphPad prism 
5.0  
Statistical calculations/evaluation and graphical 
drawing  
GraphPad 
Image Lab 5.1 
Operating the ChemDoc MP system and for semi-




Operating the ChemDoc MP system and for semi-
quantification of western blots  
Bio-Rad 
SDS 2.4 
Operating the TaqMan 7900HT Fast Real-Time-PCR 
System, and its data analysis  
Applied 
Biosystems 
SoftMax Pro 5.4 Multi-mode microplate reader measurements Molecular Devices 
Vevo2100 1.6.0 Evaluation of Echocardiography measurements Vevo 
Zen2009 Confocal imaging of cells Zeiss 
Xcellence pro 
Operating the Olympus microscopy system for cell 
imaging  
Olympus 
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4.2 Methods 
4.2.1 Animal studies 
4.2.1.1 Animal care and experiments 
Animal care and mouse experiments were carried out in accordance with the guidelines of 
The Institutional Animal Aare and Use Committee of LAVES, the Lower Saxony, Germany, 
State Office for Consumer Protection and Food Safety. Mice were kept on a daily 12 h 
light/dark cycle with water and food ad libitum.  
4.2.1.2 Generation of a global p63RhoGEF-knockout line 
As a first step, a mouse line containing flox sites on the p63RhoGEF allele was generated by 
inGenious Targeting Laboratory, Inc. (New York, USA). Using the Cre/loxP recombination 
system, flox sites with putative start codons were integrated flanking exon 1 and 2 of the 
p63RhoGEF gene located on chromosome 12. At an age of 2 months, heterozygous 
p63RhoGEF wt/flox mice were shipped and mated with each other to obtain homozygous 
p63RhoGEF flox/flox mice. In a second step, these mice were mated with animals of an Ella-Cre-
line, which express the enzyme Cre-recombinase from early embryonic stadium on, enabling 
a general knockout of p63RhoGEF. By expression of the Cre-recombinase, exon 1 and 2 were 
excised at the flanked flox sites resulting in a deletion of the start codon. In order to receive 
siblings with all three combinations of genoytypes (WT, HET, KO) in further F1 generations, 
heterozygous p63RhoGEF WT/- mice were mated with each other.    
Design of p63RhoGEF-knockout line, verification of the knockout and initial matings of the 
founder generation were performed by Dr. Christina Würtz, University Medical Center 
Göttingen. 
All mice experiments as well as isolation of mouse adult cardiac fibroblasts (AMCF) were 
performed using mice from the N2 generation of backcrossing. 
4.2.1.3 Genotyping 
For genotyping, DNA was extracted from tail or ear biopsies via hot-shot method [172]. For 
this, biopsies were incubated with alkaline lysis buffer for 1h at 95 °C. The reaction was 
stopped by adding neutralization buffer, and the extracted DNA was directly used for end-
point PCR as described in section 4.2.3.7. For detection of the full length p63WT allele as 
well as the respective p63KO allele, the following primer combinations were used: 




Table 4.18: Designed primer and fragment sizes for genotyping 
Primer 
combination 
Fragment and size (bp) 
WT HET KO 
Lox 1 x SDL2 345 bp 345 bp no PCR product 
Lox 1 x Nrev no PCR product 591 bp 591 bp 
 
Genotyping was carried out with the support of technical assistant Beate Ramba. 
 
 4.2.1.4 Transverse aortic constriction (TAC) surgery 
Ten to twelve-week-old male and female mice (mixed C57/Bl6-J x 129S1 x SvIm-J 
background) were used for transverse aortic constriction (TAC) or sham surgery.  In this 
process, mice were anesthetized by intraperitoneal (i.p.) injection of Medetomidin 
(0.5 mg/kg) and Midazolam (5 mg/kg), for pain relief Fentanyl (0.05 mg/kg) was injected. The 
aortic arch was exposed via median thoracotomy and a constriction between the first and 
second left carotid artery was created using a 6-0 suture and tied against a 27-gauge needle. 
Sham surgeries were performed in the same way without constriction of the aorta. 
As antagonizing narcotics Atipamezol (2.5 mg/kg) and Flumazenil (0.5 mg/kg) and for post-
procedural pain relief buprenorphine (0.05-0.1 mg/kg) were injected subcutaneously (s.c). In 
addition, all animals received metamizole for pain relief in the drinking water 2 days before 
and 7 days after surgery. Body weight and physical constitution was monitored daily within 
the first week after surgery. 
 
4.2.1.5 Echocardiography 
Echocardiography was performed before and 1, 2 and 5 weeks after TAC or Sham surgery 
under 1% isoflurane anaesthesia with a 30 MHz transducer. Cardiac functional parameters 
were analyzed using the Vevo2100 system (Vevo). Transverse aortic flow velocities were 
measured by pulse-waved Doppler with a 20 MHz transducer 3 days after surgery and 
pressure gradients were calculated. 
 





Figure 4.1: Measurements of echocardiography 
Exemplified analysis of echocardiography using the Vevo2100 software. (A) Cross-sectional heart of a mouse in 
systole. (B) Longitudinal section of a mouse heart in systole. Abbreviations of measured parameters: AWTh = 
Anterior wall thickness, LVID = Left ventricular inner diameter, PWTh = Posterior wall thickness, Area = Area of 
cross-sectional left ventricular lumen, Epi  = Epicardium, Length = Longitudinal axis  
 
Following parameters of echocardiography measurements were obtained and analyzed: 
 
Table 4.19: Directly measured parameters of echocardiography 
Abbreviation Cardiac Parameter Unit 
Area d Area of cross sectional left ventricular lumen in diastole mm2 
Area s Area of cross sectional left ventricular lumen in systole mm2 
AWTh d Anterior wall thickness in diastole mm 
AWTh s Anterior wall thickness in systole mm 
BW Body weight  g 
BT Body temperature °C 
Epi s Epicardium in systole mm2 
HR Heart rate beats/min 
L d Axis longitudinal in diastole mm 
L s Axis longitudinal in systole mm 
LVID d Left ventricular inner diameter in diastole mm 
LVID s Left ventricular inner diameter in systole mm 
PWTh d Posterior wall thickness in diastole mm 
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Table 4.20: Calculated parameters of echocardiography 
Abbreviation Cardiac Parameter Unit Calculation 
AWThF Anterior wall thickness fractioning % 
(AWTh d – AWTh s)/ 
AWTh d * 100 
CI Cardiac index % CO/BW * 1000 
CO Cardiac output % SV*HR/1000 
EF Ejection fraction % 
(Vol d – Vol s)/ 
Vol d *100 
FAS Fractional area shortening % 
(Area d – Area s)/ 
Area d  * 100 
FS Fractional shortening % 
(LVID d – LVID s)/ 
LVID * 100 
LVW/BW Left ventricular weight/body weight mg/g LVW/BW 
LVW Left ventricular weight mg 
1.05 * (5/6)* (Epi s * (L s + 
(AWTh s +  AWTh d) /2)) – 
Area s * L s)) 
PWThF Posterior wall thickness fractioning % 
(PWTh d – PWTh s)/ 
PWTh d * 100 
SV Stroke volume µL Vol d – Vol s 
Vol d Volume diastole µL (5/6) * (Area d * L d) 
Vol s Volume systole µL (5/6) * (Area s * L s) 
TAC surgeries and echocardiography was carried out with the help of the SFB 1002 Service 
Unit (TP S). 
4.2.1.6 Organ withdrawal 
At the end of the study, mice were sacrificed by cervical dislocation under isoflurane 
anaesthesia. Organs were quickly excised and either directly fixed with 4% PFA over night for 
histological analysis and/or immediately frozen in liquid nitrogen and kept at -80 °C for RNA 
and protein isolation.  
In the case of heart samples, the organs were perfused with PBS to remove residual blood 
and cut axially in two pieces. The upper half of the hearts was used for histological 
investigations, whereas the apex was used for RNA and/or protein isolation. 
In addition, the tibias of the hind legs were prepared and the length measured.  
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4.2.2 Cell biological methods 
4.2.2.1 Isolation of adult mouse cardiac fibroblasts (AMCF) 
Cell isolation by collagenase I and dispase digestion 
Adult (around 40-60-week-old) female and male mice were anesthetized with isoflurane and 
sacrificed by cervical dislocation. Chests were opened by cutting the diaphragm and costal 
arch of the animals and hearts were excised and kept in basal DMEM/F12 on ice. All 
following steps were carried out under sterile condition at a workbench. To remove the 
blood, hearts were washed with ice-cold PBS until no further blood was visible. After that, 
atria were removed, and ventricles were cut into pieces of 1-2 mm2 in size. The minced 
tissue was washed with ice-cold PBS until the supernatant remained clear. Then, 2.5 mL pre-
warmed digestion buffer per heart was added and incubated for 10 min in a metal block at 
37 °C shaking the tubes every 2 min. After sedimentation of the tissue pieces, the 
supernatant containing the cardiac fibroblasts was collected in a new tube. In order to stop 
the activity of the collagenase I/dispase enzymes, DMEM/F12 growth medium containing 
FCS was added and the samples were kept on ice. The above described digestion step was 
repeated 5-7 times until the tissue was almost completely digested and the supernatant 
stayed clear. Afterwards, the collected supernatants were centrifuged for 5 min at 1200 rpm 
at 4 °C, the cell pellet was washed with ice-cold PBS and centrifuged again. Then the cell 
pellet was resuspended in AMCF growth medium and cells were counted using the CASY cell 
counting system and seeded in cell culture flasks. After 1 h at 37 °C in an incubator with 5% 
CO2, the supernatant was aspirated, cells were washed twice with PBS and AMCF growth 
medium was added. The next day, cells were washed again once with PBS, and fresh AMCF 
growth medium was added. The obtained cardiac fibroblasts were further cultivated in a 
humidified incubator at 37 °C with 5% CO2 with medium changes every 2-3 days until they 
reached 70-80% confluency. Cells were then further passaged as described in section 4.2.2.3. 
For experiments only passage 1 and 2 cardiac fibroblasts were used. 
Cell isolation by Langendorff method 
Another technique to obtain cardiac fibroblasts is the isolation via Langendorff perfusion. 
This method is primarily used to isolate cardiomyocytes, but cardiac fibroblasts can also be 
obtained [173]. 
In brief, adult male mice were sacrificed under isoflurane anesthesia by cervical dislocation, 
hearts together with the Aorta ascendens were excised, washed and perfused in ice-cold 1x 
perfusion buffer, and then digested for 10 min at 37 °C with liberase containing digestion 
buffer. Digestion was stopped by adding BSA-containing stop buffer 1. Hearts were first 




mechanically disrupted for 30 sec and then triturated for 2 min. After sedimentation of the 
cardiomyocytes, the supernatant containing mainly cardiac fibroblasts was collected. Next, 
the cardiomyocyte pellet was resuspended with stop buffer 2 and incubated for 10 min. 
Both supernatants were then combined and cells were preplated for 45 to 60 min in AMCF 
growth medium. Afterwards, the medium was changed and fibroblasts were cultivated in a 
humidified incubator with 5% CO2 at 37 °C until confluency was reached.  
Cardiac fibroblasts isolated via Langendorff digestion were kindly provided by Sebastian 
Pasch, Institute of Pharmacology, University Medical Center Göttingen. 
 
 4.2.2.2 Isolation of neonatal rat cardiac fibroblasts (NRCF) 
Cardiac fibroblasts were isolated from neonatal Wistar rats (postnatal day 0 to 3) following 
the instructions of the Neonatal Heart Dissociation Kit (gentleMACS, Miltenyi Biotec).  
Briefly, rats were sacrificed by decapitation and hearts were collected in ice-cold CBFHH 
buffer. Continuing under sterile conditions, atria were removed and ventricular tissue was 
cut into pieces of 1-2 mm2 size and washed two times with CBFHH buffer. Next, the tissue 
was transferred into two gentleMACS C tubes, and 2.5 mL or 3.75 mL of enzyme mix per 
tube was added (as shown in table 4.21) and incubated for 15 min at 37 °C.  
 





Enzyme mix 1 Enzyme mix 2 
Enzyme P Buffer X Buffer Y Enzyme A Enzyme D 
40 5 mL 125 µL 4600 µL 50 µL 25 µL 200 µL 
60  7.5 mL 
187.5 µL 6900 µL 75 µL 37.5 µL 300 µL 
 
Afterwards, tissue was further disrupted using a gentleMACS Dissociator (h_tumor 3.01). 
Incubation and dissociation steps were repeated alternating 2-3 times. Digestion was 
stopped with 7.5 mL of FCS containing NKM medium, and cell suspension was filtered 
through a mesh of stainless steel with a 250 µm pore size and centrifuged for 20 min at 
60 x g. The pelleted cells were resuspended in 20 mL NKM medium, and cell number was 
determined by using a Neubauer counting chamber. To exclude dead cells, 0.4% trypan blue 
was added, which stains only non-viable cells. 
Freshly isolated cells were either used directly for EHM preparation or seeded at a density of 
106 cells per 15 cm cell culture dish for 40-45 min to separate fibroblasts from 
cardiomyocytes. To remove all non-attached cells, the dish was thoroughly rinsed with NKM 
medium and growth medium was added to the attached fibroblasts. Cardiac fibroblasts were 
cultivated under humidified condition at 37 °C with 5% CO2 circulation until cells reached 
confluency. For experiments only cells from passage 1 and 2 were used. 




 4.2.2.3 Cultivation and passaging of primary cells 
Cardiac fibroblasts were cultivated on cell culture surfaces in a humidified incubator at 37 °C 
with 5% CO2 circulation until they reached 70-80% of confluency. For passaging, medium was 
aspirated, cells were washed with pre-warmed PBS and after removal of PBS, 0.05% pre-
warmed trypsin-EDTA was added. Cells were treated with trypsin around 5 min at RT until 
the majority of cells detached from the bottom surface. The process was assessed by light 
microscopy. Then, trypsin activity was stopped by adding FCS-containing medium. For cell 
collection, the surface of the dish was rinsed several times. After centrifugation for 5 min at 
300 x g, the cell pellet was resuspended in growth medium containing FCS and counted using 
the CASY cell counting system. In addition, viability, size and volume of the detached cells 
were assessed. Cells were seeded for experiments according to the needed cell number, and 
cultivation was continued in a humidified incubator at 37 °C with 5% CO2. For 
immunofluorescence staining, fibroblasts were seeded on glass cover slips coated with 
collagen (3 mg/mL) diluted 1:100 in PBS. 
Prior to any treatment, cells were starved in serum-free medium for 24 h. For this, the 
medium was aspirated, cells were washed 1-2 times with pre-warmed PBS and low glucose 
medium without FCS was added (serum-free medium). 
 
 
 4.2.2.4 Deep freezing and thawing of primary cells 
 
For long-term storage of cultivated cardiac fibroblasts, cells of a confluent T75 flask were 
trypsinized as described above (section 4.2.2.3) and the cell pellet was resuspended in 1 mL 
growth medium containing 10% DMSO. This cell suspension was transferred into cryotubes 
and frozen down at -80 °C by the use of Mr. Frosty freezing containers filled with 
isopropanol, allowing a gradual decrease in temperature with a gentle cooling rate of  
-1 °C/min. 
In order to re-cultivate the frozen fibroblasts, cells were thawed immediately to room 
temperature, mixed with an appropriate volume of growth medium and seeded on flasks. 
The next day, medium was removed and exchanged with fresh growth medium. 
 
 
 4.2.2.5 Adenoviral infection of neonatal rat cardiac fibroblasts (NRCF) 
Fibroblasts cultivated in a monolayer were serum-starved and infected with recombinant 
adenovirus for 24 h to 72 h with a multiplicity of infection (MOI) of around 500-1000. For 
ECT preparation, the respective viruses were added directly to the mixture prior to the 
casting of rings. Efficiency of transduction was verified by fluorescence microscopy 
examination of the co-expressing EGFP as part of the encoding gene sequence.  
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4.2.2.6 Proliferation Assay 
To evaluate the proliferative capacity, AMCF were trypsinized as described in section 4.2.2.3 
and counted using the CASY cell-counting system. Cells were seeded on 24-well plates with a 
density of 10.000 cells per well and cultivated in AMCF growth medium. The next day, cells 
were washed once with pre-warmed PBS and further cultivated in AMCF growth medium 
supplemented with or without 10% serum. In addition, cells of one plate (referred as time 
point t = 0h) were immediately fixed with 4% PFA for 15 min and nuclei were stained with 
DAPI diluted in PBS (see section 4.1.7) for 30 min in the dark. After three washing steps with 
PBS, the cell number was determined by nuclei staining using the Cellavista system (Roche). 
For the following period of cultivation, medium was changed every day. On day 1, 2, 3, 4 and 
6 cells were fixed and stained and cell number was assessed as described above. Each 
sample was run in 4 replicates. 
4.2.2.7 Generation of 3D engineered tissue 
Figure 4.2: Overview of EHM preparation, cultivation and force measurement setup 
(A) Example of a rat mouse mold used for casting of the tissue. (B) Image of EHM on a phasic stretcher. (C)
Contraction setup (left) and EHM clamped on hooks of an organ bath (right). 
Generation of engineered heart muscle (EHM) 
EHMs were prepared with 2.5 x 106 freshly isolated total heart cells (section 4.2.2.2) and 
0.5 x 106 adenovirally transduced NRCF (section 4.2.2.5). 
All steps of EHM preparation were performed on ice with pre-cooled equipment. First, an 
equal amount of collagen (table 4.22) and 2x DMEM was mixed and pH was adjusted with 
0.1 NaOH until the colour changed from yellow (acidic pH) to a more pink-red colour (neutral 
pH). Then, matrigel and cells were added, mixed carefully and casted into circular molds. 
After incubation at 37 °C and 5% CO2 for 1 h, tissues were covered with EHM medium. The 
next day, the medium was replaced by fresh EHM medium and further changed every other 
day for the remaining time of cultivation. After 5 days of culture, the condensed EHMs were 
transferred on phasic stretchers for 12 consecutive days. EHM tissue was stretched at 1 Hz 
A B C
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for the first 24 h, and then frequency was increased to 2 Hz. Subsequently, contractile force 
measurements were performed 17 days after casting as described in section 4.2.2.8. 
Table 4.22: Master mix for the preparation of one rat EHM 
EHM component Volume (µL) rat molds 
Collagen type 1 (0.8 mg/EHM); Stock solution 3.0 mg/mL 280 µL 
2x DMEM 280 µL 
0.1 NaOH  20 µL 
Matrigel 100 µL 
Cell suspension: 
2.5 x 106 total heart cells plus 
0.5 x 106 virally infected P1 NRCF
220 µL 
Total 900 µL 
Generation of engineered connective tissue (ECT) 
ECTs were prepared in a similar way as described for EHMs by mixing only cardiac fibroblasts 
(1.5 x 106 NRCF) with collagen and 2x DMEM in circular molds. For transduction, virus was 
directly added to the mixture before casting the tissue. After 60 min of condensation 
growth, medium was added and ECTs were cultivated in molds for 5 consecutive days with 
medium changes every second day. Stiffness of the tissue was analyzed in an organ bath as 
described in section 4.2.2.8.  
Table 4.23: Master mix for the preparation of one rat ECT 
ECT components Volume (µL) rat molds 
Collagen type 1 (1.2 mg/ECT); stock solution 3.0 mg/mL 400 µL 
2x DMEM 400 µL 
0.2 NaOH 40 µL 
Cell suspension 60 µL (1.5 x 106 NRCF ) 
Total 900 µL 
4.2.2.8 Force measurement of 3D-engineered tissue 
Both EHM and ECT were transferred into an organ bath filled with Tyrode’s solution 
constantly kept warm at 37 °C and gassed with 95% O2 and 5% CO2. Rings were clamped on 
hooks connected to a force meter, which were calibrated with a 50 mg weight disk for EHM 




or a 500 mg weight disk for ECT. Prior to force, measurement images of the tissues were 
taken to determine the cross-sectional area. 
 
EHM force measurements 
For synchronous contraction of the tissue, EHMs were paced with 2 Hz over the entire term 
of measurement. First, Lmax defined by Frank Starling as the length, where the maximal force 
is generated, was determined for each EHM ring. To do this, EHMs were stepwise (125 µm 
per step) stretched in the presence of 1.8 mM calcium. As soon as Lmax was reached, the 
measurement was stopped, Tyrode’s solution was exchanged, and EHM were equilibrated to 
baseline. Then the contractile force of EHM under increasing calcium concentrations from 
0.2 to 3.2 mM was recorded. The minimum (diastolic) force was considered as resting force 
normalized to the cross-sectional area, whereas the difference between minimal (diastolic) 
and maximal (systolic) force was defined as force of contraction (FOC) normalized to the 
cross-sectional area. 
 
ECT force measurement  
To evaluate the passive force and hence the stiffness of the tissue, ECTs were stepwise 
(62,5 µm per step) elongated in the presence of 1.8 mM calcium concentration and the 
results were presented as resting force normalized to the cross-sectional area. 
 
After measurements, stretch rings were either frozen immediately in liquid nitrogen and 
kept at -80 °C for RNA and protein isolation or were fixed with 4% paraformaldehyde in PBS 
overnight at 4 °C for histological analysis. In case of ECT tissue, unstretched rings were also 
included for further analysis. 
 
 
4.2.3 Molecular biochemical methods 
 
 4.2.3.1 SRF activation assay  
To determine the activation of the serum response factor (SRF), neonatal rat cardiac 
fibroblasts were seeded on 24-well plates, cultivated and starved in serum-free medium for 
2 days prior to treatment. For transfection, 0.5 g empty pCMV-Tag3, pCMV-Tag3-p63RhoGEF 
or pCMV-Tag3-p63ΔN plus 0.4 µg of pSRE.L luciferase reporter plasmid (firefly luciferase) 
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and 0.1 µg pRL.TL control reporter vector (renilla luciferase) were mixed with Lipofectamine 
3000 (Invitrogen) according to the manufacturer’s protocol. After incubation for 24 to 48 h, 
cells were washed with PBS, serum starved for 24 h, pre-incubated with 10 µM CCG1423 for 
30 min and treated with 100 nM Ang II for another 24 h. SRF activation was determined by 
luciferase activity measurement with the Dual-Luciferase reporter assay system (Promega) 
following the manufacturer’s instructions and detected using a luminometer (Glomax). The 
firefly luciferase activity was normalized to the respective renilla luciferase activity and ratios 
of untreated controls were set to 1. 
4.2.3.2 Isolation of total RNA from monolayer cultured cells 
Since RNA is very susceptible to degradation by RNases, all surfaces that could get in contact 
with RNA samples were thoroughly cleaned beforehand with RNA Zap (Ambion) for an 
RNase-free environment.  
For total RNA isolation from a monolayer culture, cells were seeded on a 6 or 10 cm dish, 
treated with or without 100 nM of angiotensin II (Ang II) for 3 and 24 h, and harvested by 
trypsinization (section 4.2.2.3). After centrifugation for 5 min at 300 x g, supernatant was 
removed and cell pellets were either frozen down at -20 °C for short-term storage or 
immediately processed for isolation of RNA with the RNeasy Kit (Qiagen) according to the 
manufacturer’s protocol. The RNA was eluted in RNase-free water and the amount of total 
RNA was assessed by use of a Nanodrop device. For long-term storage RNA was kept at 
-80 °C.
4.2.3.3 Isolation of total RNA from tissue 
For an RNase-free environment, surfaces were cleaned with RNA Zap (Ambion). 
Frozen heart tissue was mechanically ground with mortar and pestle in a metal block and 
constantly cooled down with liquid nitrogen. The powdered hearts were processed with 
peqGold TriFast (peqLab) in accordance to the manufacturer’s protocol. In short, the 
powdered hearts were dissolved in 1 mL of peqGold TriFast and further disrupted and 
homogenized using the TissueLyser II (Qiagen) for 90 sec with a speed of 30 Hz with tungsten 
beads of 5 mm2 size. The beads were removed, and in order to separate RNA from DNA and 
protein fraction, chloroform was added and thoroughly mixed. After an incubated period of 
10 min and centrifugation for 5 min at 12000 x g, three different phases occurred. The upper 
aqueous and clear phase containing the RNA was carefully removed and transferred into a 
new collection tube. For precipitation of the RNA, isopropanol was added, mixed and 
incubated overnight at -80 °C. The next day, the precipitated RNA was centrifuged for 10 min 
with 12000 x g at 4 °C, washed twice with 70% ethanol, and resolved in RNase-free water at 
55 °C for 10 min. An additional purification step (Clean-up) with an RNeasy Kit was 
performed following the instructions of the manufacturer (Qiagen). RNA was eluted in 




RNase-free water and concentration was determined with the Nanodrop. For long-term 
storage RNA was kept at -80 °C. 
 
 4.2.3.4 Formaldehyde agarose gel electrophoresis 
RNA is very susceptible to degradation by RNases. To check the level of degraded RNA 
isolated from heart tissue, FA gel electrophoresis was performed. For this purpose, a 1.2% 
agarose gel with RNase-free water, 37% formaldehyde, and ethidium bromide was cast. For 
sample preparation, RNA was mixed with 5x RNA loading buffer, incubated for 5 min at 
65 °C, and was loaded along with a DNA marker ladder on the gel. FA gel electrophoresis was 
performed at 120 V for 45-60 min in 1x FA gel running buffer. Intact Ribosomal RNA was 
visualized by UV exposure using the GelDoc XR device and images were taken with the 
Quantity One programme. 
 
 4.2.3.5 cDNA synthesis 
The cDNA was synthesized by reverse transcription of isolated total RNA using the RevertAid 
First Strand cDNA Synthesis Kit (Thermo Scientific). The master mix for a single reaction 
contained the following components: 
Component Volume (µL) 
Template 150 - 500 ng    
Oligo dT   1 µL 
ad H2O 12 µL 
 
For annealing of the oligonucleotides, the mixture was incubated for 5 min at 65 °C, cooled 
down on ice, and buffer, nucleotides, RNase inhibitor as well as enzyme were added. 
Component Volume (µL) 
5x Reaction buffer 4 µL 
dNTPs 2 µL 
Rl (Ribolock) 1 µL 
Reverse Transcriptase  1 µL 
 
Synthesis of cDNA was performed for 60 min at 42 °C followed by a termination step of the 








 4.2.3.6 Endpoint polymerase chain reaction (PCR) 
To analyze the expression of cell type-specific marker, an endpoint PCR was performed. To 
do this, cDNA samples were diluted 1:20, the respective primers (stock solution 100 pmol) 
were diluted 1:10 and mixed with the ready-to-use GoTaq Master Mix containing Taq DNA 
Polmerase, dNTPs, MgCl2 and buffer for efficient amplification of DNA templates (Promega).  
The mixture of one reaction is shown below: 
 
Table 4.24: Reaction mixture for endpoint PCR 
Component Volume (µL) 
Template cDNA (1:20)/DNA from genotyping   1 µL/2 µL 
Forward primer (stock solution 100 pmol) (1:10)   1 µL 
Reverse primer (stock solution 100 pmol) (1:10)   1 µL 
GoTaq Green Master Mix 10 µL 
ad H2O 20 µL 
 
Exponential amplification of a specific DNA fragment was performed in a Mastercycler 
gradient device using the following programme: 
 
Table 4.25: PCR programme for endpoint PCR 
No. Step Temperature (°C) Time Repitition 
1 Initialization  94 °C 3 min 1 time 
2 Denaturation 94 °C 30 sec 
30 times 3 Annealing 56 °C  30 sec 
4 Elongation 72 °C 2 min 
5 Final elongation 72 °C 5 min 1 time 
6 Final hold   4 °C ∞  
 
After this, the PCR product was separated by size via DNA agarose gel electrophoresis 
(section 4.2.3.7). 
 
 4.2.3.7 Agarose gel electrophoresis 
For separation and detection of an amplified PCR product of a specific size, the PCR reaction 
was loaded on a DNA agarose gel. For preparation of a gel, agarose was mixed with 1x TAE 
buffer and heated until the agarose was dissolved. The viscous solution was cooled down to 
approximately 50 °C, ethidium bromide was added, and the gel was cast. After solidification, 
the gel was transferred into a gel electrophoresis chamber and covered with 1x TAE buffer. 
4 Material & Methods 
51 
Gel electrophoresis was performed at 120 V for 45-60 min depending on the expected size of 
the DNA fragment. DNA bands were visualised by UV exposure using the GelDoc XR device, 
and images were taken with the Quantity One software application.  
4.2.3.8 Quantitative real-time polymerase chain reaction (qRT-PCR) 
For quantitative analysis of an expressed gene on mRNA level, qRT-PCR was performed using 
the 5x HOT FIREPol Eva Green qPCR Plus Kit (Solis BioDyne), according to the manufacturer’s 
instructions. Each cDNA sample was diluted 1:20 and run in four replicates. For each primer 
pair, a standard curve using a pool of all cDNAs was included. For each gene, a master mix 
was prepared as shown in table 4.26 and scaled up to the required number of samples. The 
experiment was performed in a Micro-Amp optical reaction 384 plate (Applied Biosystems) 
with 1 µL of the diluted cDNA and 19 µL of the master mix per well. After loading of all 
samples, the plate was sealed with a Micro-Amp optical adhesive film and centrifuged for 5 
min at 300 x g. 
Table 4.26: Reaction mixture for qRT-PCR 
Component Volume (µL) 
Forward primer (10 pmol)  1 µL 
Reverse primer (10 pmol)  1 µL 
5x HOT FIREPol Eva Green qPCR Plus Kit  4 µL 
H2O 13 µL 
The reaction was performed using TaqMan 7900HT Fast Real-Time-PCR instrument, 
according to the programme depicted in table 4.27. Relative cDNA amount was calculated by 
SDS 2.4 software with the help of a standard curve and normalized to the housekeeping 
gene porphobilinogen deaminase (PBGD). 
Table 4.27: qRT-PCR programme 
No. Step Temperature (°C) Time Repitition 
1 Initialization 95 °C 10 min 1 time 
2 
Denaturation 95 °C 15 sec 
40 times Annealing 60 °C 20 sec 
Elongation 72 °C 40 sec 
3 
Denaturation 95 °C 15 sec 
1 time 
Melting curve start 
(Ramp rate: 1.6°C/sec) 
60 °C 15 sec 
Melting curve end 95 °C 15 sec 




4.2.4. Histological methods 
 
 4.2.4.1 Sample preparation, embedding and sectioning of ECT and EHM 
ECT and EHM tissue were fixed in 4% PFA in PBS overnight. The next day, tissues were 
washed once with PBS and 70% ethanol and embedded in a 6- or 12-well plate with 
2% agarose solved in 1x TAE buffer. After solidification at 4 °C over night, a block of tissue 
and agarose was cut out, fixed with superglue (Uhu) on a magnetic disk, and positioned in a 
container filled with ice-cold PBS. Slices of 100 µm thickness were cut in automatic modus at 
a speed of 6 and frequency of 10 using a Leica vibratome (Leica). During sectioning, the 
container was permanently cooled with ice. Tissue slices were transferred into PBS filled well 
plates and stored at 4 °C until proceeding further with immunofluorescence staining (section 
4.2.5.2). 
 
4.2.4.2 Sample preparation and embedding of heart tissue 
Excised hearts were fixed with 4% PFA overnight at 4 °C on a rotating shaker and washed 




In order to embed hearts in hydrophobic paraffin, water inside of the tissue was removed by 
stepwise increase of ethanol concentration and toluol treatment. All incubation steps of the 
“ascending” ethanol series were performed at 4 °C on a rotating shaker for the period of 
time shown in table 4.28. 
Table 4.28: Incubation steps of “ascending” ethanol series 
Reagent Incubation time (min) 
  70% ethanol 72 hours 
  80% ethanol 30 min 
  90% ethanol 30 min 
  96% ethanol 60 min 
  96% ethanol 30 min 
100% ethanol 60 min 
100% ethanol 30 min 
Toluol/ethanol (1:1) 15 min 
Toluol  60 min 
Toluol 30 min 
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After toluol treatment, hearts were transferred into preheated liquid paraffin and kept at 
65 °C over night. The next day, hearts were fixed in embedding molds with fresh preheated 
liquid paraffin, cooled down on ice, and solidified at 4 °C over night. Until preparation of 
sections, paraffin-tissue blocks were further kept at 4 °C. 
Cryo-embedding 
After fixation with 4% PFA and washing twice with PBS, hearts were transferred into 30% 
sucrose solution and kept at 4 °C until the organ, when fully infused with the solution, had 
moved to the bottom of the tube. After this, hearts were put in a 1:1 mixture of 30% sucrose 
and O.C.T. compound (Sakura), kept again at 4 °C until the organ had reached the bottom, 
and were subsequently transferred into O.C.T. solution and incubated at 4 °C over night. 
Finally, hearts were embedded in cryo molds with O.C.T. compound, which was constantly 
cooled down on a metal block with liquid nitrogen until it had become solid. Cryo molds 
were kept and stored at -20 °C until crytome sectioning (section 4.2.4.3).  
4.2.4.3 Sectioning of heart tissue (microtome and cryotome) 
Microtome sectioning 
Heart tissue embedded in paraffin was cut with a microtome (Zeiss), preparing cross-
sectional slices of 7-10 µm thickness. During sectioning, paraffin block and collecting tray 
were cooled with ice-cold PBS. Single slices were transferred briefly into 37 °C pre-warmed 
distilled water and after unfolding, slices were transferred on glass slides, dried over night at 
room temperature, and further stored in slide boxes at RT. 
Cryotome sectioning 
In O.C.T. solution embedded hearts were sectioned using a crytome (Zeiss). Cross-sectional 
slices with a thickness of 100 µm were prepared. During the course of sectioning, all material 
and chamber were permanently cooled at -20 °C and slices were immediately transferred on 
glass slides and kept at -20 °C until further processing. 
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4.2.4.4 Immunohistochemistry (IHC) and immunofluorescence staining of heart tissue 
Paraffin-sections 
Prior to any staining of paraffin-embedded tissue sections, a deparaffinization procedure 
was performed to remove the hydrophobic paraffin and to moisturize the dried sections for 
aqueous dye and antibody incubation. All steps of the “descending” ethanol series were 
performed at RT for the period of time shown in table 4.29. 
Table 4.29: Incubation steps of “descending” ethanol series 
Reagent Incubation time (min) 
Histol 10 min 
Histol 10 min 
100% ethanol  5 min 
100% ethanol  5 min 
 96% ethanol  5 min 
 96% ethanol  5 min 
 80% ethanol  5 min 
 70% ethanol  5 min 
Bidest. H2O  5 min 
PBS  5 min 
For detection of collagen within the tissue, IHC staining was performed. To do this, a Fast 
Green/Sirius Red dye (Chondrex) was used and incubated for 30 min in a humidified 
chamber to prevent dehydration of heart sections. Afterwards, the dye was removed and 
slides were washed with distilled water, mounted, and dried overnight at RT. Preservation 
was carried out in the Institute of Pathology, UMG Göttingen. To prevent desiccation of the 
sections during long-term storage, slides were additionally sealed with nail polish. 
To evaluate the cross-sectional area of cardiomyocytes, heart sections were stained with 
wheat germ agglutinin (WGA), visualizing glycosylated proteins of the ECM. To do this, 
deparaffinized sections were stained with WGA and DAPI (for concentration see section 
4.1.7) diluted in PBS for 30-60 min, washed 3 times with PBS, and mounted with 
Fluoromount (Sigma). For long-term storage, slides were sealed with nail polish and kept at 
4 °C protected from light. 
Cryo-sections 
Heart tissue embedded in O.C.T. medium were briefly thawed at room temperature, washed 
5 min in PBS and stained for collagen with Fast Green/Sirius Red dye or for ECM with WGA 
and DAPI as described above. 
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4.2.5 Immunofluorescence 
4.2.5.1 Preparation and staining of monolayer cells 
Cells seeded on a 12-well plate with or without covers slips were fixed with 4% PFA for 15 
min at room temperature, washed 3 times with PBS followed by permeabilization of the cell 
membrane with 0.2% of the detergent Triton X-100 solved in PBS for 3 min. Again, cells were 
rinsed 3 times with PBS. Blocking of free binding sites was carried out for 1 h using Roti-block 
(Roth). Thereafter, incubation with the first antibody diluted in PBS was performed at 4 °C 
overnight on a shaking plate. Continuing the next day, the solution was apirated, cells were 
washed 3 times with PBS, and second antibody incubation was conducted for 1 h at room 
temperature in the dark along with fluorophore-labelled Phalloidin or WGA and DAPI. After 
washing with PBS 3 times, cells cultured on plastic surface were stored in PBS at 4 °C in the 
dark. Cells seeded on glass cover slips were mounted with Fluoromount (Sigma), sealed with 
nail polish, and stored at RT protected from light until imaging. 
4.2.5.2 Preparation and staining of ECT and EHM 3D tissue 
Longitudinal sections obtained from 3D engineered tissue were simultaneously blocked with 
Roti-block (Roth) and permeabilized with 0.2 Tween X-100 at 4 °C over night.  First and 
fluorocrome-labeled second antibody were each incubated at 4°C overnight in 
blocking/permeabilization buffer, and fluorophor-coupled Phalloidin or WGA and DAPI were 
incubated for 1 h at RT in the dark. Between every staining period, tissues were washed 3 
times with PBS. Finally, agarose was removed and tissue sections were mounted with 
Fluoromount (Sigma) and sealed with nail polish the day after. Until microscopy analysis, 
samples were stored at RT in the dark.   
4.2.6 Protein biochemical methods 
4.2.6.1 Preparation of protein samples from monolayer cells for SDS-PAGE 
For protein analysis, cells were seeded on 6-well plates, cultivated until 90% confluency, and 
treated as indicated. All steps of cell lysate preparation were performed with pre-cooled 
solutions and equipment on ice. First, conditioned medium was collected, then cells were 
rinsed twice with PBS, lysed and scraped off with an adequate volume of GST-Fish buffer 
(250 µL/6-well for NRCF or 150 µL/6-well for AMCF)  containing 1x phosphatase and 
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protease inhibitor (PhosSTOP and cOmplete, Roche). In case of AMCF, cell lysates from 2 to 3 
single 6-wells were pooled. To remove cell debris, lysates were centrifuged for 10 min at 
14000 x g at 4 °C and the supernatants were transferred into new reaction tubes. For SDS-
PAGE, 4x SDS loading buffer without glycerol was added to the lysate fraction. Medium 
samples were mixed with 4x loading buffer with glycerol. Samples were incubated for 5 min 
at 95 °C in a heating block, cooled down briefly on ice, shortly centrifuged and kept cooled 
until gel electrophoresis. Native cell lysates and conditioned medium without loading buffer 
were immediately snap-frozen in liquid nitrogen and kept at -20 °C for short-term and at -80° 
for long-term storage.  
4.2.6.2 Preparation of protein samples from 3D tissue for SDS-PAGE 
Frozen EHM, ECT and heart tissue were mechanically ground with mortar and pestle in a 
metal block that was constantly cooled down with liquid nitrogen. Ice-cold GST-Fish-buffer 
containing 1x phosphatase and protease inhibitor (PhosSTOP and cOmplete, Roche) were 
added to the powdered tissue and homogenized using a Polytron (Kinematica). After this, 
protein lysates were centrifuged and SDS-PAGE samples were prepared as described above 
(section 4.2.6.1). 
4.2.6.3 Discontinuous sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
For detection of proteins, lysate samples obtained from 2D or 3D (EHT/ECT) cell culture and 
heart tissue (see section 4.2.6.1 and 4.2.6.2) were first separated by size according to 
Laemmli et al. [174]. Depending on the corresponding size of the proteins, SDS 
polyacrylamide gels with a concentration between 8 and 15% were cast (see table 4.3) or 
commercially available gradient gels (Bio-Rad) were used. Samples and a protein standard 
ladder were loaded onto a gel, and SDS gel electrophoresis was performed with an electrical 
current of 200 V in 1x SDS-PAGE electrophoresis buffer. The run was stopped as soon as the 
loading front reached the bottom line of the gel.  
4.2.6.4 Immunoblotting 
Proteins separated by SDS-PAGE were transferred onto a nitrocellulose membrane by 
voltage application of 100 V for 60 min. For improved transfer, ice-cold blotting buffer was 
used and constantly kept chilled with the help of a frozen thermal pack inside the chamber. 
Afterwards, efficiency and equality of the protein transfer were assessed by Ponceau S 
staining of the membrane for approximately 5 min. The solution was aspirated and the 
membrane washed with distilled water 3-4 times to remove staining residues until single 
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bands became visible. The membrane was cut for individual protein sizes and washed once 
with TBS-T. To cover all putative free binding sites on the proteins, the membrane was 
blocked with Roti-block for 60 min at RT on a shaking plate. Incubation with the first 
antibody in concentrations depicted in table 4.7 was performed over night at 4 °C.  
The next day, the antibody solution was removed and membrane was washed 3 times with 
TBS-T for 5 min each before the second HRP-coupled antibody used in concentration shown 
in table 4.8 in TBS-T was incubated for 60 min at room temperature. Antibodies were always 
diluted in TBS-T and incubated on a shaker. After the second antibody incubation, the 
membrane was washed again 3 times with TBS-T and kept in distilled water. Finally, 
detection of proteins was assessed by the measurement of chemiluminescence. To do so, 
the membrane was covered with HRP-substrate solutions and signals were recorded using 
the VersaDoc Imaging system. For highly abundant proteins, Lumi Light (Roche) was used, 
whereas for lower expressed proteins, the more sensitive reagent Super signal west Femto 
(Thermo Scientific) was chosen. Semi-quantitative protein analysis was performed with the 
Image Lab 5.1 software.  
4.2.7 Statistical analysis 
All results are presented as means ± SEM. Data were analyzed by 1way or 2way ANOVA, 
followed by Bonferroni’s Multiple Comparison Test when comparing 3 or more groups or by 





5.1 The relevance of p63RhoGEF expression in the pathophysiology of 
cardiovascular diseases 
5.1.1 Expression of p63RhoGEF and CTGF is up-regulated during afterload-induced cardiac 
remodeling 
To investigate the role of p63RhoGEF under pathophysiological conditions of cardiac 
diseases, tissue from an animal study with female mice subjected to transverse aortic 
constriction (TAC), as an afterload- and pressure-induced disease model, was used to analyze 
p63RhoGEF expression. Heart samples were collected 1 week after surgery, when the left 
ventricular hypertrophy as indicated by left ventricular weight to tibia length ratio (LVW/TL) 
was increased by 22% and a significant 4.9-fold increase in myocardial fibrosis in the 
perivascular region was observed [175]. Immunoblot analysis revealed that expression of 
p63RhoGEF and CTGF was elevated by 2.2-fold and 6.6-fold, respectively, in TAC animals 
compared to sham group (Figure 5.1). This change was independent of the used 
normalization marker used vimentin or calsequestrin.  
Figure 5.1: Expression of p63RhoGEF and CTGF in murine hearts after TAC 
Heart samples from female mice subjected to transverse aortic constriction (TAC) or sham surgery were lysed 
in GST-Fish buffer 7d after operation. (A) Representative immunoblots (left) and Ponceau staining (right) of 
p63RhoGEF, CTGF, vimentin and calsequestrin-2 (CSQ) are shown. (B) Quantification of p63RhoGEF and CTGF 
expression normalized to vimentin and calsequestrin relative to sham group. Values are given as means ± SEM, 


































































In addition to the TAC model, shunt surgeries as a preload- and volume-induced cardiac 
model were performed [175]. While these mice developed a left ventricular hypertrophy 
similar to TAC animals, no elevated amount of fibrotic tissue was observed one week after 
intervention. Protein expression of p63RhoGEF and CTGF was analyzed one week after shunt 
and showed only a moderately 1.5-fold and 1.9-fold rise respectively in comparison to TAC 
(Figure 5.2).  
Figure 5.2: Comparison of p63RhoGEF and CTGF expression after TAC and shunt intervention 
Heart samples from female mice subjected to TAC, shunt or sham surgery were lysed in GST-Fish buffer 7d 
after operation. Quantification of p63RhoGEF and CTGF expression normalized to calsequestrin and relative to 
sham group are shown. Values are given as means ± SEM, n=6; *p < 0.05 vs. sham.  
This data suggest that p63RhoGEF and CTGF expression seems to be more relevant for 
afterload-dependent cardiac remodeling than for preload-induced processes. 
5.1.2 p63RhoGEF expression correlates with CTGF expression and cardiac function during 
afterload-induced cardiac remodeling 
To further elucidate the influence of p63RhoGEF and CTGF, a second mouse study was 
performed in which male and female mice were subjected to TAC or sham surgery. Over a 
time period of 5 weeks after surgery, mice developed a more severe hypertrophic 
phenotype with an increase in LVW/BW by 70% accompanied by a 25% reduction in ejection 
fraction (EF) and a rise in systolic (Vs) as well as diastolic volume (Vd) in the left ventricle by 






































Figure 5.3: Analysis of cardiac parameter and p63RhoGEF expression after TAC 
Male and female mice (10-12 weeks old) were subjected to TAC or sham surgery for 5 weeks. (A) Left 
ventricular dimension (given as ratio to the body weight, LVW/BW), ejection fraction (EF), and ventricular 
volume in systole (Vs) and diastole (Vd) were analyzed by echocardiography. Values are given as means ± SEM, 
n=4 (sham) and n=8 (TAC), *p < 0.05 vs. sham. (B-C) RNA was isolated from male and female hearts of TAC and 
sham-operated mice and expression of p63RhoGEF and CTGF was assessed by qPCR and normalized to the 
housekeeping gene PBGD. Correlation between p63RhoGEF and CTGF (B) and correlation of cardiac parameters 
(LVW/BW, EF, Vs and Vd) to p63RhoGEF expression is shown (C). The p and r
2
 values are depicted above the 
graphs.  
 
Analysis of heart samples by qPCR showed a 1.5- and 3.3-fold higher expression of 
p63RhoGEF and CTGF in TAC-operated mice compared to the sham group. Importantly, in 
both male and female mice, a positive correlation between p63RhoGEF expression and CTGF 
expression could be determined (Figure 5.3 B). Likewise, p63RhoGEF expression correlates 




































































































































p = 0.01, r2 = 0.5















Vs: p = 0.002, r2 = 0.64
Vd: p < 0.001, r2 = 0.71p = 0.04, r2 = 0.32





















5.2 Cellular function of p63RhoGEF in neonatal cardiac fibroblasts 
Previous data investigating the role of p63RhoGEF in cardiac fibroblasts clearly 
demonstrated that p63RhoGEF expression regulates the Ang II-dependent RhoA activation, 
as well as CTGF expression and secretion (see chapter 3). To further establish the function of 
p63RhoGEF in the underlying mechanism of auto- and paracrine signaling in cardiac 
fibroblasts, involvement of the serum-response factor in the signaling cascade as well as 
localization of p63RhoGEF was examined. 
5.2.1 p63RhoGEF regulates the activation of the serum response factor (SRF) 
The serum response factor (SRF) is an abundant transcription factor and thereby a 
downstream target of many pathways involved in cell-cycle regulation, apoptosis, cell 
growth and differentiation [176]. The SRF regulates the expression of immediate early genes 
and is involved in the organization of the actin cytoskeleton. To investigate whether SRF 
plays a role in the downstream signaling of p63RhoGEF, NRCF were transfected with either a 
construct for p63RhoGEF overexpression or the dominant negative p63ΔN construct 
blocking the signaling cascade downstream of Gαq/11 (Figure 5.4). SRF activity was assessed 
by luciferase gene reporter measurements (as described in section 4.2.3.1) in the absence or 
presence of Ang II. 
Figure 5.4: Schematic overview of the Ang II-dependent-p63RhoGEF-RhoA signaling cascade and targets for 
intervention 
Abbreviations: Ang II (angiotensin II), AT1R (angiotensin II receptor subtype 1), MRTF (myocardin-related 
transcription factor), SRF (serum response factor), CTGF (connective tissue growth factor), PLC-β 
















Stimulation of control NRCF with Ang II resulted in a significant 1.5-fold increase in SRF 
activity (Figure 5.5). Overexpression of p63RhoGEF increased SRF activity significantly by 1.7-
fold, and treatment with Ang II further raised the activity up to 4-fold compared to control 
condition. In contrast, blocking of the Gαq/11 pathway by p63ΔN almost completely inhibited 
the SRF activation in presence of Ang II, demonstrating that p63RhoGEF is involved in the 
Ang II-dependent activation of the SRF.  
 
 
Figure 5.5: Effect of p63RhoGEF on the SRF activation  
NRCF were co-transfected with pCMV-control, pCMV-p63RhoGEF, pCMV-p63ΔN plus pSRE.L and pRL.TK, serum 
starved for 24 h and stimulated with 100 nM Ang II for another 24 h. Ratios of firefly/renilla luciferase 
measurements are normalized to control, and values are shown as means ± SEM, n = 4-6, *p < 0.05 vs. control, 
#
p < 0.05 vs. control + Ang II. 
 
5.2.2 p63RhoGEF regulates CTGF expression and secretion via the serum response factor  
To validate the involvement of the SRF in the p63RhoGEF-dependent CTGF regulation, the 
SRF inhibitor CCG-1423 was implemented in the experiments. In detail, CCG-1423 binds to 
the myocardin-related transcription factor (MRTF), a co-factor of the SRF. In doing so, it 
prevents the translocation of the MRTF/SRF complex into the nucleus, where the SRF 
otherwise binds to the serum response element (SRE) in the promotor region of its potential 
target genes (Figure 5.4) [177, 178]. 
First, SRF activity was investigated in NRCF after stimulation with Ang II or serum for 24 h 
and in combination with or without prior CCG treatment for 1 h. Similar to the result seen in 
Figure 5.5, Ang II stimulation increased the SRF activity by 2-fold, while serum led to an 
approximately 15-fold increase in SRF activity (Figure 5.6 A). Although treatment of cardiac 
fibroblasts with the inhibitor CCG blocked the Ang II-dependent SRF activation, the level of 
SRF activity in CCG-treated cells was significantly higher compared to the control. Moreover, 
CCG treatment followed by stimulation with serum resulted in an even higher increase in 
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SRF activity compared to fibroblasts treated only with serum. These data suggest that the 
MRTF is involved in the Ang II-dependent SRF activation, but other co-factors must also be 
considered to be involved in SRF activation. 
Figure 5.6: Effect of SRF activity on the p63RhoGEF-dependent CTGF regulation 
(A) NRCF were co-transfected with pSRE.L and pRL.TK, serum-starved for 24 h and pre-incubated with 10 µM
CCG-1423 for 1h. Afterwards, cells were treated with serum or 100 nM Ang II for additional 24 h. Ratios of 
firefly/renilla luciferase measurements are normalized to control and values are shown as means ± SEM, n = 4, 
*p < 0.05 vs. control, 
#
p < 0.05 vs. serum. (B-C) NRCF were pre-treated with 10 µM CCG-1423 for 1 h and
stimulated with 100 nM Ang II for 24 h. The actin cytoskeleton was stained with FITC-phalloidin and nuclei with
DAPI. Scale bar 100 µm. (B) Cell lysates and conditioned medium were collected and the amounts of
intracellular and secreted CTGF were determined by immunoblot (C). Representative immunoblots (left) and
protein quantification (right) are shown. Values are given as means ± SEM, normalized to tubulin and relative to
control, n = 5, *p < 0.05 vs. control.
Next, the influence of MRTF/SRF inhibition on the organization of the actin cytoskeleton was 
determined. Control NRCF formed typically thick actin fibers, so-called stress fibers, upon 
Ang II stimulation, whereas treatment with CCG for 1 h followed by stimulation with Ang II 















































































































Finally, the effect of the MRTF/SRF inhibition on the regulation of CTGF as a downstream 
target was investigated. Immunoblot analysis revealed that 24 h of Ang II stimulation led to a 
1.6- and 2.8-fold increase of intracellular and secreted level of CTGF, respectively. Treatment 
with CCG blocked the Ang II-dependent CTGF secretion, reducing it to its basal level, 
whereas only a slight decrease in the intracellular amount of CTGF of CCG-treated cells 
compared to Ang II stimulated control NRCF was detected (Figure 5.6 C). 
5.2.3 p63RhoGEF localizes at intracellular membrane structures involved in secretion 
Finally, localization of p63RhoGEF in cardiac fibroblasts was examined. For this purpose, 
NCRF were adenovirally infected with a c-myc tagged construct allowing the detection of 
overexpressed p63RhoGEF in the cell via a specific anti-c-myc-antibody. In addition, viral 
transduction of fibroblasts was verified by EGFP fluorescence.  Confocal imaging revealed 
that p63RhoGEF localizes close to WGA-stained membranes rich in glycosylated proteins and 
with the trans-Golgi network (Figure 5.7 A, E), both membrane structures that are highly 
involved in the secretory machinery of mammalian cells. In addition, co-localization of 
p63RhoGEF with CTGF was detected (Figure 5.7 F), whereas localization with lysosomes, the 
endoplasmatic reticulum and cis-Golgi membranes could be excluded (Figure 5.7 B, C, D).  





Figure 5.7: Localization of p63RhoGEF in cardiac fibroblasts 
NRCF were transduced with Ad-p63RhoGEF for 24 h, fixed and stained for confocal imaging. Adenoviral 
transduction was verified by EGFP fluorescence. Fibroblasts were stained for p63RhoGEF (c-myc), glycosylated 
membrane proteins (WGA) (A), and lysosomes (Lamp2) (B), endoplasmatic reticulum (ER; KDEL) (C), cis-Golgi 
network (GM130) (D), trans-Golgi network (GOPC) (E) and CTGF (F). Nuclei were stained with DAPI. 
Representative merged images and magnifications of the nuclear region are shown. Scale bar 50 µm. (Stainings 
and confocal imaging was performed together with Sebastian Pasch, Institute of Pharmacology and Toxicology, 
University Medical Center Göttingen.) 
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Interestingly, staining of p63RhoGEF in NCRF (Figure 5.8 A) as well as AMCF (Figure 5.9 A) 
showed a very distinct punctual accumulation near or on top of the nuclei. Co-staining with 
acetylated tubulin, the main component of primary cilia, revealed that p63RhoGEF is 
localized within the transition zone and basal body of a primary cilium (Figure 5.8 B). Z-stack 
recording of the nuclear region (Figure 5.9 B) could confirm the localization of p63RhoGEF 
close to the nucleus and not inside it.  
 
 
Figure 5.8: Analysis of p63RhoGEF localization with primary cilia 
(A) NRCF were transduced with Ad-p63RhoGEF for 24 h, fixed and confocal imaging was performed. Adenoviral 
transduction was verified by EGFP fluorescence and fibroblasts were stained for p63RhoGEF (c-myc) and 
acetylated tubulin (ac-Tub). Nuclei were stained with DAPI. Scale bar 50 µm. (B) Schematic illustration of a 
primary cilium (modified according to Seeley and Nachury, 2010). (Stainings and confocal imaging was 
performed together with Sebastian Pasch, Institute of Pharmacology and Toxicology, University Medical Center 
Göttingen.) 
 
Beside the function as mechanoreceptors, primary cilia are supposed to be specialized 
compartments for secretion [179, 180] and in line with the described localization of 
p63RhoGEF at trans-Golgi membranes, an active participation of p63RhoGEF in the 

















Figure 5.9: Localization of p63RhoGEF with primary cilia  
AMCF were transduced with Ad-p63RhoGEF for 24 h, fixed and confocal imaging was performed. (A-B) 
Adenoviral transduction was verified by EGFP fluorescence and fibroblasts were stained for p63RhoGEF (c-myc) 
and acetylated tubulin (ac-Tub). Nuclei were stained with DAPI. Scale bar 25 µm. (B) Computational 3D image 
of the nuclear region based on z-stack recordings. 
 
 
5.3 Influence of p63RhoGEF and its downstream effector CTGF on viscoelastic and 
contractile properties of 3D engineered tissue 
 
To manifest the importance of p63RhoGEF expression in auto- and paracrine signaling of 
cardiac fibroblasts in effecting tissue properties and thereby contractile performance of 
cardiomyocytes, experiments using 3D engineered tissue models were carried out. 
 
5.3.1 p63RhoGEF regulates viscoelastic properties of engineered connective tissue (ECT) 
In a first experimental setup, ECTs consisting mainly of collagen and neonatal cardiac 
fibroblasts with the respective p63RhoGEF encoding adenovirus were generated, and 
passive force, as an indicator for the rigidity of a tissue, was measured (for detailed 












Figure 5.10: Effect of p63RhoGEF expression on viscoelastic properties of ECT 
NRCF, collagen, and the respective adenovirus (Ad-EGFP, Ad-p63RhoGEF, Ad-p63ΔN) were mixed and cultivated 
for 5 days. (A) Representative images of ECT. Scale bar 5 mm. (B) ECTs were elongated stepwise in an organ 
bath and passive force was detected. Shown are the cross sectional area (CSA) (left graph) and measured forces 
normalized to CSA (right graph) as means ± SEM, n = 4-5, 10-22 ECT were measured each, *p < 0.05 vs. EGFP. 
 
Overexpression of p63RhoGEF significantly enhanced rigidity of the tissue accompanied by a 
slight decrease of the cross-sectional area (CSA), whereas in ECTs containing p63ΔN 
transduced fibroblasts, the stiffness was reduced compared to EGFP ECTs (Figure 5.10 B). In 
line with this, p63ΔN ECTs were less condensed (Figure 5.10 A), and the cross-sectional area 
of these tissues was increased by approximately 40% (Figure 5.10 B). Protein lysates of 
unstretched and stretched ECT samples were prepared, and expression of CTGF was 
analyzed by immunoblot. In unstretched tissue overexpressing p63RhoGEF, the overall 
amount of CTGF was elevated by 2.2-fold compared to the EGFP control, while in p63ΔN 
ECTs the CTGF level was unchanged (Figure 5.11 A). After stretching, p63RhoGEF ECT 
showed a significant 75% decrease in CTGF content, arguing for enhanced secretion of CTGF 
during mechanical elongation of the tissue (Figure 5.11 B). In contrast, in stretched p63ΔN 
ECTs, the level of CTGF was increased after tensile force measurement. Independent from 
the stretching condition, sm-actin was increased when p63RhoGEF was overexpressed in the 
tissue, pointing to a more pronounced myofibroblast character of the NRCF within these 
tissues. 
Taken all together, these results emphasize the contribution of p63RhoGEF in regulating 
viscoelastic tissue properties by mechanically induced stress and confirm the regulation of 

















Figure 5.11: Impact of p63RhoGEF on CTGF expression and secretion in ECT  
NRCF, collagen, and respective adenovirus (Ad-EGFP, Ad-p63RhoGEF, Ad-p63ΔN) were mixed and incubated for 
5 days. (A) Unstretched and (B) stretched ECTs were minced, and lysates were used for immunoblot analysis. 
Representative immunoblots (left) and quantification of CTGF and sm-Actin (right) are shown. Values are given 
as means ± SEM, normalized to tubulin and relative to EGFP, n = 3 with 2-6 replicates each, *p < 0.05 vs. EGFP. 
 
5.3.2 CTGF overexpression does not influence stiffness properties of ECTs 
Based on literature, CTGF was found to be upregulated in diverse fibrotic diseases and was 
therefore widely accepted as a profibrotic factor [52]. Recent published studies showed 
conflicting data on the function of CTGF within the heart, from being cardioprotective, 
detrimental or without any influence regarding cardiac diseases [90, 181, 182]. In this 
context, the influence of CTGF expression on viscoelastic properties was examined by 
generation of ECT with adenovirally infected cardiac fibroblasts (Ad-CTGF). The 
overexpression of CTGF did not alter the rigidity of the tissue and showed only a minimal 
reduction in CSA compared to control infected ECTs (Figure 5.12). Thus, CTGF might not be 
















































































































































































Figure 5.12: Influence of CTGF expression on viscoelastic properties of ECT  
NRCF, collagen, and the respective adenovirus (Ad-EGFP and Ad-CTGF) were mixed and incubated for 5 days. 
(A) Representative images of ECTs. Scale bar 5 mm. (B) ECTs were elongated stepwise in an organ bath, and 
passive force was detected. Shown are the cross sectional area (CSA) (left) and measured forces normalized to 
CSA (right) as means ± SEM, n = 3, with a minimum of 6 ECTs in total. (C) ECTs were minced, and lysates were 
subjected to immunoblot analysis. Representative immunoblot of CTGF and tubulin are shown.  
 
 
5.3.3 Inhibition of the SRF activation leads to a decreased stiffness of ECTs 
As data from 2D culture experiments demonstrated a MRTF/SRF-dependent regulation of 
CTGF, the influence of the MRTF/SRF inhibition by CCG was also examined in 3D engineered 
tissue. Similar to the effect observed with the inhibition of Gαq/11 by the use of the p63ΔN 
construct (Figure 5.10), treatment with CCG led to a reduction in tissue rigidity, which was, 
however, not significant and accompanied by an increased CSA (Figure 5.13 A, B). On protein 
level, the amount of CTGF in the tissue after stretch was 2.7-fold higher, with CCG treatment 
pointing to reduced secretion and/or increased expression of CTGF. Inhibition of the SRF 
activity via the MRTF had no effect on the expression of sm-actin in these tissues. This 
indicates that MRTF/SRF activity plays a role in the regulation of tissue rigidity, and it further 















Figure 5.13: Effect of the SRF-dependent regulation of CTGF on viscoelastic properties of ECT  
NRCF and collagen were mixed and incubated in the presence or absence of 10 µM CCG-1423 for 5 days. (A) 
Representative images of ECT. Scale bar 5 mm. (B) ECTs were elongated stepwise in an organ bath, and passive 
force was detected. Shown are the cross sectional area (CSA) (left) and measured forces normalized to CSA 
(right) as means ± SEM, n = 3, 9-10 ECT were measured each, *p < 0.05 vs. control. (C) Stretched ECTs were 
minced and lysates were subjected to immunoblot analysis. Representative immunoblots (left) and 
quantification of CTGF and sm-Actin (right) are shown. Values are given as means ± SEM, normalized to tubulin 
and relative to control, n = 3 with 3-4 replicates, *p < 0.05 vs. control. 
 
 
5.3.4  p63RhoGEF expression in cardiac fibroblasts regulates contractility of engineered 
muscle tissue (EHM) 
For further evidence that p63RhoGEF is involved in auto- and more importantly paracrine 
signaling in cardiac fibroblasts and thus could effect the function of other cell types, e.g. the 
contractility of cardiomyocytes, NCRF transduced with p63RhoGEF or the Gαq/11 inhibiting 
p63ΔN adenovirus was added to a mixture of isolated heart cells in a 1:5 ratio, and 
engineered heart muscle tissue (EHM) were cast. Cultivation of these tissues was performed 
as described in section 4.2.2.7.  
First, equal distribution of infected NRCF was confirmed by EGFP detection (Figure 5.14 A, 
5.15 A). In addition, α-actinin staining of cardiomyocytes displayed a distinct striated pattern 
of the sarcomeres as proof for cardiomyocyte maturation within the tissue. It could be ruled 
out that cardiomyocytes were transduced by the respective virus, as no EGFP signal was 
visible in these cells. 
Isometric force measurement revealed that overexpression of p63RhoGEF increased the 
resting tension, comparable to the diastolic force generated in a heart, indicating higher 












































































calcium concentration, pointing to a better contractile performance of the cardiomyocytes in 
the EHM (Figure 5.14 B). Immunoblot analysis showed a CTGF increase of about 80%, while 
sm-actin on the protein level was unchanged (Figure 5.14 C). 
 
 
Figure 5.14: Impact of p63RhoGEF overexpression in cardiac fibroblasts on contractile function and CTGF 
expression of EHM  
NRCF were transduced with Ad-EGFP and Ad-p63RhoGEF for 24 h and added to cardiac cells for EHM 
preparation. (A) Representative images of Ad-EGFP EHM (left) and Ad-p63RhoGEF (right) by confocal 
microscopy are shown. EGFP expression was detected in sections of EHM to ensure equal distribution of 
modified fibroblasts. Cardiomyocytes were visualized by α-actinin and nuclei by DAPI staining. (B) Analysis of 
resting force (top graph) and contractile force (bottom graph) of EHM normalized to cross sectional area at 
different calcium concentrations is depicted. Shown are means ± SEM, n = 3-5, 15-20 EHM per group were 
analyzed, *p < 0.05 vs. EGFP. (C) Homogenized EHMs were used for immunoblot analysis. Representative 
immunoblots are shown. The expression of CTGF, calsequestrin-2 and sm-actin were normalized to β-actin and 
given relative to Ad-EGFP EHM. In addition, p63RhoGEF was detected by c-myc-tag and specific antibody. 
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Interestingly, when p63RhoGEF overexpressing adenovirus was added after tissue 
condensation on day 2 of cultivation, mainly cardiomyocytes of the EHM were infected 
(Figure 5.15 A) and no change in either resting tension or twitch tension was measured. 
(Figure 5.15 B). Immunoblot analysis revealed an elevated level of CTGF, which was, 
however, not significant (Figure 5.15 C). Thus, the improved contractility seems to be rather 
an effect of paracrine signaling initiated by p63RhoGEF expression in cardiac fibroblasts. 
 
 
Figure 5.15: Influence of p63RhoGEF overexpression in cardiomyocytes on contractile function and CTGF 
expression of EHM 
EHM were prepared with freshly isolated cardiac cells from neonatal rats and transduced with Ad-EGFP or Ad-
p63RhoGEF after tissue condensation on day 2. After cultivation and phasic stretch for 7 days, EHM were used 
for contraction analysis. (A) Representative images of Ad-EGFP (left) and Ad-p63RhoGEF (right) EHM by 
confocal microscopy are shown. Adenovirally infected cells were detected in sections of EHM by EGFP 
expression. Additionally, cardiomyocytes were visualized by α-actinin and nuclei by DAPI staining. (B) Analysis 
of contractile force (FOC; top graph) and resting force (RF; bottom graph) of EHM at different calcium 
concentrations is depicted. Shown are means ± SEM, n = 4, with a total of 12-16 EHM per condition were 
analyzed. (C) Homogenized EHMs were used for immunoblot analysis. Representative immunoblots are shown. 
The expression of CTGF, calsequestrin-2, and sm-actin were normalized to β-actin and given relative to control- 
transduced EHM. In addition, p63RhoGEF was detected by c-myc-tag and specific antibody. Values are given as 















EHM supplemented with p63ΔN-infected NRCF showed adverse effects as described 
previously for the overexpression of p63RhoGEF in EHM, presenting a lower resting tension 
accompanied by reduced twitch tension (Figure 5.16 B). CTGF as well as sm-actin were 
decreased by about 50% on protein level (Figure 5.16 C). 
 
 
Figure 5.16: Impact of p63RhoGEF inhibition in cardiac fibroblasts on contractile function and CTGF 
expression of EHM 
NRCF were transduced with Ad-EGFP and Ad-p63ΔN for 24 h and added to cardiac cells for EHM preparation. 
(A) Representative images of Ad-EGFP EHM (upper panel) and Ad-p63ΔN (lower panel) by confocal microscopy 
are shown. EGFP expression was detected in sections of EHM to ensure equal distribution of modified 
fibroblasts. Cardiomyocytes were visualized by α-actinin and nuclei by DAPI staining. (B) Analysis of resting 
force (top graph) and contractile force (bottom graph) of EHM normalized to cross sectional area at different 
calcium concentrations is depicted. Shown are means ± SEM, n = 3-5, 15-20 EHM per group were analyzed. (C) 
Homogenized EHMs were used for immunoblot analysis. Representative immunoblots are shown. The 
expression of CTGF, calsequestrin-2, and sm-actin were normalized to β-actin and given relative to Ad-EGFP 
EHM. In addition, p63ΔN was detected by c-myc-antibody and tubulin by specific antibody. Values are given as 
means ± SEM, n = 7-10, *p < 0.05 vs. EGFP. 
 
In conclusion, p63RhoGEF expression in cardiac fibroblasts clearly regulates contractile and 
viscoelastic properties in 3D engineered heart tissue and affects CTGF expression and 
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5 Results 
75 
5.4 Impact of the genetic deletion of p63RhoGEF in pressure overload-induced 
processes of cardiac remodeling 
So far, 3D experiments revealed that p63RhoGEF expression in cardiac fibroblasts regulates 
contractility and stiffness of engineered heart tissue. Overexpression of p63RhoGEF in EHM 
increased both contractility and tissue stiffness, while blocking the Gαq/11-pathway by the 
use of p63ΔN led to reduced contractile function and rigidity. Preliminary data in TAC mice 
demonstrated that p63RhoGEF expression is changed in pressure overload-dependent 
processes, and its up-regulation correlates with the deterioration of cardiac function. 
Therefore, the impact of a reduced and complete loss of p63RhoGEF expression in mice 
under healthy and pathological conditions of the heart was investigated. 
5.4.1 Mice with a global p63RhoGEF knockout are viable and fertile 
Due to the lack of a suitable approach to establish a mouse line with a fibroblast-specific 
deletion of p63RhoGEF at that time, a mouse line with a global knockout of p63RhoGEF was 
generated. For this purpose, flox-sites were integrated in the genome flanking exon 1 and 2 
of the p63RhoGEF allele (Figure 5.17 A). These p63flox/flox-mice were then mated with animals 
of an EIIa-Cre-line, which express the Cre-recombinase from early embryonic stadium on, 
resulting in a flox site-directed excision of exon 1 and 2; thus the start codon is removed by 
the Cre-recombinase. In order to receive homozygous p63RhoGEF-/--knockout animals in the 
next generations, heterozygous p63RhoGEF WT/- mice were mated with each other.    
Figure 5.17: Strategy for the generation of p63RhoGEF knockout mice 
(A) Schematic illustration of the p63RhoGEF genomic sequence with exon 1 and 2 flanked by flox sites for the
generation of a p63RhoGEF knockout allele. In addition, the binding sites of the respective primer for 
genotyping are shown. (B) Verification of p63RhoGEF deletion in the heart by immunoblot analysis. 
To prove the homozygous knockout (-/-) on genomic level, genotyping was performed as 
described in section 4.2.1.3. For verification of the knockout on protein level, heart samples 





















p63RhoGEF demonstrated a clear absence of a 63 kDa protein in knockout mice compared to 
mice carrying the homozygous floxed allele (Figure 5.17 B). 
For further experiments, mice with a homozygous (KO) as well as heterozygous (HET) 
knockout of p63RhoGEF were implemented. As control group, wild-type littermates (WT) 
were used.  All mice were viable and fertile and showed no abnormal phenotype under basal 
conditions. 
 
5.4.2 Partial deletion of p63RhoGEF influences cardiac function at basal condition 
To evaluate the influence of the genetic deletion of p63RhoGEF in the heart, cardiac 
performance was analyzed under basal condition by echocardiography. Analysis of cardiac 
parameter revealed that the ratio of the left ventricular weight to body weight (LVW/BW) 
was unchanged in male and female mice regardless of the genotype (Figure 5.18 A). In 
contrast, contractile parameters were considerably impaired in the heterozygous groups. As 
a marker for contractility, the fractional area shortening (FAS) was reduced by 10% and, 
significantly by 15% in HET male and female mice, respectively, showing a similar trend for 
the ejection fraction (EF) depicted in Table 5.1. Accompanied by this, the systolic volume 
(Vol s) (Figure 5.18 A) and left ventricular inner diameter (LVID s) (Table 5.1), indicators of 
changes in the left ventricular lumen, were elevated significantly in HET male and by trend in 
HET female mice. Interestingly, no difference was observed between the KO group and the 




Figure 5.18: Impact of the genetic deletion of p63RhoGEF in vivo 
(A) Evaluation of basal cardiac function in 10-12 week old mice by echocardiography. Shown are left ventricular
weight per body weight (LVW/BW), fractional area shortening (FAS), and systolic volume (Vol s). Values are 
given as means ± SEM, *p < 0.05 vs. WT group, 
#
p < 0.05 vs. KO group by ANOVA or two conditions by unpaired
t-test. The n-numbers are annotated in the respective bars. (B) Glycosylated proteins of ECM were visualized by
staining with WGA. A representative image is shown as an example (left), scale bar 50 µm. Cardiomyocyte area 
(middle) and perimeter (right) of cross-sectional heart sections were analyzed (CSA = cross-sectional area). 
Results are shown as median with maximal and minimal value, n = 6-10 with more than 200 cells per heart, *p < 
0.05 vs. WT group, 
#
p < 0.05 vs. KO group by ANOVA or two conditions by unpaired t-test.
On a cellular level, the dimension of cardiomyocytes in cross-sections of the heart was 
determined. Morphometric analysis exhibited an increased cardiomyocyte area and 
perimeter in KO male mice, whereas in KO female mice, both parameters are decreased. In 
the HET groups, no alteration to the control WT group regarding the cell area of 





































































































































































Table 5.1: Analysis of basal characterization by echocardiography  
Parameter WT M HET M KO M WT F HET F KO F 
n 28 16 43 30 17 24 
HR (beats/min) 435.9 ± 7.32  442.1 ± 9.28  435.8 ± 5.66  434.3 ± 8.28  433 ± 8.77 449.8 ± 9.39  
BW (g) 25.88 ± 0.45  26.68 ± 0.37  27.14 ± 0.32 
* 
20.81 ± 0.35  19.85 ± 0.36  20.9 ± 0.47  
LVW/BW 
(mg/g) 
4.04 ± 0.11  3.98 ± 0.1  4.05 ± 0.12  3.96 ± 0.12  4.19 ± 0.1     4.31 ± 0.15  
FAS (%) 34.94 ± 1.21  31.68 ± 1.02 
# 
34.92 ± 0.86  34.84 ± 1.36 29.59 ± 1.47 
*  
37.13 ± 1.72  
EF (%) 41.33 ± 1.3   38.06 ± 1.13 
# 
41.39 ± 0.84  40.66 ± 1.34  37.11 ± 1.36  42.74 ± 1.61  
Vol s (µL) 63.86 ± 2.65  72.9 ± 3.19 
 *  
68.28 ± 2.23  53.25 ± 2.26  56.67 ± 2.26  50.45 ± 2.29  
Vol d (µL) 108.4 ± 3.3  117.5 ± 4.5  
* 
118.8 ± 3.46 
* 
89.03 ± 2.62  89.78 ± 2.48  88.23 ± 2.56  
LVID s (mm) 3.71 ± 0.07  3.95 ± 0.08 * 3.76 ± 0,06  3.45 ± 0.08  3.57 ± 0.08  3.43 ± 0.09  
LVID d (mm) 4.63 ± 0.07  4.8 ± 0.08  4.75 ± 0.06  4.28 ± 0.06  4.32 ± 0.06  4.32 ± 0.08  
CI (%) 771.3 ± 
29.96  










CO (%) 19.7 ± 0.91  20.25 ± 1.3  21.51 ± 0.81  15.59 ± 0.67  14.55 ± 0.67  17.26 ± 0.84  
Abbrevations: n = number; HR = heart rate; BW = body weight; LVW/BW = left ventricular weight/body weight; 
FAS = fractional area shortening; EF = ejection fraction; Vol s = systolic volume; Vol d = diastolic volume; LVID s 
= left ventricular inner diameter in systole; = LVID d = left ventricular inner diameter in diastole; CI = cardiac 




5.4.3 Partial genetic deletion of p63RhoGEF leads to deterioration of contractility along 
with increased dilation in male mice after TAC 
Next, the impact of the reduced and lost expression of p63RhoGEF under pathophysiological 
condition was investigated. For this, male and female mice were subjected to either TAC or 
sham surgery and were monitored over a time period of 5 weeks. Analysis of 
echocardiography showed that in all male and female groups, the transverse aortic flow 
velocity given as the gradient increased equally, from 5-8 mmHg (sham group) to an average 








Table 5.2: Gradients measured by a pulse-waved Doppler 3 days after TAC surgery 
Para-
meter 
WT M HET M KO M WT F HET F KO F 
Sham TAC Sham TAC Sham TAC Sham TAC Sham TAC Sham TAC 













































*p < 0.05 vs. WT basal group, 
§
p < 0.05 vs. HET basal group, 
¥
p < 0.05 vs. KO basal group by ANOVA or two 
conditions by unpaired t-test. 
 
As a result of the TAC surgery, mice of all groups developed severe hypertrophy with a 
significant doubling of the LVW/BW from around 4 mg/g to 8 mg/g within 5 weeks (Figure 
5.19 and 5.20, upper panel) with the strongest effect seen already after 1 week. 
 
 
Figure 5.19: Influence of the genetic deletion of p63RhoGEF in male mice on cardiac function after TAC  
Evaluation of cardiac parameter after transverse aortic constriction (TAC) by echocardiography. Shown are 
pressure gradient, left ventricular weight per body weight (LVW/BW), fractional area shortening (FAS), and 
systolic volume (Vol s) of male mice. Values are given as means ± SEM, *p < 0.05 vs. WT basal group, 
§
p < 0.05 
vs. HET basal group, 
¥
p < 0.05 vs. KO basal group, 
#
p < 0.05 vs. WT and/or KO group by ANOVA or two 
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Along with the progression of hypertrophy, male mice showed clear worsening of contractile 
properties and transition to a dilative cardiac phenotype, with the most pronounced 
impairment in the HET male group.  
Within 5 weeks after surgery, the FAS decreased gradually by approximately 45% in all male 
groups, while the systolic volume was doubled compared to basal level (Figure 5.19 lower 
panel). Moreover, the EF also declined by approximately 40%, and the systolic LVID elevated 
by 28% (Table 5.3). Although the change in parameter progressed at a similar rate over the 
monitored time, the predisposed heterozygous male mice displayed the most severe 
deterioration of contractility, characterized by an overall decrease in FAS to 15% and EF to 
21%, accompanied by an earlier transition to a dilative left ventricular phenotype depicted 
as a high increase in systolic volume and LVID up to 162 µL and 5.2 mm, respectively (Table 
5.3). As already observed under basal conditions, the KO male group revealed a very similar 























Table 5.3: Analysis of cardiac parameters by echocardiography in male mice with TAC surgery  
Abbrevations: 1 w = 1 week after TAC, 2 w = 2 weeks after TAC, 5 w = 5 weeks after TAC 
Para- 
meter 
WT M HET M KO M 
basal 1 w 2 w 5 w basal 1 w 2 w 5 w basal 1 w 2 w 5 w 







































































































































































































































































































































































































































































































Abbrevations: n = number; HR = heart rate; BW = body weight; LVW/BW = left ventricular weight/body weight; 
FAS = fractional area shortening; EF = ejection fraction; Vol s = systolic volume; Vol d = diastolic volume; LVID s 
= left ventricular inner diameter in systole; = LVID d = left ventricular inner diameter in diastole; CI = cardiac 
index; CO = cardiac output; *p < 0.05 vs. WT basal group, §p < 0.05 vs. HET basal group, ¥p < 0.05 vs. KO basal 
group, 
#
p < 0.05 vs. WT and/or KO group by ANOVA or two conditions by unpaired t-test. 




In female mice, the overall effect of the pressure overload increase was less prominent than 
in the corresponding male mice, resulting in an approximately 21% decline in FAS and EF as 
well as a 45-50% and 15-20% increase in systolic volume and LVID, respectively, within 5 
weeks after TAC intervention. Additionally, the adverse effects seen in the HET male mice 
were less pronounced in the female HET group, showing only small differences in FAS and 
systolic volume compared to the female WT group (Figure 5.20; Table 5.4). Comparison of 
KO female and WT female mice again displayed a similar response to pressure overload, 
confirming the results observed in the male groups.  
These findings suggest that female mice in general can adapt to the increased afterload by 
TAC surgery better than male mice. 
 
 
Figure 5.20: Influence of the genetic deletion of p63RhoGEF in female mice on cardiac function after TAC 
Evaluation of cardiac parameter after transverse aortic constriction (TAC) by echocardiography. Shown are 
pressure gradient, left ventricular weight per body weight (LVW/BW), fractional area shortening (FAS) and 
systolic volume (Vol s) of female mice. Values are given as means ± SEM, *p < 0.05 vs. WT basal group, 
§
p < 0.05 
vs. HET basal group, 
¥
p < 0.05 vs. KO basal group, 
#
p < 0.05 vs. WT and/or KO group by ANOVA or two 















































































































Table 5.4: Analysis of cardiac parameters by echocardiography in female mice with TAC surgery 
Abbrevations: 1 w = 1 week after TAC, 2 w = 2 weeks after TAC, 5 w = 5 weeks after TAC 
Para- 
meter 
WT F HET F KO F 
basal 1 w 2 w 5 w basal 1 w 2 w 5 w basal 1 w 2 w 5 w 
























































































































































































































































































































































































































































Abbrevations: n = number; HR = heart rate; BW = body weight; LVW/BW = left ventricular weight/body weight; 
FAS = fractional area shortening; EF = ejection fraction; Vol s = systolic volume; Vol d = diastolic volume; LVID s 
= left ventricular inner diameter in systole; = LVID d = left ventricular inner diameter in diastole; CI = cardiac 
index; CO = cardiac output; *p < 0.05 vs. WT basal group, 
§
p < 0.05 vs. HET basal group, 
¥
p < 0.05 vs. KO basal 
group, 
#
p < 0.05 vs. WT and/or KO group by ANOVA or two conditions by unpaired t-test. 
 




Finally, the echocardiography parameters of the sham groups are given in table 7.1 for male 
and in table 7.2 for female mice (see appendix). No impact of the sham surgery was found. 
 
 
5.4.4 Genetic deletion of p63RhoGEF expression has no major influence on afterload 
induced hypertrophy  
At the endpoint of 5 weeks after TAC or sham surgery, hearts were collected for further 
histological investigations. As a hypertrophic response to the afterload induction, the excised 
hearts of TAC mice showed a prominent increase in the heart weight to tibia length ratio 
(HW/TL) of approximately 70-80% in all male groups and to a slightly lesser extent in female 
mice groups compared to the respective sham group, confirming the results obtained by 
echocardiography analysis (Figure 5.21). 
 
 
Figure 5.21: Influence of p63RhoGEF expression on afterload-induced hypertrophy 
Evaluation of hypertrophic hearts 5 weeks after transverse aortic constriction (TAC). (A) Representative images 
of excised hearts from male mice. Scale bar 1 cm. (B) Analysis of male (left) and female (right) heart weight 
(HW) normalized to tibia length (TL) is depicted. Values are given as means ± SEM, male n = 4-10, female n =  
3-8, *p < 0.05 vs. respective sham group by ANOVA or two conditions by unpaired t-test. 
 
To further verify the observed hypertrophy of the hearts on a cellular level, the cross-
sectional area (CSA) of ventricular cardiomyocytes were determined and showed a 
significant rise in cell size after TAC (Figure. 5.22 A). In all TAC male groups the 
cardiomyocyte area was increased by 160 ± 5.5 µm2 compared to the respective sham 
groups (Figure 5.22 B; upper panel). In the female mice, the cross-sectional area of 
cardiomyocytes was elevated by about 64.7 ± 3.6 µm2 in the WT as well as KO TAC group 
and, with 165.4 ± 5.5 µm2, even more in HET female mice compared to the sham group 



















































































reached the largest cross-sectional area (median 384.5 µm2), whereas KO female mice 




Figure 5.22: Evaluation of cardiomyocyte area and cell distribution after TAC 
Analysis of hypertrophy and heart cell composition 5 weeks after transverse aortic constriction (TAC). Cross-
sectional heart sections were prepared, and ECM was visualized by staining glycosylated proteins of the ECM 
with wheat germ agglutinin (WGA). Nuclei were stained using DAPI. (A) Representative images of sham and 
TAC hearts from male mice are depicted. Scale bar 50 µm. (B) Cross-sectional area (CSA) of cardiomyocytes 
from male (upper panel) and female (lower panel) hearts were determined. In addition, the ratio between 
cardiomyocytes (CM) and non-cardiomyocytes (NCM) were analyzed by cell and nuclei counting. Results are 
given as median with maximal and minimal value, male n = 4-9, female n = 3-7, *p < 0.05 vs. respective sham 
group, 
#
p < 0.05 vs. WT/KO group by ANOVA or two conditions by unpaired t-test. 
 
Furthermore, the distribution of cardiomyocytes (CM) and non-cardiomyocytes (NCM) 
within the cross-sections of the hearts was assessed by cardiomyocyte and nuclei counting 
(Figure 5.22 A). In sham-operated mice, the percentage of CM and NCM was around 60% to 
40%, respectively, while the proportion was shifted after TAC leading to a 50% : 50% 











































































































































































due to enhanced cell death of cardiomyocytes and/or proliferation by the non-
cardiomyocyte population was not further elucidated.  
In summary, the hypertrophic growth of the heart reflected by LVW/BW, HW/TL and 
cardiomyocyte size was similar in all analyzed animals. Moreover, no difference in the 
proportion of CM and NCM was found. 
On a molecular level, the expression of hypertrophy-associated marker in tissue of the left 
ventricle was determined by qPCR. Natriuretic peptides, such as ANP and BNP, are highly 
secreted by heart muscle cells in response to excessive stretching of the heart and high 
blood volume and are considered to be cardioprotective. The expression of ANP was 
significantly increased by about 17-fold and 20-fold in WT and KO animals after TAC, 
whereas the HET group revealed only an 8.5-fold up-regulation compared to the respective 
sham group. For BNP a 7.5-fold up-regulation in WT was found after TAC, while in the HET 
and KO group it was less increased compared to the WT group (Figure 5.23). 
 
 
Figure 5.23 Impact of p63RhoGEF expression level on the regulation of hypertrophy-associated factors  
Evaluation of gene expression 5 weeks after transverse aortic constriction (TAC). RNA was isolated from male 
and female hearts of TAC and sham operated mice, cDNA was synthesized, and expression of respective 
markers was assessed by qPCR. Values were normalized to the housekeeping gene PBGD and are given as 
means ± SEM, n = 4-10, *p < 0.05 vs. Sham group, 
#
p < 0.05 vs. WT/KO by ANOVA or two conditions by unpaired 
t-test. Abbrevations: ANP = atrial natriuretic peptide, BNP = brain natriuretic peptide, β-MHC = β-myosin heavy 
chain, CSQ = calsequestrin. 
 
The ratio of the contractile isoform of the myosin heavy chain α-MHC and β-MHC showed a 
4-fold up-regulation in the WT and KO TAC animals. In contrast, the ratio was already 2-fold 
higher in the HET sham group by trend compared to the WT sham animals and was not 
further up-regulated in the HET group after TAC. No significant changes on mRNA level were 
detected for calsequestrin. 
All together, no major difference in the up-regulation of molecular marker of cardiac growth 
in KO and WT TAC animals was found. In the HET group, the cardioprotective marker ANP 
and BNP were less up-regulated, and the β-isoform of myosin heavy chain was not increased 












5.4.5 Partial expression of p63RhoGEF decreases fibrosis in TAC animals by trend 
Next to hypertrophy, the influence of reduced and loss of p63RhoGEF expression on the 
appearance of fibrotic tissue due to pressure overload was assessed. Staining of cross-
sections of hearts for collagen, the main component of the ECM, revealed that the amount 
of fibrotic tissue was reduced in the HET TAC group of male and female mice in comparison 
to the WT TAC groups, however not significantly (Figure 5.24 A, B). In WT and KO TAC 
animals the level of collagen deposition in the perivascular as well as interstitial regions was 
massively increased.  
 
 
Figure 5.24: Impact of p63RhoGEF expression on myocardial fibrosis 
Evaluation of fibrotic tissue 5 weeks after transverse aortic constriction (TAC). Cross-sectional heart sections 
were stained with Fast Green (non-collagen in green) and Sirius Red (collagen in red). (A) Representative 
images of sham and TAC male hearts are shown. Scale bar 1 mm. (B) Amount of collagen was analyzed in male 
and female hearts using Image J and is given in percent, *p < 0.05 vs. sham group by ANOVA or two conditions 
by unpaired t-test. 
 
Notably, the KO mice displayed a clear overall increase in collagen deposition in comparison 
to the respective sham group, while in the WT group, two subgroups emerged. As described, 
one subgroup developed elevated levels of fibrosis ranging from 3-7% of collagen per cross-
sectional area, whereas in the other subgroup, the collagen amount remained within the 
same range (below 1%) as in the respective sham group. 
To further validate these findings on a molecular level, expression of fibrosis-associated 
marker was investigated by quantitative RT-PCR. In general, most of these factors were 
highly up-regulated after TAC (Figure 5.25).  
The myofibroblast marker sm-Actin was already approximately 2-fold and 3-fold up-
regulated in the sham animals of the HET and KO groups, respectively. In the WT and HET 
animals a similar increase in sm-actin was observed after TAC, while in the KO TAC group no 
further up-regulation occurred. Collagen type 1 (Col1a1) was increased 5-fold and 4-fold in 





























































increase on mRNA level. Collagen type 3 (Col3a1) was increased 4-fold in both the HET and 
KO TAC groups, with a slightly lower amount of mRNA in the WT group.  
 
 
Figure 5.25: Impact of p63RhoGEF expression level on the regulation of fibrosis-associated factors  
Evaluation of fibrotic factors 5 weeks after transverse aortic constriction (TAC). RNA was isolated from male 
and female hearts of TAC and sham operated mice, cDNA was synthesized, and expression of fibrotic markers 
was assessed by qPCR. Values were normalized to the housekeeping gene PBGD and are given as means ± SEM, 
n = 4-10, *p < 0.05 vs. sham group, 
#
p < 0.05 vs. WT/KO, 
§
p < 0.05 vs. WT Sham by ANOVA or two conditions by 
unpaired t-test. Abbrevations: sm-Actin = smooth muscle-Actin, Col1a1 = collagen type 1, Col3a1 = collagen 
type III, LGALS3 = galectin-3, biglycan, MMP2 = matrix metalloproteinase 2, TGF-β = transforming growth 
factor-β, CTGF = connective tissue growth factor. 
 
In contrast, the β-galactoside binding lectin LGALS3 showed a 7- to 8-fold rise on mRNA level 
in KO and WT TAC animals, but was significantly less increased in the HET group. Biglycan, a 
proteoglycan involved in collagen fibril assembly, displayed similar elevated levels for the WT 
and HET TAC group, with an even higher increase in the KO TAC group.  For MMP2, a matrix 
degrading proteinase, already an up-regulation in the HET and KO Sham group in a dose-
dependent manner was found to have reached a 2.5-fold increase in the KO Sham group. 
After TAC, MMP2 was approximately 10-fold up-regulated in both HET and KO animals, while 
the WT group showed a less increased level. CTGF increased by approximately 9-fold in WT 
and HET TAC groups and was slightly less up-regulated in the KO animals after TAC. 
Interestingly, TGF-β showed similarly elevated mRNA levels in the WT and KO TAC groups, 























The results obtained from the histological staining of collagen and the expression profile of 
fibrotic marker point to a changed regulation of the ECM turnover in the HET mice after TAC 
that was different from the WT group. Thus, reduction of p63RhoGEF expression might have 
a beneficial effect on afterload-induced fibrosis. 
 
 
5.4.6 The knockout of p63RhoGEF increases the mortality in male mice in afterload 
induced cardiac disease 
Comparison between KO and WT groups after TAC surgery showed no huge difference in 
cardiac performance within the 5 weeks of monitoring. Furthermore, hypertrophy and 
fibrosis were established in a similar way. Interestingly, a dramatic increase in mortality was 
observed among KO male mice within the first two weeks after TAC leading to a survival rate 
of less than 60% (Figure 5.26). 
 
 
Figure 5.26: Impact of p63RhoGEF knockout on survival rate after TAC 
Kaplan-Meier survival rate over a time period of 3 weeks after TAC is shown. WT F n = 9, HET F n = 7, KO F n = 
10, WT M n = 12, HET M n = 6, KO M n = 28.  
 
To elucidate possible reasons that might have led to this impaired survival in afterload-
dependent cardiac disease, underlying processes of cardiac remodeling were examined 
more closely. Heart samples from KO male mice, which had to be sacrificed, were used for 
evaluation on the histological level. Analysis of the cross-sectional area and perimeter of 
cardiomyocytes revealed a significant decrease in cell size and perimeter compared to basal 
KO mice and WT mice. In contrast, 2 weeks after TAC, the cardiomyocyte area and perimeter 
were already increased, showing a hypertrophic response due to pressure overload (Figure 

































5.27 B). In addition, no change in the proportional distribution of cardiomyocytes (CM) and 
non-cardiomyocytes (NCM) was detected in the sacrificed male mice keeping a 60% CM to 
40% NCM ratio like the basal KO and WT group. 
Figure 5.27: Analysis of cardiomyocyte area and cell distribution in the context of increased mortality in KO 
male mice after TAC  
Analysis of hypertrophy and heart cell composition within 2 weeks after transverse aortic constriction (TAC). 
Cross-sectional heart sections were prepared from male mice before TAC surgery (WT M basal and KO M 
basal), 2 weeks after TAC surgery (WT M TAC and KO M TAC), and sacrificed male mice between 2-7 days after 
TAC (KO M dead). The ECM was visualized by staining glycosylated proteins of the ECM with wheat germ 
agglutinin (WGA) for glycosylated proteins of the ECM. Nuclei were stained using DAPI. (A) Representative 
images of basal and TAC hearts from WT and KO male mice are depicted. Scale bar 50 µm. (B) Cardiomyocyte 
area (left) and perimeter (middle) of cross sectional heart sections were analyzed. In addition, the ratio 
between cardiomyocytes and non-cardiomyocytes was analyzed by cardiomyocyte and nuclei counting (right). 
n = 3-6 with more than 200 cells per heart *p < 0.05 vs. respective basal group by ANOVA or two conditions by 
unpaired t-test. 
For this reason, extensive hypertrophy and changes in cell proportions can be excluded as 
putative factors influencing the death rate shortly after TAC.  
Likewise, the amount of fibrosis by analysis of collagen as well as the WGA amount was 
examined and revealed no excessive fibrotic response in the sacrificed mice compared to KO 
and WT male mice 2 weeks after TAC. Rather, the amount was similar to the basal KO group 
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Figure 5.28: Evaluation of fibrosis in the context of increased mortality in KO male mice 
Evaluation of fibrotic tissue in short term after transverse aortic constriction (TAC). Cross-sectional heart 
sections were prepared from male mice before TAC surgery (WT M and KO M basal), 2 weeks after TAC surgery 
(WT M TAC and KO M TAC), and sacrificed male mice between 2-7 days after TAC (KO M dead) and stained with 
Fast Green (non-collagen in green) and Sirius Red (collagen in red). (A) Representative images of basal and TAC 
male hearts are shown. Scale bar 1 mm. (B) Amount of collagen was analyzed using Image J and is given in 
percent, *p < 0.05 vs. sham group by ANOVA or two conditions by unpaired t-test. 
In summary, the data obtained regarding the role of p63RhoGEF in vivo in healthy and under 
pathophysiological condition argue for an ambivalent role of p63RhoGEF. 
The partial deletion of p63RhoGEF, especially in case of the male group, display a pre-
disposed cardiac phenotype with an impaired cardiac function characterized by a decrease in 
contractility together with a dilative heart geometry due to an increased lumen of the left 
ventricle. Upon induction of pressure-overload using the TAC model, these phenotype is 
worsening over time, leading to extremely poor cardiac performance among these mice. The 
reduced expression had no major effect on the development of hypertrophy in 
cardiomyocytes, but it diminished the amount of fibrosis by trend. 
The general knockout of p63RhoGEF in mice led to a phenotype similar to that described for 
the WT mice, arguing for compensatory mechanisms that occur for the loss of p63RhoGEF 
expression. As a result, in the first instance, KO mice showed no major difference in cardiac 
function and associated processes at basal and under pressure-load condition in comparison 
to the WT control. Nonetheless, KO male mice depicted a higher mortality rate within the 
first 2 weeks after TAC. Neither hypertrophy nor fibrosis was detected in the sacrificed KO 
mice within this time window, thereby ruling out a direct contribution regarding the 
increased death rate shortly after TAC. 
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5.5 Influence of the genetic deletion of p63RhoGEF in adult mouse cardiac 
fibroblasts 
Finally, the effect of the genetic deletion of p63RhoGEF in adult cardiac fibroblast was 
investigated. For this purpose, fibroblasts were isolated from female and male mice with an 
age of 40-60 weeks and mixed equally for cultivation. 
5.5.1 Genetic deletion of p63RhoGEF has no effect on the myofibroblast phenotype of 
isolated cells, but might influence the reorganization of the actin cytoskeleton 
First, characterization of the isolated adult mouse cardiac fibroblasts (AMCF) was carried 
out. Since the method of isolation does not include a further purification step to separate 
the cardiac fibroblasts from other fast-attaching cardiovascular cells e.g. smooth muscle 
cells, which show a similar morphological phenotype in culture, the homogeneity of 
fibroblasts within the population was assessed by marker expression on mRNA level. 
Endpoint RT-PCR revealed that regardless of the genotype, AMCF strongly express (myo-) 
fibroblast-associated marker FSP-1 (fibroblast specific protein 1) and Col1a1 (collagen type 1) 
(Figure 5.29). In addition, sm-actin (smooth muscle actin) is similarly expressed on mRNA 
level. The smooth muscle-associated calcium binding protein Calp1 (calponin 1) was 
detected in all genotypes at low level. None of the other smooth muscle cell markers such as 
smMHC (smooth muscle myosin heavy chain), desmin, or sm22 (smooth muscle protein) was 
detected, and the endothelial markers VE-cadherin (vascular endothelial cadherin) and CD31 
(PECAM-1) were also absent.  
Analysis of the expression profile suggests that, independent of the deletion of p63RhoGEF, 
isolated cardiac fibroblast displays a pronounced myofibroblast phenotype in culture, and 
contamination by other non-myocyte cell types were low. 





Figure 5.29: Evaluation of marker expression in AMCF  
Cardiac fibroblasts isolated from adult p63RhoGEF wildtype (WT), heterozygous (HET), and knockout mice (KO) 
were cultivated, RNA was isolated, and cDNA was synthesized. Endpoint RT-PCR was performed using 
fibroblast/myofibroblast (FSP-1, Col1a1), smooth muscle cell (sm-actin, smMHC, Desmin, Calp1, sm22), and 
endothelial (CD31, VE-Cad) specific marker. As a housekeeping gene, porphobilinogen deaminase (PBGD) was 
included.  Abbrevations: FSP1 = fibroblast specific protein 1, Col1a1 = collagen type 1, sm-actin = smooth 
muscle actin, smMHC  = smooth muscle myosin heavy chain, Calp1 = Calponin 1, sm22 = smooth muscle 
protein 22, VE-Cad = VE-cadherin, CD31 = PECAM1. Representative PCR of 3-4 replicates is shown.  
 
Next, the morphology of AMCF was examined. For this, cultured and serum-starved cells 
were fixed and stained for actin structures with fluorescent-labelled phalloidin. On a planar 
cell culture dish, adult fibroblasts showed a flat, widespread morphology and formed thick 
actin fibers, so-called stress fibers, which is a typical feature of a myofibroblast character 
(Figure 5.30 A). Analysis of the surface area revealed that the cell area can vary from 4000-
40000 µm2, with the majority of cells ranging in a smaller fraction between 4000 and 12000 
µm2 (Figure 5.30 B). Regarding the genotype, no difference was observed, but in general 

























Figure 5.30: Morphometric analysis and protein expression of isolated AMCF 
Cardiac fibroblasts were isolated from WT, HET and KO adult mice and cultivated. (A) Representative images of 
actin-stainings of AMCF after 48 h of serum-free cultivation. Scale bar 100 µm. (B) Analysis of cell surface area 
of cardiac fibroblasts  cultivated  for 48 h under serum-free condition, n =5. (C) Size measurement of detached 
cardiac fibroblasts by low voltage field resistance measurements (CASY). Values are given as means ± SEM, n= 
16-22, *p < 0.05 vs. WT by ANOVA or two conditions by unpaired t-test. (D) Cardiac fibroblasts isolated from
adult mice were cultivated and serum-starved for 24 h prior to the experiment. Protein lysates were collected
and immunoblot analysis was performed. Representative immunoblots (left) and quantification of proteins
(right) are shown. Given are means ± SEM normalized to tubulin, n=4 (p63RhoGEF), n=12 (RhoA), n = 8
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5 Results 
95 
Apart from the cell surface area, the volume of detached cells was assessed by voltage-field 
measurements depicting a significant 20% decline in cell volume in HET and KO AMCF (Figure 
5.30 C). Therefore, expression of cytoskeletal proteins was examined by immunoblot 
analysis. Regardless of the genotype, expression of sm-actin, tubulin and the focal adhesion 
protein vinculin was unchanged (Figure 5.30 D).  
In addition, the genetic deletion of p63RhoGEF could be validated on protein level using a 
specific antibody against p63RhoGEF. While in the HET AMCF the expression of p63RhoGEF 
was reduced significantly, more than 50% compared to the WT fibroblasts, in the KO AMCF 
no expression was detectable. Interestingly, the amount of total RhoA expression was not 
altered by the deletion of its upstream activator. 
To investigate a possible effect of the genetic deletion on downstream targets of 
p63RhoGEF-RhoA signaling, the impact of ROCK (Rho-associated protein kinase) activity was 
examined. In particular, phosphorylation of the ROCK targets cofilin as well as proteins of the 
ERM family (ezrin, radixin, moesin) were determined. While cofilin controls the 
reorganisation of actin filaments, proteins of the ERM complex serve as a crosslink between 
actin filaments and the plasma membrane. 
Figure 5.31: Influence of the genetic deletion of p63RhoGEF on ROCK targets 
Cardiac fibroblasts isolated from adult mice were cultivated and serum-starved for 24 h. Protein lysates were 
prepared and immunoblot analysis was performed. (A) Representative immunoblots (left) and quantification of 
cofilin and ezrin/radixin/moesin (ERM) (right) are shown. In addition, β-Actin and tubulin were included for 
equal protein loading. Ratios of phosphorylated and unphosphorylated cofilin and ERM are given as means 
± SEM and relative to WT group, n = 5-6. 
As immunoblot analysis indicated, both targets showed elevated phosphorylation levels in 
p63RhoGEF KO cells, which was, however, not significant (Figure 5.31). In the HET AMCF, no 














































































In summary, isolated AMCF in culture display a prominent myofibroblast phenotype by 
strong expression of sm-actin and collagen type 1 accompanied by a strong stress fiber 
formation, which is independent of the genotype. While no major effect of the p63RhoGEF 
deletion on general expression of cytoskeletal protein and the total RhoA amount was seen, 
the knockout of p63RhoGEF led to increased phosphorylation and thereby activation of 
ROCK targets involved in actin reorganization. 
5.5.2 Genetic deletion of p63RhoGEF increases CTGF expression and up-regulates sm-actin, 
TGF-β as well as collagen in AMCF 
As the fact that p63RhoGEF regulates the expression and secretion of CTGF was 
demonstrated in neonatal cardiac fibroblasts by gain- and loss-of-function studies, the 
impact of the genetic deletion on CTGF in adult cardiac fibroblasts was examined. 
On basal level, CTGF was significantly increased by 2-fold in KO AMCF compared to the WT 
control, while no difference in cardiac fibroblasts with the partial deletion was observed. 
Upon treatment with angiotensin II for 3 h, an up-regulation by around 2-fold in WT and HET 
AMCF was detected, whereas the strongest effect was seen in the KO AMCF with a 6-fold 
increase in CTGF mRNA (Figure 5.32 A). After 24 h of angiotensin II incubation, this effect 
was reversed to its unstimulated level independent of the genotype of the cells, suggesting 
that prolonged stimulation with Ang II has no additional effect on CTGF up-regulation. This is 




Figure 5.32: Evaluation of the genetic deletion of p63RhoGEF on CTGF expression in AMCF 
Cardiac fibroblasts isolated from adult mice were cultivated and serum-starved for 24 h prior to the 
experiments. (A) AMCF were treated for 3 h and 24 h with 100 nM Ang II, and total RNA was isolated, cDNA 
synthesized, and qPCR was performed. Values were normalized to the house-keeping gene PBGD and are given 
relative to WT group. Results are shown as means ± SEM n = 3-8, *p < 0.05 vs. WT control, 
#
p < 0.05 vs.
respective control group/WT 3h by ANOVA or two conditions by unpaired t-test. (B) AMCF were treated for 
24 h with 100 nM Ang II, and conditioned media and protein lysates were collected. Immunoblot analysis was 
performed. Representative immunoblots (upper panel) and quantification of intracellular and secreted CTGF 
(lower panel) are shown. Values are given as means ± SEM, normalized to tubulin and relative to WT group, n = 
5, *p < 0.05 vs. WT by ANOVA or two conditions by unpaired t-test. 
On protein level, deletion of p63RhoGEF had no effect on the intracellular level of CTGF 
under control condition, but led to a significantly higher secretion, 1.75 and 2 fold, of CTGF 
in HET and KO cells, respectively. Stimulation with angiotensin II for 24 h resulted in a 30% 
rise in intracellular and secreted CTGF in WT AMCF, while in HET and KO AMCF, no further 













































































































































































As several factors were unexpectedly found to be increased in p63RhoGEF KO AMCF, the 
impact of the genetic deletion regarding several myofibroblast genes was analyzed. Results 
of the qPCR revealed a significant augmentation in a dose-dependent manner, resulting in 
approximately a 2-fold up-regulation of TGF-β and Col1a1 in KO AMCF (Figure 5.33), 
validating the myofibroblast phenotype. 
While no difference in sm-actin expression was detected on protein level (Figure 5.30 D), the 
mRNA level of sm-actin was significantly increased by 3- and 5-fold in HET and KO AMCF, 
respectively. This might argue for a higher mRNA degradation rate in HET and KO AMCF.  
 
 
Figure 5.33: Basal characterization of gene transcription in AMCF 
Cardiac fibroblasts isolated from adult mice were cultivated and serum-starved for 24 h. (A) Total RNA was 
isolated, cDNA was synthesized and qPCR was performed for RhoA, TGF-β (Transforming growth factor-β), 
Col1a1 (collagen type 1) and sm-Actin (smooth muscle-Actin). Values were normalized to the house-keeping 
gene PBGD and are given relative to WT group. Results are shown as means ± SEM, n = 4, *p < 0.05 vs. WT by 
ANOVA or two conditions by unpaired t-test. 
 
5.5.3 Loss of p63RhoGEF expression improves cell survival/growth and proliferative 
capacity 
In line with the paradox signaling in AMCF with a knockout of p63RhoGEF, immunoblot 
analysis for targets involved in survival and cell growth was performed. Detection of Akt, as a 
marker for cell survival, and ERK1/2 indicative of cell growth signaling, revealed a significant 
60% higher phosphorylation for Akt and ERK1/2 (Figure 5.34 A). This points to a beneficial 
effect on survival and growth for KO AMCF in general. 
In order to substantiate the results obtained by immunoblot analysis, a proliferation assay 
was carried out over a time period of 6 days. Cultivation with serum-containing medium led 
to a 4-fold rise in cell number in WT AMCF, whereas in KO AMCF an approximately 5-fold 






























































































Figure 5.34: Influence of the genetic deletion of p63RhoGEF on cell survival/growth and proliferative capacity 
(A) Cardiac fibroblasts isolated from adult mice were cultivated and serum-starved for 24 h. Protein lysates
were prepared, and immunoblot analysis was performed. Representative immunoblots (left) and quantification 
of phosphorylated Akt and ERK1/2 (right) are shown. Values are given as means ± SEM normalized to the 
loading control Rab11 and relative to WT group, n = 5-6, *p < 0.05 vs. WT. (B) Cardiac fibroblasts isolated from 
adult mice were seeded on a 24-well plate (10.000 cells/well) and cultivated with or without serum-containing 
medium for up to 6 days. For each time point, cells were fixed and stained with DAPI and cell number was 
determined by cell nuclei counting. Values are presented as means ± SEM, WT n=11, HET n=6 and KO n=11, 
*p < 0.05 vs. 0 hours.
In contrast, cultivation under serum-free condition led to a 25% decrease in cell number of 
all 3 genotypes after 6 days. Interestingly, the KO AMCF showed almost no reduction or even 
a slight increase in cell number until day 4 of culture without serum compared to WT, 
suggesting a pro-survival effect for the KO AMCF in absence of serum, presumably due to 
activated survival pathways. 
All together, the loss of p63RhoGEF in adult cardiac fibroblasts leads to a paradox signaling 
by up-regulation of downstream effectors demonstrated by CTGF and changes in the 
phosphorylation pattern of ROCK targets mostly in a dose-dependent manner. Moreover, in 
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The aim of this thesis was to investigate the role of the guanine nucleotide exchange factor 
p63RhoGEF, a specific activator of the RhoGTPase RhoA, in the heart and in cardiac 
fibroblasts in particular. 
By gain-and-loss-of-function studies, the role of p63RhoGEF within the Gαq/11-p63RhoGEF-
RhoA signaling cascade in cardiac fibroblasts was further investigated. In the context of auto- 
and paracrine signaling, the impact of p63RhoGEF in cardiac fibroblasts on tissue properties 
as well as its influence on the contractile function of cardiomyocytes in 3D engineered tissue 
models was elucidated. A special focus was thereby laid on the regulation of the fibrosis 
marker CTGF. In the second part of the study, the relevance of p63RhoGEF expression and its 
genetic deletion in the healthy myocardium and under load-induced cardiac disease 
conditions was determined. Consequently, the role of p63RhoGEF expression and its 
deletion in isolated adult cardiac fibroblasts (AMCF) of the generated mouse line was 
examined. 
6.1 Cellular function of p63RhoGEF in neonatal cardiac fibroblasts 
In the scope of this project, the cellular function of p63RhoGEF in cardiac fibroblasts was 
further characterized. Previous research had demonstrated that p63RhoGEF regulates the 
Gαq/11-dependent RhoA activation as well as CTGF expression and secretion induced by 
Ang II (as described in section 3). RhoA controls many different cellular functions including 
migration, proliferation and contraction mainly by regulating the actin cytoskeleton [183]. 
Activation of RhoA results in the formation of focal adhesion complexes [184] and induces 
the formation of actin stress fibers, which involves actin polymerization. In this process, actin 
filaments (F-actin) are assembled from monomeric globular actin (G-actin), which also binds 
the myocardin-related transcription factor MRTF, a co-factor of the SRF. High levels of 
cytoplasmatic G-actin retain the MRTF in the cytoplasm and negatively regulate MRTF 
function. Incorporation of G-actin into filamentous actin polymers during actin fiber 
assembly reduces the concentration of free G-actin in the cytosol and hence releases the 
bound MRTF enabling the translocation into the nucleus [185]. Within the nucleus MRTF 
interacts with the serum response factor (SRF) and activates the transcription of genes 
encoding for many contractile and cytoskeletal proteins as well as for fibrotic factors, e.g. 
sm-actin and CTGF [186-188]. In turn, nuclear MRTF can be complexed by nuclear G-actin, 
which prevents the MRTF-mediated activation of the SRF-dependent transcription and 
thereby promotes the MRTF nuclear export [189]. In this way, RhoA activation by 
p63RhoGEF could potentially influence actin dynamics and actin-dependent gene 
transcription.  
With respect to cardiovascular cells, the influence of p63RhoGEF and RhoA on the actin 
cytoskeleton in smooth muscle cells of the rat aorta was investigated. The knockdown of 
p63RhoGEF in these cells reduced the formation of actin stress fibers along with 
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rearrangements of focal adhesions [169]. So far, for neonatal rat cardiac fibroblasts it has 
been possible to show that the knockdown of RhoA expression resulted in a less organized 
actin network with impaired actin structures [190] emphasizing the impact of p63RhoGEF 
and RhoA expression on the regulation and organization of the actin cytoskeleton. In 
addition, the actin-dependent regulation of the SRF by the co-factor MRTF in the underlying 
mechanisms of RhoA signaling was demonstrated in these cells [190]. Accordingly, the 
impact of p63RhoGEF expression on the SRF was implemented in the presented study. 
The data revealed that p63RhoGEF regulates the Ang II-dependent activation of the SRF, as 
overexpression of p63RhoGEF increased SRF activity, while blocking the Gαq/11-pathway 
using p63ΔN blunted its activity in the presence of Ang II. Consequently, inhibition of the 
MRTF by CCG1423 (CCG) blunted the Ang II-induced response of the SRF and reduced CTGF 
secretion. In this way, a direct link between SRF and CTGF in cardiac fibroblast could be 
established, which had previously been demonstrated in LPA-treated peritoneal fibroblasts 
[191]. Interestingly, CCG itself enhanced the basal SRF activity and increased the intracellular 
amount of CTGF. This could be explained by the involvement of other co-factors of the SRF. 
Inhibition of the MRTF translocation into the nucleus, where it activates the SRF and thereby 
regulates gene transcription, could result in a more effective interaction of the SRF with 
other co-factors like ETS-domain containing co-factors, e.g. Elk1 [192] leading to the 
observed higher SRF activity. Another plausible reason includes the contribution of other 
actin-dependent transcription factors, like of the YAP/TEAD complex, which was proven by 
Pobbati et al. to be important for CTGF regulation [193]. In this context, involvement of the 
Rho/ROCK signaling has already been reported [194]. As ROCK inhibition by H1152p was not 
effective in blocking the Ang II-dependent SRF activation, but reduced CTGF expression 
[195], a role of Rho/ROCK on CTGF expression via YAP/TEAD might be conceivable.  
To date, no localization studies by immunostaining of p63RhoGEF in cardiac fibroblasts have 
been performed and results by confocal imaging demonstrated in both NRCF and AMCF that 
p63RhoGEF is localized at membrane structures which has been reported before [152]. A 
predominant localization at the trans-Golgi compartment and the base or pocket of primary 
cilia was found. These structures are highly involved in the secretion process suggesting that 
p63RhoGEF might be actively participating in the secretory mechanism. In addition, 
p63RhoGEF co-localizes with CTGF. As part of the pocket of primary cilia p63RhoGEF could 
be involved in controlling the secretion of specific proteins into the extracellular space [196]. 
Further studies will be needed to determine the localization and putative interaction 
partners involved in signaling within the basal body of primary cilia more specifically. 
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6.2 Influence of p63RhoGEF and its downstream effector CTGF on viscoelastic and 
contractile properties of 3D engineered tissue 
A central part of this thesis covered the analysis of the role of p63RhoGEF in cardiac 
fibroblasts in the context of auto-and paracrine signaling. This involved the implementation 
of 3D engineered models to address the topic. In ECT (engineered connective tissue of 
collagen matrix and fibroblasts), it was demonstrated that p63RhoGEF regulates tissue 
stiffness. Overexpression of p63RhoGEF resulted in a greater rigidity, while blockade of the 
Gq/11-induced RhoA activation by p63∆N resulted in a lower tissue rigidity. Moreover, 
p63RhoGEF seems to facilitate the secretion of CTGF, since after mechanical stress the CTGF 
content decreased dramatically when p63RhoGEF was overexpressed in these tissues. This 
result was not observed in ECT expressing p63ΔN suggesting that with the help of 
p63RhoGEF the release of secreted factors is more effective. This further substantiates the 
finding that in 2D culture p63RhoGEF led mainly to a change in the secreted proportion of 
CTGF. These findings strongly argue for a role of p63RhoGEF as a regulator of secretion per 
se. 
In terms of cardiac fibrosis, the role of CTGF is not clear and is a subject of controversy in the 
literature. As CTGF was found to be upregulated in diverse fibrotic diseases, it has been 
widely accepted as a profibrotic factor [52]. However, recently published studies depicted 
conflicting data on the function of CTGF within the heart. While several studies support a 
cardioprotective function and thereby a beneficial effect of CTGF expression for 
cardiomyocyte survival [181, 182, 197, 198], other reports state that its expression has 
detrimental effects on cardiac fibrosis [69]. Still other studies postulate that CTGF has no 
influence in regard to cardiac diseases. Accornero et al. demonstrated that neither a heart-
specific deletion nor overexpression of CTGF had any impact on cardiac remodeling and 
function with aging or after multiple acute stress stimuli [90]. This was further supported by 
another study showing that a conditional knockout of CTGF failed to prevent TAC-induced 
cardiac fibrosis and hypertrophy [86]. Therefore, in the present study, the direct 
contribution of CTGF in cardiac fibroblasts on tissue rigidity was investigated with the use of 
the defined ECT model. The data clearly showed that CTGF overexpression had no effect on 
the stiffness of the tissue suggesting that CTGF is not the determining factor causing the 
change of the biomechanical properties. In addition, the impact of the MRTF/SRF inhibition 
by CCG was analyzed in ECTs resulting in a decreased stiffness. As already seen in 2D the 
SRF/MRTF inhibition led to an increased expression of CTGF, which substantiates that CTGF 
is not relevant for tissue properties and, furthermore, that other transcriptional activities are 
regulating CTGF when MRTF is blocked. Therefore, the data of this thesis supports the latest 
studies that CTGF is likely not a mediator of cardiac fibrosis. 
As a second 3D model, engineered heart muscle was generated to explore the impact of 
p63RhoGEF expression in fibroblasts and consequently the influence on cardiomyocyte 
function via paracrine signaling. Overexpression of p63RhoGEF in cardiac fibroblasts 
increased contractility and tissue rigidity in EHM accompanied by an enhanced CTGF level, 
whereas EHM with cardiac fibroblasts transduced with the p63ΔN construct showed a 
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decrease in contractility by trend and a reduction in CTGF level. Interestingly, when 
p63RhoGEF was mainly overexpressed in cardiomyocytes, no improved contractility was 
measured clearly pointing to a relevant contribution of p63RhoGEF expression in cardiac 
fibroblasts.  
The improved contractility and the simultaneous higher resting tension, indicative of tissue 
stiffness seems to be contradictory at first, but might be explained by the different response 
of cardiac fibroblasts and cardiomyocytes in auto- and paracrine signaling. It is likely that 
cardiac fibroblasts not only secrete factors influencing the viscoelastic properties of the 
myocardium, but also factors that influence the contractile performance of cardiomyocytes. 
Factors like TGF-β1, FGF-2, LIF and CT-1 are just a few examples of bioactive molecules that 
are known to act in a bidirectional crosstalk [199]. Nonetheless, secretome analysis needs to 
be performed to identify responsible factors downstream of p63RhoGEF-RhoA signaling to 
explain the observed changes in tissue properties. 
6.3 The relevance of p63RhoGEF expression in the pathophysiology of cardiovascular 
diseases 
In 2002 p63RhoGEF was first characterized and shown to be predominantly expressed in 
heart and brain tissue [162]. However, since then no data has been added to its role in the 
heart in vivo. Therefore, the regulation of p63RhoGEF was analyzed in a pilot study that 
included tissue samples from two different heart disease mouse models: a pressure-induced 
afterload model obtained by transverse aortic constriction (TAC) and a volume-induced 
preload model generated by an aortocaval shunt (Shunt) surgery. Comparison of these two 
different hypertrophy models revealed that both p63RhoGEF and also CTGF were higher up-
regulated after TAC, while only a slight up-regulation of both factors was detected in the 
shunt model. Interestingly, at the time points investigated, no cardiac fibrosis was detected 
in the shunt model but was apparent in the TAC model [175]. This demonstrates that 
p63RhoGEF plays a more relevant role in the underlying mechanisms of cardiac remodeling 
in pressure overload-associated heart disease. In this process, the TAC model mimics 
pressure-induced stress such as hypertension and valve dysfunction, causing a higher 
workload for the heart to be able to fulfill the body´s nutrient and oxygen demands, which 
initially induces a hypertrophic response as a compensatory mechanism. The results of this 
first pilot mouse study supports the findings in hypertensive patients, in whom p63RhoGEF 
expression correlates with the degree of blood pressure and deterioration of the cardiac 
function [171]. Moreover, this pilot study indicated that p63RhoGEF is also involved in 
mechanisms leading to cardiac fibrosis also in vivo as already suggested by the in vitro data.  
To further address the function of p63RhoGEF in vivo, the genetic deletion of p63RhoGEF in 
mice was studied under basal and pathological conditions. This involved generation of a 
transgenic mouse line with a global knockout of p63RhoGEF from embryonic stage on. The 
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offspring of these mice were viable, fertile and showed no abnormal behavior. This first 
observation suggests that p63RhoGEF expression is not essential for embryonic 
development and its deletion is not lethal. In addition to mice with a total knockout (KO), 
animals with only a partial deletion and thus with only one p63RhoGEF allele (HET) were 
implemented in the study, reflecting a 50% knockdown of the protein.  
One initial goal of this thesis was the establishment of a mouse line harboring a specific 
deletion of p63RhoGEF in cardiac fibroblasts. Towards this aim, the floxed p63RhoGEF mice 
were crossbred with a mouse line expressing the cre recombinase under control of an 
inducible collagen 1a2 promoter (Col1a2-Cre(ER)). This mouse model was first described in 
2002 [200] and has been used several times for the knockout of a target gene in fibroblasts 
[201-203]. However, in our hands no knockout of p63RhoGEF in cardiac fibroblasts could be 
achieved with this model (data not shown). Recently, a study was published using a 
tamoxifen-inducible approach under a periostin promotor to ablate the population of 
activated fibroblast (myofibroblasts). This model is useful to induce a knockdown after 
induction of any stress (TAC, MI, Ang II infusion), as Periostin is up-regulated only in 
myofibroblasts and its expression in the healthy heart is restricted to valvular fibroblasts 
[204]. This approach could be implemented in the future to generate a mouse line, in which 
a knockdown of p63RhoGEF expression in myofibroblasts is achieved and its impact can be 
determined after TAC. However, this technique is not applicable to study any influence of a 
reduced p63RhoGEF expression in fibroblasts under healthy conditions. 
6.3.1 Impact of the partial genetic deletion of p63RhoGEF in pressure overload-induced 
cardiac remodeling 
On a basal level, the HET animals already manifested an impaired contractility as illustrated 
by a decrease in fractional area shortening (FAS) and ejection fraction (EF), accompanied by 
an enlargement of the left ventricular lumen measured by increase in volume. Upon 
induction of pressure overload by TAC surgery, these parameters were further aggravated, 
resulting in a phenotype with severe contractile dysfunction and a faster dilation within 5 
weeks after intervention. Thus, it can be concluded that the partial deletion of p63RhoGEF 
seems to have a strong negative effect on the cardiac function. In the context of the 
underlying processes of cardiac remodeling, the reduced expression had no major effect on 
the development of cardiac hypertrophy. Left ventricular weight to body weight ratio, heart 
weight to tibia length ratio, and cardiomyocyte size after TAC were increased to the same 
extent as in the WT group. However, analysis of hypertrophy-associated marker expression 
showed that in the HET group, less of the cardioprotective ANP and BNP is expressed in the 
ventricle. In addition, the level of β-MHC to α-MHC was not increased after TAC, suggesting 
that the impaired contractile phenotype might be linked to reduced levels of protective 
marker expression as well as contractile proteins. Validation on protein level would 
substantiate these findings. 
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Moreover, partial deletion of p63RhoGEF led to a reduction of cardiac fibrosis by trend. In 
these hearts less interstitial and perivascular collagen deposition was detected. Surprisingly, 
on mRNA level the typical fibrosis marker like collagen type 1 and type 3 and CTGF were not 
largely different between the WT, HET and KO TAC groups. However, LGALS3 and TGF-beta 
were significantly less increased in the HET mice compared to the WT and KO animals. 
LGALS3 (Gal-3) is a lectin that binds to β-galactosides, e.g. lactose and is thereby involved in 
cell-matrix interactions, cell-cell adhesion, apoptosis and inflammation. LGALS3 serves as a 
clinical biomarker for cardiac diseases and was shown to be markedly up-regulated in TAC 
mouse studies, where it was also associated with the severity of detrimental cardiac 
remodeling and inflammation [205]. In contrast, mice deficient in LGALS3 (Gal-3) were 
protected from fibrosis. For instance, Gonzales et al. showed that a Gal-3 deficiency in an 
angiotensin II-induced hypertension model prevents left ventricular dysfunction by reducing 
immune responses and myocardial fibrosis [206]. This is in good agreement with the results 
obtained, as a reduced level of LGALS3 seems to correlate with a decline in collagen 
deposition and thus fibrosis in the HET mice. Precisely, how LGALS3 interferes is still unclear.  
The pro-fibrotic cytokine TGF-β is known to up-regulate collagen by Smad 3/4, to inhibit 
matrix metalloproteinase (MMP) expression and to enhance tissue inhibitor of 
metalloproteinase (TIMP) expression, leading to higher collagen synthesis and less 
degradation by MMPs [207]. In line with this, the level of MMP-2, a collagen-degrading 
MMP, was higher in the HET animals than in the WT animals, suggesting that an enhanced 
degradation of collagen could be one reason for the reduced fibrosis. However, the interplay 
between the numerous secreted proteins in the heart is complex and the analysis of single 
factors can only give a hint about the underlying processes. To gain deeper insight into the 
occurring changes, large screenings are necessary, which are still difficult to accomplish on 
protein level due to the low abundance of many bioactive molecules. Moreover, it is likely 
that also secreted non-protein components are involved in the overall regulation of cardiac 
function and fibrosis including, e.g. glycosaminoglycans and low molecular weight hormones 
[208-210]. 
The results observed in the HET group regarding contractile function and fibrosis are largely 
in line with the results obtained by the 3D cell culture models. As demonstrated in EHM, 
p63RhoGEF in cardiac fibroblasts not only influenced tissue stiffness but also the contractility 
of these tissues. Although this is a strong hint for a predominant function of p63RhoGEF in 
cardiac fibroblasts, especially as there was no effect when p63RhoGEF was expressed mainly 
in cardiomyocytes, this does not fully exclude a potential role of this activator of RhoA in 
cardiomyocytes. In that respect, it has to be considered that in the genetic HET mouse model 
p63RhoGEF expression is diminished during all developmental steps and so far it is not clear 
at which time point the impairment of the cardiac function occurs in these animals. 
Moreover, the cardiomyocytes in the EHM model display an immature neonatal state and do 
not reach full maturation or even resemble the diseased heart. Therefore, further studies 
are needed to clarify the role of p63RhoGEF in cardiomyocytes.  
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By comparing the phenotype of the HET mice with other genetic mouse models, targeting 
proteins residing in the same or similar signaling pathways, a potential role of p63RhoGEF in 
cardiomyocytes seems at least likely. In a recent mouse study, mice with a cardiomyocyte-
specific knockout of RhoA were described to harbor a very similar phenotype upon chronic 
pressure overload as the partial genetic deletion of p63RhoGEF in this work. While the 
development of hypertrophy was not affected compared to the control group, the RhoA KO 
mice displayed an impaired contractile function associated with a greater dilation and less 
fibrosis accompanied by a reduced expression of fibrotic genes, e.g. TGF-β [144]. 
Furthermore, the authors were able to demonstrate that the cardiomyocyte-specific 
deletion of RhoA might affect the contractile properties by a modulated calcium signaling 
and myosin light chain (MLC) activation by a rapid decrease in phosphorylation of PLC-β, PKC 
and MLC shortly after TAC [144]. Although the analyses of the phosphorylation levels of 
these proteins were not analyzed within this work, it might be a reasonable point to explain 
the underlying molecular mechanisms leading to an impaired contractility in p63RhoGEF HET 
mice. 
Apart from p63RhoGEF, LARG (RhoGEF12) represents another GEF, which can activate RhoA 
downstream of GPCRs. While the p63RhoGEF activation is Gαq/11-dependent, LARG is 
activated by Gα12/13-signaling. For the heart it was demonstrated that LARG mediates the 
integrin-β stretch-induced RhoA activation and hypertrophic gene transcription in 
cardiomyocytes. Mice with a cardiomyocyte specific deletion of LARG displayed no 
hypertrophy, less fibrosis and were protected from the development of cardiac 
decompensation. The beneficial effects of the deletion of LARG were further validated, when 
the ablation of LARG was initiated in preexisting hypertrophy and prevented further 
progression of cardiomyocyte growth, improved cardiac function and enhanced survival 
[131]. In comparison to the p63RhoGEF HET group, these mice not only developed less 
fibrosis due to reduced expression of fibrotic genes as the p63RhoGEF mice, but they were 
also protected from hypertrophic response. Even more relevant, these mice did not show 
any sign of decompensation by contractile dysfunction and dilation of chambers [131]. On a 
molecular level, hypertrophic markers, such as ANP, BNP and β-MHC were similarly less up-
regulated in the p63RhoGEF HET mice compared to the mice with the cardiomyocyte-
specific KO of LARG. Nevertheless, p63RhoGEF mice developed hypertrophy accompanied by 
a faster decompensation. Since both GEFs activate RhoA, the discrepancy between the 
completely different outcomes might be explained by the differential Gα signaling of these 
GEFs, which involves other RhoA-independent regulatory pathways. 
Beside the activation of the p63RhoGEF-RhoA-ROCK pathway, Gαq/11 can also activate the 
phospholipase C-β (PLC-β) pathway, which regulates calcium signaling by release of Ca2+-ions 
from the ER [211]. Upon activation, PLC-β hydrolyzes phosphatidylinositol 4,5-bisphosphate 
(PIP2) to diacyl glycerol (DAG) and inositol triphosphate (IP3). Acting as second messengers, 
DAG activates protein kinase C (PKC), while IP3 triggers the calcium release from the ER. The 
level of DAG is controlled by phosphorylation of the DAG kinase (DGK). In the heart, the 
isoform DGKε has been reported to act specifically on DAG produced by inositol cycling and 
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inactivates DAG by producing phosphatic acid (PA). In a transgenic mouse model, 
overexpression of DGKε was shown to restore the cardiac dysfunction upon chronic pressure 
overload, which is usually downregulated during a hypertrophy-associated response. Hearts 
of these mice exhibited reduced level of hypertrophy, fibrosis and apoptosis. Moreover, 
contractility was less impaired and the expression of TRPC 6 calcium channels, which 
regulate the entry of calcium into the cell, was decreased [212]. In summary, the 
interference with the PLC-β signaling pathway resembled the phenotype of the 
cardiomyocyte-specific LARG KO mouse model after TAC.  
Interestingly, under normal condition mice with a cardiomyocyte-specific deletion of RhoA 
and LARG or with a reduction in DAG levels showed no functional or structural difference to 
the control mice. In contrast, under basal condition the p63RhoGEF HET mice displayed a 
contractile phenotype, which might be a consequence of the global genetic deletion, 
pointing to an influence of other cardiac cells on the contractile function of cardiomyocytes. 
In addition, cardiomyocyte-specific deletion of LARG and RhoA and the global partial 
deletion of p63RhoGEF result in reduced fibrosis, emphasizing their roles in the regulation of 
fibrosis, most likely via RhoA/ROCK signaling, involving the MRTF/SRF-dependent activation, 
as shown by Lauriol and colleagues [144]. In mice with the overexpression of DGKε in 
cardiomyocytes as intervention within the PLC-β pathway, also less fibrosis occurred [212], 
arguing for an interaction with other pathways involved in fibrosis. Moreover, this points to 
an important contribution of cardiomyocytes for the development of fibrosis in paracrine 
signaling, as all comparing mouse studies except the p63RhoGEF mouse line included the 
modification of gene expression in cardiomyocytes only. 
Regarding the development of cardiac fibrosis, the data obtained on the HET mice can be 
further confirmed by mouse studies investigating ROCK deletion. In a model of global 
haploinsufficient ROCK1+/- mice, the authors demonstrated in an Ang II infusion model as 
well as in the TAC model, that perivascular fibrosis and associated factors as TGF-beta, CTGF 
and collagen type 3 were less increased, while hypertrophy was established to the same 
extent after 4 weeks [142]. In the p63RhoGEF mouse study, concomitant with the reduced 
fibrosis only TGF-β was reduced out of the marker set compared to the study by Rikitake et 
al. The level of CTGF on mRNA was found to be similarly up-regulated in all 3 genotypes 
arguing that CTGF is not the causing factor for fibrosis. In this context, it was shown that 
CTGF and TGF-β on their own are considered to just weakly promote fibrosis and only in 
combination both were efficient in promoting fibrosis [74, 87, 213]. This fits very well with 
the data of the HET group, as the reduced level of TGF-β corresponds to less fibrotic tissue 
despite the highly up-regulated level of CTGF. Accordingly, when TGF-β and CTGF are both 
similarly up-regulated, more fibrosis occurs as seen in the WT and KO TAC groups. 




6.3.2 Impact of the knockout of p63RhoGEF in pressure overload-induced cardiac 
remodeling 
In contrast to the mice with the partial deletion of p63RhoGEF (HET), mice with a complete 
p63RhoGEF knockout (KO) displayed a similar phenotype as the WT group under basal 
condition and after TAC. The KO mice developed hypertrophy to the same extent as the WT 
group emphasizing that p63RhoGEF is not involved in the hypertrophic response. No major 
difference in contractile function and development of cardiac fibrosis compared to the WT 
TAC group was observed. Furthermore, analysis of hypertrophic and fibrotic marker 
expression revealed a similar up-regulation as detected in the WT. These data point to a 
compensatory processes that occur when p63RhoGEF is fully absent. Whether the loss of 
p63RhoGEF is compensated by other direct Gq/11-dependent RhoGEFs like Kalirin or Trio 
[164], by other Gα-signaling mediators (Gα12/13), or by the Gαq/11 competing PLC-β-
dependent calcium signaling, which is RhoA independent, has to be further elucidated in 
these mice. The available data of other mouse studies examining the cardiomyocyte-specific 
deletion of RhoA, LARG and inhibition of the PLC-β pathway by DGKε overexpression 
discussed above might be possible candidates. As the RhoGEF LARG controls cardiac 
remodeling by the RhoA-dependent signaling and its cardiomyocyte-specific deletion 
protects mice from development of cardiac remodeling and heart failure [131], it could be a 
responsible factor for the compensation of the loss of p63RhoGEF expression by maintaining 
the function of RhoA. This would explain the development of hypertrophy, fibrosis and 
cardiac dysfunction to the same extent in the p63RhoGEF KO mice as in the WT mice. 
Interestingly, in the same study Takefuji showed that amongst the various RhoGEFs 
expressed in mouse cardiomyocytes and whole human heart, beside RhoGEF12 a high 
expression of Trio was found, whereas p63RhoGEF was only minimally expressed [131]. This 
might point to a relevant role for Trio in cardiomyocytes. Therefore, compensation for the 
loss of p63RhoGEF by maintaining the function of RhoA via Trio is conceivable. Although so 
far no data is available for Trio in animal studies with respect to cardiac diseases, its role in 
the regulation of the Gq/11-dependent RhoA activation for endothelial cells has recently been 
established in vivo proving for the first time the relevance of this pathway [214]. 
During the course of this study it became however obvious that the knockout of p63RhoGEF 
is not without effect. The loss of p63RhoGEF had a detrimental effect on the survival of these 
mice within the first 2 weeks after TAC intervention. Massive hypertrophy and fibrosis could 
be excluded, since LVW/BW, HW/TL and cardiomyocyte area as well as the collagen amount 
in the heart was only marginally increased at that time point. What other underlying 
mechanisms in the course of compensation might be activated and evoke the higher 
mortality rate is speculative at this point. 
One possible compensatory effect includes the calcium signaling via the activation of PLC-β 
by Gαq/11 leading to a release of Ca
2+-ions from the ER and regulating calcium signaling [211]. 
Due to loss of p63RhoGEF expression, the signaling downstream of Gαq/11 might be shifted to 
the PLC-β pathway, which in turn can contribute to change in calcium signaling. As 
demonstrated, interfering with the PLC-β signaling pathway by cardiomyocyte-specific 
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overexpression of DGKε restored cardiac dysfunction and improved the survival rate [212]. It 
can be assumed that, in turn, an increased activation of this pathway would cause even 
more detrimental effects, such as dysregulation in calcium signaling and hence arrhythmias, 
which could explain the increased mortality rate seen in the KO male mice. In order to prove 
this hypothesis, further experiments, including ECG monitoring recordings by telemetry 
under basal and TAC conditions, could be implemented. 
6.4 Influence of the genetic deletion of p63RhoGEF in adult mouse cardiac fibroblasts 
In order to investigate the impact of the genetic deletion of p63RhoGEF in isolated cardiac 
fibroblasts, their marker profile was first assessed. In all isolated and cultivated AMCF, high 
levels of collagen type 1, FSP-1 and sm-actin were found on mRNA. Fibroblasts in culture 
tend to differentiate and adopt a more myofibroblast phenotype expressing high level of sm-
actin. This also makes it challenging to study the function and behavior of a typical fibroblast 
residing in the tissue. Apart from sm-actin, only a slight amount of calponin was detected 
and no expression of other markers specific for smooth muscle cells and endothelial cells 
were detected on mRNA level. Consequently, it can be assumed that the isolated cell 
population contains hardly any other typical cardiovascular cells but mainly (myo)fibroblast-
like cells. One obstacle in this approach is the lack of specific fibroblast and myofibroblast 
marker. As cardiac fibroblasts and myofibroblasts can be derived from very different cell 
sources, including amongst others resident cardiac fibroblasts, endothelial cells and bone 
marrow-derived circulating progenitor cells like monocytes and fibrocytes [32], they share 
many markers with other cell types. Therefore, their nature is normally identified by a 
combination of different markers and exclusion of other cell types harboring specific marker. 
Further possible fibroblast markers that could be included are the discoidin domain-
containing receptor 2 (DDR2), platelet-derived growth factor receptor alpha (PDGFR-2) and 
Thy1/CD90 [8, 15, 215]. 
The morphology of the isolated AMCF was quite diverse in shape and degree of stress fiber 
formation amongst all cell populations. Stress fibers are a result of RhoA activation and are 
also another typical feature of myofibroblasts. However, the deletion of p63RhoGEF had no 
influence on the cell surface area, the level of cytoskeletal protein expression and actin fiber 
formation. In accordance with these contradictory results, expression and even more 
secretion of CTGF and further fibrotic marker such as sm-actin, TGF-β and collagen type 1 
were likewise increased in HET and KO AMCF in a dose-dependent manner. Moreover, in 
these cells Ang II had no further effect on CTGF, while in WT fibroblasts a response to this 
stimulus was observed. This suggests that Ang II-dependent pathways are already active 
under basal condition and cannot be further induced by Ang II application. This is in sharp 
contrast to the 2D and 3D experiments with NCRF, where a p63RhoGEF-dependent 
regulation of CTGF expression, and especially secretion in response to Ang II, was validated 
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in multiple experiments and a knockdown in p63RhoGEF expression reduced the amount of 
CTGF on mRNA and protein level. The discrepancy might be explained by the different cell 
source and the approach used for the knockdown or knockout of p63RhoGEF. In NCRF cells, 
the knockdown or blocking was achieved by transient adenoviral infection, while AMCF are 
isolated from adult mice that carried the modification from embryonic stage on and initiate 
compensatory effects, even resulting in overcompensation in case of KO AMCF. The 
underlying mechanisms that are involved in the compensation for p63RhoGEF loss or 
reduction might include other Gα-signaling (Gα12/13), Gαq/11-dependent RhoGEFs 
(Trio/Kalirin), other transcription factors than MRTF/SRF for CTGF, or PLC-β-dependent 
calcium signaling, as discussed in detail in section 6.3. 
Conclusion 
Although a reduction in p63RhoGEF expression has a beneficial effect on the degree of 
cardiac fibrosis by decreasing the amount of collagen deposition, its expression is needed to 
maintain normal cardiac function under basal and stress condition. It thereby fulfills a role 
similar to RhoA, namely being both cardioprotective and cardiodeleterious, as it prevents 
the transition to dilation and failure, but initiates the fibrotic response in the heart under 




Table 7.1: Analysis of cardiac parameters by echocardiography in sham male mice 
Abbrevations: 1 w = 1 week after surgery, 2 w = 2 weeks after surgery, 5 w = 5 weeks after surgery 
Para- 
meter 
WT M Sham HET M Sham KO M Sham 
basal 1 w 2 w 5 w basal 1 w 2 w 5 w basal 1 w 2 w 5 w 


























































































































































































































































































































































































































Abbrevations: n = number; HR = heart rate; BW = body weight; LVW/BW = left ventricular weight/body weight; 
FAS = fractional area shortening; EF = ejection fraction; Vol s = systolic volume; Vol d = diastolic volume; LVID s 
= left ventricular inner diameter in systole; = LVID d = left ventricular inner diameter in diastole; CI = cardiac 
index; CO = cardiac output; §p < 0.05 vs. HET basal group.
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Table 7.2: Analysis of cardiac parameters by echocardiography in sham female mice 
Abbrevations: 1 w = 1 week after surgery, 2 w = 2 weeks after surgery, 5 w = 5 weeks after surgery 
Para- 
meter 
WT F Sham HET F Sham KO F Sham 
basal 1 w 2 w 5 w basal 1 w 2 w 5 w basal 1 w 2 w 5 w 

























































































































































































































































































































































































































Abbrevations: n = number; HR = heart rate; BW = body weight; LVW/BW = left ventricular weight/body weight; 
FAS = fractional area shortening; EF = ejection fraction; Vol s = systolic volume; Vol d = diastolic volume; LVID s 
= left ventricular inner diameter in systole; = LVID d = left ventricular inner diameter in diastole; CI = cardiac 
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